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ABSTRACT 
 
Overview: Mycoplasmas and ureaplasmas are not routinely diagnosed and 
are under researched in South Africa. Prevalence, population shifts especially 
concerning genital flora and implications in infection or other conditions are 
unknown. Information pertaining to Mycoplasma pneumoniae in respiratory 
disease is similarly lacking. There is little information on antimicrobial 
susceptibilities and resistance development against Sexually Transmitted 
Infections (STI) syndromic management approaches. 
 
Aims: a) Elucidate mycoplasmal and ureaplasmal prevalence and 
contributing factors concerning cervical colonisation or preterm delivery in 
conjunction with HIV and Chlamydia trachomatis b) Investigate prevalence of 
M. pneumoniae in respiratory infections in conjunction with HIV, 
Mycobacterium tuberculosis and Pneumocystis jiroveci. c) Determine 
antimicrobial susceptibilities of mycoplasmas and ureaplasmas and analyse 
resistance genes. d) Assess the inter-generic transfer potential of resistance 
gene (tetM) between Ureaplasma spp. and Neisseria gonorrhoeae. 
 
Genital setting: The prevalence of genital mycoplasmas, ureaplasmas and 
Chlamydia on women attending their first prenatal visit, in conjunction with 
preterm labour or HIV status was investigated. For preterm labour (2003), 199 
women were monitored for preterm delivery (<37 weeks); for colonisation and 
HIV (2005), 219 women were screened. Microbial detection was performed on 
DNA extracted from endocervical swabs employing PCR techniques. 
Colonisation was seen to be highest in the 14–20 year group from 2003. In 
women aged ≥21 years, co-colonisation was 13% although there was a shift 
from co-colonisation with Mycoplasma hominis and Ureaplasma spp. in 2003 
to other dual/triple combinations in 2005. Overall major trends from both 
collection periods were that the prevalence of Ureaplasma spp. tended to be 
higher in women ≥26 years, whilst prevalence of C. trachomatis and M. 
hominis were lower. No association was evident between colonisation with M. 
hominis, U. urealyticum, Ureaplasma parvum and labour outcome. HIV status 
 ii 
had no effect on the prevalence/co-colonisation of M. hominis, Ureaplasma 
spp. or C. trachomatis. 
 
Respiratory setting: Studies were conducted to determine the prevalence of 
community acquired atypical pneumonias in adults (M. pneumoniae and P. 
jiroveci) and neonates (mycoplasmas, ureaplasmas and Chlamydia 
trachomatis) in order to improve treatment management programmes in the 
Port Elizabeth region. Sputum specimens from 102 adult patients presenting 
with pneumonia/symptoms of pneumonia admitted to hospitals were assessed 
by PCR. Details of patient’s gender, age, HIV and Mycobacterium 
tuberculosis status were provided by the hospitals. Women were seen to be at 
high risk for community-acquired P. jiroveci colonisation. Overall, prevalence 
of P. jiroveci was 52.9% (54/102 patients). P. jiroveci was mainly associated 
with HIV (25/74) (P. jiroveci and HIV positive patients in patient sample for 
which clinical data and HIV status was available) and co-infection with M. 
tuberculosis was observed in 12 HIV cases and one HIV negative patient. No 
DHPS (20) or DHFR (17) resistance associated mutations were found in P. 
jiroveci. M. pneumoniae was detected in one patient. For prevalence studies 
(2007-2008) on atypical pneumonia in neonates, 69 endotracheal aspirates 
were obtained. PCR detection of M. hominis, U. urealyticum and C. 
trachomatis was performed and U. parvum detected in two specimens. 
 
Antibiotic susceptibilities and resistance genes: The following 
investigations on clinical isolates of U. parvum and U. urealyticum were 
conducted (i) antibiotic susceptibility profiles, (ii) detection of drug target gene 
mutations, or gene acquisitions and (iii) inter-generic resistance gene transfer 
potential to Neisseria gonorrhoeae. Culture techniques applied to 132 
endocervical specimens provided 66 Ureaplasma cultures (35 U. parvum, 9 
U. urealyticum, 22 U. parvum + U. urealyticum). MIC determinations to 
ofloxacin, erythromycin, tetracycline, doxycycline, azithromycin and josamycin 
were performed. Thirty-seven ureaplasma cultures were fully susceptible to all 
antibiotics tested; 21 showed intermediate resistance to erythromycin, 
azithromycin and ofloxacin; while seven were resistant to tetracycline, three of 
which were also resistant to doxycycline and one also resistant to 
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azithromycin. Concerning ofloxacin resistance directed at quinolone 
resistance determining regions, a substitution of Ser83Leu in ParC was 
demonstrated in one intermediately-resistant Ureaplasma (MIC 4 µg/ml) while 
a triple substitution of Asp112Glu in GyrA along with Ala125Thr and 
Ala136Thr in ParC was found in six further intermediately-resistant strains. No 
mutations were found in strains with MICs 1 µg/ml. No mutations were 
detected in 23S rRNA operons, L4 or L22 proteins. TetM and int-Tn genes 
were found in seven tetracycline-resistant strains. On screening 59 
tetracycline-susceptible and -intermediate strains, eleven whilst possessing 
an int-Tn gene lacked a large region of tetM and 48 only contained small 
regions of tetM. The tetM genes of the seven tetracycline-resistant strains 
were sequenced and comparisons performed against GenBank sequences of 
Neisseria gonorrhoeae, Streptococcus pneumoniae and U. urealyticum. For 
five strains tetM was seen to be highly mosaic in structure containing regions 
that were similar to those of the GenBank strains and others that were unique. 
In the tetM leader region, four hot spot recombination sites were identified that 
could certainly influence the formation of the mosaic structures, upstream 
insertion sequences/open reading frames and transposon regions that 
regulate expression. On characterising the int-Tn genes of the seven 
tetracycline-resistant strains, three types were present indicating transposons 
from different origins had integrated into ureaplasma genomes. Reciprocal 
tetracycline resistance gene transfer between ureaplasmas and N. 
gonorrhoeae were unsuccessful. However, low-level tetracycline resistance 
(MICs 4-8 µg/ml) was transferred to a U. parvum recipient from one U. 
urealyticum and three U. parvum donors that carried tetM with MICs 16-64 
µg/ml. On tetM PCR analysis, tetM was not detected in the transformants. 
 
Conclusions: The importance of genital mycoplasmas, ureaplasmas and C. 
trachomatis in long term aetiologies requires further investigations, certainly in 
relation with syndromic management regimens that fail to reduce colonisation 
rates. The high prevalence of P. jiroveci, the presence of M. pneumoniae in 
cases of pneumonia and detection of U. parvum in two cases of neonatal 
pneumonia investigated emphasises that in the absence of definitive 
diagnoses, it is crucial to monitor treatment responses carefully, especially 
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when first line antibiotic preferences are β-lactams, in order to ensure 
adequate and informed delivery of medical care. The finding of transposon 
and/or tetM regions in all ureaplasmas investigated with or without full 
expression of tetracycline resistance, in conjunction with tetM gene diversity, 
certainly places ureaplasmas strongly in the picture for intra- and inter-generic 
exchange of antibiotic resistance genes. 
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OPSOMMING 
 
Oorsig: Mikoplasma en ureaplasma word nie roetineweg gediagnoseer nie 
en in Suid Afrika is nog min navorsing daaroor gedoen. Prevalensie, 
populasie verskuiwings, veral in genital flora, en die impliksies van infeksie en 
ander toestande is onbekend. Inligting rakende Mycoplasma pneumoniae in 
respiratoriese siekte is ook gebrekkig. Daar is min inligting beskikbaar 
rakende die antimikrobiale vatbaarheid en die ontwikkeling van 
weerstandigheid gesien teen die benadering tot sindromiese hantering van 
seksueel oordraagbare siektes. 
 
Doelwitte: a) Om iInligting te verskaf oor die prevalensie van mikoplasma en 
ureaplasma en bydraende faktore betreffende voortydige kraam tesame met 
MIV en Chlamydia trachomatis. b) Ondersoek van die prevalensie van M. 
pneumoniae in respiratoriese infeksies tesame met MIV, Mycobacterium 
tuberculosis en Pneumocystis jiroveci. c) Bepaling van die antimikrobiale 
vatbaarheid van mikoplasma en ureaplasma en analisevan  weerstandigheids 
gene. d) Bereken die inter-genetiese oordrag potensiaal van 
weerstandigheids gene (tetM) tussen Ureaplasma spp. en Naisseria 
gonorrhoeae. 
 
Genitale omgewing: Die prevalensie van genitale mikoplasma, ureaplasma 
en Chlamydia in vroue tydens hul eerste prenatale besoek, tesame met 
vroegtydige kraam en MIV status is ondersoek. In voortydige kraam (2003), is 
199 vroue gemonitor vir voortydige kraam (<37 weke); vir kolonisasie en MIV 
(2005), is 219 vroue getoets. Mikrobiale toetsing is gedoen deur DNS te win 
vanaf endoservikale deppers met PKR tegnieke. Kolonisasie was die hoogste 
in die ouderdomsgroep 14–20 jaar, in 2003. In vroue van ≥21 jaar was mede-
kolonisasie 13% alhoewel daar ‘n verskuiwing was van mede-kolonisasie met 
Mycoplasma hominis en Ureaplasma spp. in 2003 tot ander dubbel/trippel 
kombinasies in 2005. Die oorkoepelende tendens in altwee die tydperke van 
waarneming was dat die prevalensie van Ureoplasma spp. geneig was om 
hoër te wees in vroue ≥26 jaar, terwyl prevalensie van C. trachomatis en M. 
hominis laer was. Geen assosiasie kon getoon word tussen koloniesasie met 
 vi 
M. hominis, U. urealyticum, Ureaplasma parvum en uitkoms van kraam nie. 
MIV status het geen effek gehad op die prevalensie/mede-kolonisasie van M. 
hominis, Ureaplasma spp. of C. Trachomatis nie. 
 
Respiratories: Studies is gedoen om die prevalensie van gemeenskaps 
verworwe atipiese pneumonie in volwassenes (M. pneumoniae en P. jiroveci) 
en neonate (mikoplasma, ureaplasma en Chlamydia trachomatis) te bepaal 
om behandeling en hantering programme in die Port Elizabeth area te 
verbeter. Sputum monsters van 102 volwasse pasiënte wat presenteer het 
met pneumonie of simptome van pneumonie en wat tot hospitale toegelaat 
was, is ontleed. Besonderhede van die pasiënte se geslag, ouderdom, MIV en 
Mycobacterium tuberculosis status is deur die hospitale verskaf. PKR is 
gedoen met inleiers gerig teen die volgende gene: P. jiroveci vir die aantoning 
van mitokondriale groot subeenheid RNS en vir die analise van mutasies vir 
ko-trimoksasool weerstandigheid dihydropteroaat sintetase (DHPS) en 
dihydrofolaat reduktase (DHFR); M. pneumoniae vir die aantoning van P1 
adhesien en 16S rRNS. Vroue het ‘n hoë risiko vir gemeenskapsverworwe P. 
jiroveci kolonisasie gehad. In die algemeen was die prevalensie van P. 
jiroveci 52.9% (54/102 pasiënte). P. jiroveci was hoofsaaklik geassosieerd 
met MIV (25/74) (P. jiroveci en MIV positiewe pasiënte in die pasiënt monster 
waarvoor daar kliniese data en MIV status bekend was) en mede-infeksie met 
M. tuberculosis is gesien in 12 MIV gevalle en een MIV negatiewe pasiënt. 
Geen DHPS (20) of DHFR (17) weerstandigheids geassosieerde mutasies is 
gevind in P. Jiroveci nie. M. pneumoniae was aangetoon in een pasiënt. Vir 
prevalensie studies (2007-2008) op atipiese pneumonie in neonate is 69 
endotrageale aspirate verkry. PKR toetsing vir M. hominis, U. urealyticum en 
C. trachomatis is gedoen met ‘primers’ soos voorheen gepubliseer. 
Ureaplasma parvum is aangetoon in twee neonate met PKR met negatiewe 
kultuur resultate. 
 
Antibiotika sensitiwiteite en weerstandigheids gene: Die volgende toetse 
is gedoen op kliniese isolate van U. parvum en U. urealyticum (i) antibiotika 
sensitiwiteits profiele, (ii) aantoning van teiken geen mutasies, of geen 
aanwinste en (iii) potensiaal  vir inter-generiese weerstandigheids geen 
 vii 
oordrag na Neisseria gonorrhoeae. Kultuur tegnieke toegepas op 132 
endoservikale monsters het 66 Ureaplasma kulture gelewer (35 U. parvum, 9 
U. urealyticum, 22 U. parvum + U. urealyticum). MIK bepaling vir ofloksasien, 
eritromisien, tetrasiklien, doksisiklien, azitromisien en josamisien is gedoen. 
Sewe-en-dertig kulture was ten volle sensitief vir alle antibiotika wat getoets 
is; een-en twintig het intermediêre weerstandigheid teenoor eritromisien, 
azitromisien en ofloksasien getoon, terwyl sewe weerstandig was vir 
tetrasiklien, drie daarvan was ook weerstandig vir doksisiklien. Wat betref 
ofloksasien weerstandigheid gemik teen kwinoloon weerstandigheids 
bepalende gebiede, is vervanging van Ser83Leu in ParC gedemonstreer in 
een intermediêr weerstandige Ureaplasma (MIK 4 µg/ml) terwyl ‘n trippel 
vervanging van Asp112Glu in GyrA saam met Ala125Thr en Ala136Thr in 
ParC gevind is in ses ander intermediêr weerstandige stamme. Geen 
mutasies is gevind in stamme met MIKs van MICs 1 µg/ml nie. Geeneen van 
die ureaplasma was weerstandig vir eritromisien/azitromisien nie en geen 
mutasies is gevind in 23S rRNA operons , L4 of L22 proteine nie. TetM en int-
Tn gene is gevind in sewe tetrasiklien weerstandige stamme. 58 Tetrasiklien 
sensitiewe en –intermediêre stamme is getoets, waarvan elf ‘n int-Tn geen 
gekort het sowel as ‘n groot deel van tetM, terwyl 48 slegs klein dele van 
TetM bevat het. Die tetM gene van die sewe tetrasiklein-werstandige stamme 
se geenvolgorde is bepaal en vergelykings is getref teenoor die GenBank 
volgordes van Neisseria gonorrhoeae, Streptococcus pneumoniae en U. 
urealyticum. In vyf stamme is gevind dat die tetM geen hoogs mosaïek in 
struktuur was met areas wat ooreenstem met die in GenBank stamme, en 
ander areas wat uniek is. In die tetM leier area, is vier ‘hot spot’ 
herkombinasie areas geïdentifiseer wat sekerlik die vorming van die mosaïiek 
strukture kon beïnvloed, asook transposon areas wat geenuitdrukking bepaal. 
Met karakterisering van die int-Tn gene van die sewe tetrasiklein-
weerstandlige stamme, was drie tipes teenwoordig waarin transposons vanaf 
verskillende oorsprong aangedui was, geïntegreerd met die ureaplama 
genome. Resiprokale tetrasiklien weerstandigheids geen oordrag tussen 
ureaplasma en n. gonorrhoea was nie suksesvol nie. Lae-vlak tetrasiklien 
weerstandigheid (MIK’s van 4 – 8 µg/ml) is wel suksesvol oorgedra na ‘n  U. 
parvum  ontvanger vanaf een U. urealyticum  en drie U. parvum ontvangers 
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wat tetM gedra het met MIKs van 16-64 µg/ml. Met die analise van tetM met 
PKR, kon tetM nie aangetoon word in die transformante nie.  
 
Gevolgtrekkings: Die belang van genitale mykoplasma, ureaplasma en C. 
trachomatis in langtermyn etologie benodig verdere ondersoek, veral in die lig 
van die sindromiese behandeling regimes wat nie kolonisasie verminder nie. 
Die hoë prevalensie van P. jiroveci, die teenwoordigheid van M. pneumoniae 
in gevalle van pneumonie en die aantoning van U. parvum in twee gevalle van 
neonatale pneumonie benadruk dat, in die afwesigheid van ‘n definitiewe 
diagnose, dit noodsaaklik is om respons tot behandeling sorgvuldig te 
moniteer, veral indien die eerste lyn antibiotika keuse β-laktam antimikrobiale 
middels of kefalosporiene is, sodat behoorlike en ingeligde gesondheidsorg 
gelewer kan word. Die bevinding van transposon en/of tetM gebiede in alle 
ureaplasma wat ondersoek is met of sonder volle uitdrukking van tetrasiklien 
weerstandigheid, in samehang met tetM diversiteit, plaas verseker 
ureaplasma sterk in die prentjie vir intra- en inter-generiese uitruiling van 
antibiotika weerstandigheids gene. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 MYCOPLASMAS AND UREAPLASMAS IN HUMAN DISEASES 
 
1.1.1 Taxonomy 
 
Mycoplasmas and ureaplasmas are pleomorphic, nonmotile microorganisms 
that lack cell walls, and are among the smallest independently living 
organisms. Sixteen Mycoplasma and Ureaplasma species that can be 
pathogenic/ opportunistic to humans in some settings have been identified, 
the most known species include: Mycoplasma hominis, Mycoplasma 
pneumoniae, Mycoplasma genitalium, Mycoplasma fermentans, Mycoplasma 
penetrans, Ureaplasma parvum and U. urealyticum.  M. amphoriforme is a 
recently identified species and its pathogenic role in human disease is 
currently under investigation (Waites and Talkington, 2005). 
 
Mycoplasmas and ureaplasmas were classified in a separate phylum of 
Gram-negative bacteria Mollicutes, however, analyses of rRNA revealed they 
were similar to Gram-positive bacteria. They are now categorised as low G+C 
Gram-positive bacteria in the Phylum Firmicutes; nevertheless they appear 
pink when stained with the Gram stain (Bauman, 2007). U. parvum and U. 
urealyticum were originally considered one species U. urealyticum with 
subdivision into two biovars. In 2002, after prolonged debate, it was agreed 
that the former U. urealyticum should be divided into two species namely U. 
parvum (biovar 1) and U. urealyticum (biovar 2) (Kong and Gilbert, 2004). U. 
parvum contains serovars 1, 3, 6 and 14 while U. urealyticum contains the 
serovars 2, 4, 5, 7, 8, 9, 10, 11, 12 and 13 (Schelonka and Waites, 2007). A 
urease gene cluster has been found that consists of seven genes, ureA, ureB, 
ureC being responsible for the structural units of urease and ureD, ureE, ureF, 
ureG being responsible for the accessory proteins. Although these urease 
genes are found within the various serovars, there are key differences in their 
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distributions between U. parvum and U. urealyticum that can be used to 
separate the two species (Mallard et al., 2004). 
 
 
1.1.2 Mycoplasma spp. and Ureaplasma spp in urogenital infections 
 
The importance of genital mycoplasmas in prematurity, pregnancy loss and 
chorioamnionitis have been topics of great interest although not satisfactorily 
resolved as analyses have been complicated by different study designs and 
inappropriate sampling sites (Waites and Talkington, 2005). Studies from 
which ureaplasmas and M. hominis were isolated from the endometrium or 
placenta have shown a consistent association with spontaneous abortion, 
however, this has not been substantiated by studies limited to sampling the 
lower genital tract such as endocervical specimens (Taylor-Robinson et al., 
2003a). 
 
M. hominis has been shown to be associated with bacterial vaginosis and 
linked to a) increased frequencies of Chlamydia trachomatis (Odendaal et al., 
2002) and b) U. urealyticum infections and genital tract HIV RNA levels (Sha 
et al., 2005). Movement of M. hominis into the chorioamnion causes 
inflammation (chorioamnionitis) and movement into the amniotic cavity results 
in the colonisation of the foetus (Kim et al., 2003). Evidence has also been 
found linking M. hominis with pelvic inflammatory disease (Taylor-Robinson, 
2007). Cervical colonisation (sample size of 218) women with M. hominis and 
U. urealyticum was associated with lower gestational age at delivery, lower 
birth weight, and increased neonatal morbidity and mortality (Luton et al., 
1994). However, no correlation was found for co-existence of M. hominis/U. 
urealyticum colonisation with typical and atypical urinary tract infections or for 
sterile pyuria (Latthe et al., 2008). M. hominis has also been shown to cause 
postpartum and postabortal fever however it has also been argued that it may 
actually be only a marker for bacterial vaginosis (Taylor-Robinson, 2007).  
 
M. genitalium has been shown to cause acute and chronic urethritis in men 
(Jensen et al., 1993; Deguchi and Maeda, 2002; Taylor-Robinson et al., 
3 
 
2003b). In women it is strongly associated with cervicitis, endometritis and 
infertility (Cohen et al., 2002; Deguchi and Maeda, 2002; Uuskula and Kohl, 
2002). Recently, studies in Peruvian women with a sample group comprising 
661 cases with spontaneous preterm birth and 667 controls, cervical M. 
genitalium detection was found to be independently associated with younger 
maternal age and preterm birth (Hitti et al., 2010). 
 
In contrast, M. genitalium was not seen to be significantly associated with 
non-gonococcal urethritis in South African men with genital ulcer disease 
(Ballard et al., 2002). Further studies from South Africa have shown M. 
genitalium infection in male urethritis syndrome and genital ulcer syndrome 
(Black et al., 2008), with a high prevalence of M. genitalium and other STIs 
observed in asymptomatic men (Lewis et al., 2008). 
 
M. penetrans has been isolated from the urogenital tracts of individuals with 
HIV infection (Hussain et al., 1999). M. fermentans has been reported to be 
an opportunist in HIV infection (Ainsworth et al., 2001; Waites and Talkington, 
2005) and to be responsible for bacteraemia in a high percentage of patients 
with rheumatoid arthritis (Gil et al., 2009). 
 
Ureaplasmas are able to colonise the vagina and cervix and have been 
implicated as a cause of preterm labour possibly through the production of 
cytokines that can cause premature contractions. They are also associated 
with spontaneous abortion, choriamnionitis, foetal body weight fluctuations, 
and the introduction of other bacterial species into the womb followed by 
intense inflammation (Taylor-Robinson, 2007; Kim et al., 2003). Vaginal 
carriage of Ureaplasma spp. is not reliably predictive of preterm labour, but 
there is an association when it is present in the amniotic fluid or placenta. In 
contrast it has been reported that women whose cervices were culture 
positive for Ureaplasma spp. were more likely to develop pregnancy 
complications than women with a negative culture (Waites et al., 2005). The 
presence of U. urealyticum in placental parenchyma before 28 weeks was 
found to higher risks of foetal and maternal inflammation and was associated 
with increased risk of preterm labour and delivery (Olomu et al., 2009). A high 
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prevalence of U. urealyticum was observed in women with unexplained 
chronic urinary (voiding) symptoms (Baka et al., 2009). Ureaplasma spp. can 
bind to sperm cells and by inhibiting free movement, infertility can result 
(Waites and Talkington, 2005). M. genitalium and Ureaplasma spp. were 
found to be widespread among infertile male patients in Tunisia (Gdoura et 
al., 2008). 
 
Extragenital infections caused by Ureaplasma spp. and M. hominis include 
neonatal pneumonia (Waites et al., 2005; Biernat-Sudolska et al., 2006), 
abscesses (Waites and Talkington, 2005), septic arthritis (Phuah et al., 2007) 
and surgical wound infections in patients with malignancies (Krijnen et al., 
2006), organ transplant recipients (Hopkins et al., 2002) and mediastinitis 
(Mattila et al., 1999). There have been reports of U. urealyticum meningitis in 
an adult patient after a complicated kidney transplantation and organ rejection 
(Gessdorfer et al., 2008) and detection of an erythromycin-resistant U. 
urealyticum meningitis in a premature infant (Chung et al., 2007). 
 
 
1.1.3 Neonatal diseases caused by genital mycoplasmas and 
ureaplasmas 
 
U. urealyticum and U. parvum can be transmitted vertically from the parent to 
offspring either in utero or perinatally (Biernat-Sudolska et al., 2006; Pinna et 
al., 2006). U. urealyticum and U. parvum infections of the newborn have been 
associated with bacteraemia, pneumonia, chronic lung disease and the 
central nervous system (Cultrera et al., 2006; Waites et al., 2005). There is 
strong evidence from clinical and experimental animal studies that 
ureaplasmas can invade the amnionic sac and induce an inflammatory 
response resulting in chorioamnionitis, preterm labour and neonatal lung 
injury (Waites et al., 2009a). 
 
Evidence of vertical ureaplasma transmission and neonatal infection comes 
from observations that ureaplasmas can be isolated from endotracheal 
secretions in up to 40% of newborn infants within 30 minutes to 24 hours after 
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birth and from maternal and umbilical cord blood at the time of delivery 
(Schelonka and Waites, 2007). Newborns with birth weights of less than 1000 
g appear to be at a higher risk of infection when the mother is colonised, with 
the rate of vertical transmission approaching 90% for these infants. The 
presumed mechanisms of infection include foetal exposure to ascending 
ureaplasmal intra-uterine infection, passage through an infected birth canal, 
and haematogenous dissemination through the placenta into umbilical 
vessels. These exposures can lead to colonisation of the skin, mucosal 
membranes, and respiratory tract, and sometimes to dissemination into the 
bloodstream and central nervous system (Schelonka and Waites, 2007). 
 
Case studies have reported the presence of M. hominis in eye infections and 
brain abscesses in the neonate (Waites et al., 2005). In addition, in neonates 
with respiratory distress, Ureaplasma spp. alone or in combination with M. 
hominis has been detected more frequently than M. hominis alone (Waites et 
al., 2005; Waites and Talkington, 2005). Hence, it would be expected for such 
infections in neonates to be predominantly caused by Ureaplasma spp. 
 
 
1.1.4 Mycoplasma spp. and Ureaplasma spp. in respiratory disease 
 
M. pneumoniae is a common cause of acute upper and lower respiratory tract 
infections particularly in children, young adults and the elderly; and 
community-acquired pneumonia which often results in hospitalisation due to 
severity of the illness (Madani and Al-Ghamdi., 2001; Waites and Talkington, 
2004). Prevalence of M. pneumoniae infections within healthy populations can 
vary from between 13.5-34% to 45% in adults with asthma (Biscardi et al., 
2004; Lauderdale et al., 2005; Braun et al., 2006; Shankar et al., 2006). M. 
pneumoniae infection may contribute to asthma exacerbation (Varshney et al., 
2009). 
 
U. urealyticum and U. parvum infections of the newborn have been 
associated with pneumonia, and chronic lung disease (Schelonka and Waites, 
2007). Cultrera et al. (2006), has suggested that U. parvum may play a 
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greater role in the pathogenesis of respiratory distress syndrome than U. 
urealyticum. 
 
As many as 25% of patients infected with M. pneumoniae, may experience 
extrapulmonary manifestations, such as neurological and central nervous 
system damage, in the form of encephalitis, motor neuron damage, 
dermatological disorders such as erythematous maculopapular and vesicular 
rashes, conjunctivitis, non-specific ear disorders and glomerulonephritis 
(Palumbo et al., 2008; Kano et al., 2007; Guleria et al., 2005; Waites and 
Talkington, 2004; Sotgiu et al., 2003; Said et al., 1999). The release of pro-
inflammatory cytokines, in association with M. pneumoniae, has been 
implicated as a possible mechanism aggravating chronic pulmonary diseases, 
such as asthma and, possibly, triggering rheumatoid arthritis or reactive 
arthritis (Bebear, 2008; Harjacek et al., 2006; Waites and Talkington, 2004; 
Haier et al., 1999). 
 
 
 
 
1.2 TREATMENT OF MYCOPLASMAS AND UREAPLASMAS 
 
As mycoplasmas and ureaplasmas lack cell walls, antibiotics that target wall 
synthesis are ineffective. 
 
Macrolide, lincosamide and streptograminin antibiotics (MLSs) are commonly 
used for the treatment of human mycoplasma and ureaplasma infections. 
Ketolides (a derivative of erythromycin), tetracyclines and fluoroquinolones 
are also used. Mycoplasmas present different phenotypes of intrinsic 
resistance to macrolides. M. pneumoniae a respiratory mycoplasma is 
susceptible to all MLSKs. In contrast, M. hominis a genital species is naturally 
resistant to 14- and 15- membered macrolides and ketolides but is susceptible 
to josamycin a 16-membered macrolide and lincosamides. Intrinsic reistance 
to 14- membered macrolides has been observed in other species, like M. 
fermentans (Bebear and Robertson, 1996; Bebear and Bebear, 2002; Pereyre 
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et al., 2002). Ureaplasma spp. are intrinsically-resistant to the lincosamides 
(eg. clindamycin) (Bebear and Bebear, 2002). 
 
Macrolides are most commonly used for the treatment of Ureaplasma spp. 
infections in pregnant women and neonates (Bebear and Kempf, 2005; 
Pereye et al., 2007a). The MLSK group, are also used for the treatment of 
respiratory tract infections or when tetracyclines or fluoroquinolones are 
contra-indicated, for instance in newborns, children or during pregnancy. For 
Ureaplasma spp. and M. hominis respiratory tract infections in neonates, 
erythromycin and josamycin respectively are normally considered first line 
treatment (Waites and Talkington, 2005). Recently, an investigational ketolide, 
CEM-101, was reported to be a potent compound, inhibiting growth of clinical 
isolates of Mycoplasma and Ureaplasma spp. at ≤0.5 µg/ml (Waites et al., 
2009b). 
 
Tetracyclines are used for the treatment of urogenital infections like non-
gonococcal urethritis and pelvic inflammatory disease in which 
mycoplasmas/ureaplasmas may be implicated. They are also indicated in 
respiratory tract infections due to M. pneumoniae in adults. 
 
Fluoroquinolones used against both Mycoplasma spp. and Ureaplasma spp. 
include ciprofloxacin, ofloxacin, gatifloxacin (Waites and Talkington, 2004; 
Blasi, 2004) and newer agents like sparfloxacin, gemifloxacin, garenfloxacin 
and moxifloxacin (Bebear et al., 2008). However, these antimicrobials cannot 
be given during pregnancy or to children due to juvenile cartilage damage 
(Bebear and Kempf, 2005). 
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1.3 DETECTION OF MYCOPLASMAS AND UREAPLASMAS 
 
1.3.1 Conventional culture 
 
Diagnosis is hampered in pathology laboratories because mycoplasmas and 
ureaplasmas are not readily/reliably visualised by staining methods and grow 
poorly or not at all on conventional media. Due to the lack of a cell wall, 
mycoplasmas are very susceptible to adverse environmental conditions 
including drying, osmotic change, toxic metabolites, and extreme 
environmental fluctuations such as temperature. Quality controlled culture 
media specifically designed to support mycoplasmal growth is expensive. In 
addition, there is no single medium formulation that will adequately support 
the growth of all species. Media components include animal serum (foetal 
calf, horse serum), peptones, yeast extract, metabolic substrates (glucose, 
cysteine, arginine, and urea) and a pH indicator (phenol red). Atmospheric 
conditions for broths are aerobic, while agar requires the addition of 5 – 10% 
CO2, with an incubation temperature of 35 - 37°C (Duffy and Waites, 2008). 
 
For genital mycoplasmas and ureaplasmas A8/ A7 agar is used, with 10B/ U9 
broth for Ureaplasma spp. and arginine broth for M. hominis recommended. 
Antibiotics such as penicillin, cefoperazone, ampicillin or nystatin can be 
incorporated into media to inhibit bacterial and fungal contamination or 
overgrowth. 
 
M. hominis produces 200 – 300 µm colonies on A8 agar and causes colour 
change in arginine broth. Colonies of Ureaplasma spp. growing on A8 agar 
have a brownish appearance due to urease activity in the presence of the 
CaCl2 indicator contained in the agar (Waites et al., 2001). U. urealyticum 
hydrolyses urea and releases ammonia, which results in an alkaline shift and 
the medium changes from yellow to pink. Broth cultures for Ureaplasma spp. 
should be examined for such colour changes twice a day for up to 7 days 
because on depletion of urea, ureaplasmas undergo a steep death phase 
(Pinna et al., 2006). Therefore ureaplasmas need to be sub-cultured 
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timeously to a medium such as A8 or A7 agar, which will support further 
growth. 
 
On the basis of colony morphology, M. pneumoniae cannot be differentiated 
from other Mycoplasmas (Daxboek et al., 2003). It has been recommended 
that culture should also be combined with additional diagnostic techniques 
(Waites and Talkington, 2004). Spiroplasma medium (SP4), which was 
developed 20 years ago, for the cultivation of Spiroplasmas, was found to 
enhance the isolation of M. pneumoniae from clinical specimens. The 
presence of M. pneumoniae is indicated, in broth cultures by a distinct colour 
change of the medium, from red to yellow, as a result of glucose utilisation 
and on agar by distinct “fried-egg”, granulated colony formation. Culture of M. 
pneumoniae from respiratory specimens is slow, insensitive, expensive, and 
requires specialised growth media, with incubation periods of up to several 
weeks (Waites and Talkington, 2004; Daxboek et al., 2003). 
 
 
1.3.2 Commercial kits 
 
The development of commercially prepared media and diagnostic kits offer 
simpler alternatives for the detection of Mycoplasma spp. and Ureaplasma 
spp. in urogenital and neonatal respiratory samples. Commercially prepared 
media or kits require laboratories to perform internal quality control and that 
product limitations should be noted (Waites et al., 2001; Duffy and Waites, 
2008). Commercially prepared culture media currently available are arginine 
broth (M. hominis) and U9 broth (Ureaplasma spp.) [Bio-Rad], while 
diagnostic test kits for identification and antibiotic susceptibility include: 
MycoDuo (Bio-Rad); MycoIST2 (bioMerieux), Mycoview (Ivagen) and 
Pneumofast kit for M. pneumoniae. 
 
In the Mycoplasma Duo kit (Bio-Rad), identification is indicated by a colour 
change (from yellow to pink) of U9 and arginine broths based on the 
metabolism of urea and arginine. Results are read within 24 – 48 hours. This 
method allows for culture, identification and differential titration of Ureaplasma 
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spp. and M. hominis. Cheah et al. (2005), showed that the overall agreement 
between the polymerase chain reaction (PCR) and Mycoplasma Duo Kit for 
detection of Ureaplasma spp. in endotracheal aspirates from neonates was 
96%.  
 
MycoIST2 (bioMerieux) allows for the identification, culture and antibiotic 
susceptibility testing of Ureaplasma spp. and M. hominis. Antibiotic 
susceptibility testing includes nine antibiotics at two different concentrations 
and uses similar antibiotics as those in the SIR kit with the inclusion of 
ciprofloxacin and clarythromycin. There have been contrasting reports 
concerning antibiotic resistance profiles when using the MycoIST2 kit 
(Smayevsky et al., 1995; Kenny and Cartwright, 2001). In addition, false 
positive results can be obtained as other bacteria (e.g. Proteus, Klebsiella) 
are capable of hydrolysing urea (Biernat-Sudolska et al., 2006). 
 
The Mycoview (Ivagen) test kit enables the identification and the differential 
titration of U. urealyticum and M. hominis from urogenital specimens. The test 
is based on natural resistance and specific metabolic properties: U. 
urealyticum is resistant to lincomycin and hydrolyses urea; M. hominis is 
resistant to erythromycin and hydrolyses arginine. Growth of the two species 
is visualised by a change in media colour from yellow – orange to red or pink. 
 
The Pneumofast kit uses an SP4-type agar plate for isolation and 
morphological identification, while the Pneumofast assay is used for the 
enumeration and identification of M. pneumoniae within a liquid medium, and 
in addition provides susceptibility testing of four antibiotics (doxycycline, 
minocycline, ciprofloxacin and erythromycin). Identification is also based on 
the typical colony morphology of M. pneumoniae, namely its granular, fried-
egg shape with a diameter of 10 to 150 μm, and its characteristic colour 
change in Pneumofast broth from red to orange to yellow (with no signs of 
turbidity) as a result of glucose utilisation (Madani and Al-Ghamdi, 2001). 
When comparing culture techniques with PCR, the sensitivity of culture is 
extremely low, with a maximum analytical sensitivity of 60% being obtained 
only in experienced, well-trained laboratories (Ieven et al., 1996). 
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Serology is also an important diagnostic tool in routine laboratory practice. 
(Daxboek et al., 2003; Tjhie et al., 1994). Numerous commercially designed 
serological tests are available, including the complement fixation test, the 
microparticle agglutination assay and various enzyme linked immunosorbent 
assay tests (Daxboek et al., 2003; Johnston and Martin, 2005; Loens et al., 
2003). A major disadvantage associated with serological assays, is that 
sensitivity is dependent on the precise timing of collection and therefore 
accurate diagnosis relies on the collection of serum samples at two specific 
points during the illness (McDonough et al., 2005). 
 
 
1.3.3 Molecular detection 
 
Although isolation by culture is considered the gold standard for detection, it 
has been shown to be inefficient for recovery of Ureaplasma spp. and M. 
hominis (Biernat-Sudolska et al., 2006; Pinna et al., 2006). Nelson et al. 
(1998), found that PCR was more sensitive than culture in specimens 
analysed soon after collection. If neonates acquire ureaplasmas during birth, 
the organism would be at a low concentration at day zero and increase over 
time. Thus rapid PCR assays in which early diagnoses are important can be 
of tremendous benefit in designing antibiotic treatment protocols (Nelson et 
al., 1998). Real time PCR assays have been shown to be extremely useful for 
the simultaneous detection and biovar discrimination of ureaplasmas in 
clinical specimens (Yi et al., 2005). Cao et al. (2007), have developed two 
Real–Time Taqman PCR assays for quantitative detection of U. parvum and 
U. urealyticum. The detection rate of real-time Taqman PCR was seen to be 
higher than that of culture methods and conventional PCR. 
 
Sequences of the 16S rRNA gene and the 16S rRNA – 23S rRNA intergenic 
spacer regions, genes for urease, and the 5’ ends of multiple-banded antigen 
genes have all been used in PCR-based assays to differentiate U. parvum 
from U. urealyticum (Blanchard, 1990; Cordova et al., 2000; Robertson et al., 
1993). Many of the primer targets used in a study carried out by Kong et al. 
(2000), were based on previous observations that heterogeneity of the 
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intergenic spacer regions was greater than that within the genes. Primers 
based on these regions would therefore be more discriminatory for 
identification and sub-typing of Ureaplasma spp. and include primers: UPSA – 
UUSA (16S rRNA – 23S rRNA gene spacer regions); UPS2 – UPA2 and 
UUS2 – UUA2 (UreA – UreB and UreB – UreC gene spacer regions, 
respectively) (Kong et al., 2000). Primers UU4 and UU5 have been used to 
target the urease gene for the identification of both U. parvum and U. 
urealyticum in cases of simultaneous infection (Cultrera et al., 2006). Various 
primers which target different areas in the 16S rRNA gene have been 
designed to differentiate between species of mycoplasmas (Cordova et al., 
2000). 
 
PCR is an appealing tool for the diagnosis of M. pneumoniae. However, false 
positive results, due to primer specificity or carry over contamination from 
previous PCR reactions, can occur (Murdoch, 2003; Ursi et al., 2003), while 
the presence of inhibitory substances in the clinical sample could produce 
false negative results. Most studies have used lower respiratory tract 
samples, such as sputum and bronchoalveolar lavage (BAL). A major 
limitation of lower respiratory tract samples is that they are difficult to collect 
and require invasive techniques (Murdoch, 2003). Reznikov et al. (1995) and 
Ramirez et al. (1996), found that upper respiratory tract samples such as 
throat and nasopharyngeal swabs were appropriate and the preferred sample 
type with convenient collection and fewer PCR inhibitors, while Menendez et 
al. (1999), concluded that PCR of throat swab samples had a lower sensitivity 
than serology. In contrast, Welti et al. (2003) and Murdoch (2003), suggested 
that nasopharyngeal secretions, sputum, endotracheal aspiration, BAL 
samples, pleural fluid and lung tissue were acceptable specimens for PCR, 
but the highest sensitivity and specificity was obtained with sputa and BAL. 
 
Different target sequences, within specific genes, have been used for M. 
pneumoniae PCR detection and include: P1 adhesin gene [Ramirez et al. 
(1996)] and 16S rRNA [Tjhie et al. (1994)]. The P1 adhesin gene is an 
appropriate target for PCR, because of its repetitive nature within the genome 
(Himmelreich et al., 1997). Although similar P1 adhesin genes have been 
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found in other Mycoplasma species, some of the highly conserved regions are 
unique to M. pneumoniae enabling PCR primers directed at these regions to 
be species specific (Su et al., 1987). Various PCR assays have been used for 
the detection of M. pneumoniae, such as real time PCR (Daxboek et al., 
2003), capillary PCR (Honda et al., 2000), multiplex PCR (Loens et al., 2003), 
loop-mediated isothermal amplification (Saito et al., 2005), nucleic acid 
sequence-based amplification and enzyme-linked gel assay (Loens et al., 
2003 and Ovyn et al., 1996). 
 
 
 
 
1.4 ANTIMICROBIAL SUSCEPTIBILITY TESTING 
 
There are no internationally recommended guidelines for susceptibility testing 
of human mycoplasmas and ureaplasmas as there are for other prokaryotes 
under the Clinical and Laboratory Standards Institute (previously known as 
the National Committee for Clinical and Laboratory Standards). 
 
Agar disk diffusion is not acceptable for susceptibility testing of ureaplasmas 
because of the small size of colonies and prolonged growth periods. The 
Etest agar gradient diffusion technique has been adapted to determine 
fluoroquinolone, tetracycline and macrolide susceptibilities of Ureaplasma 
spp. but Etests are not widely used due to restrictions associated with agar 
plate culture of ureaplasmas (Dosa et al., 1999; Waites et al., 1999; Ngan et 
al., 2004). 
 
The Mycoplasma Chemotherapy Working Team of the International 
Organisation for Mycoplasmology (IOM) is working on a guideline 
susceptibility testing document. Standard microbroth dilution methods using 
microtitre plates are currently being used for susceptibility testing of 
mycoplasmas and ureaplasmas (Duffy et al., 2000; Duffy and Waites, 2008). 
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Commercially produced broth media [U9 (Ureaplasma spp.) and arginine (M. 
hominis)] and susceptibility testing kits are available. Susceptibility testing kits 
include: SIR Mycoplasma kit (Bio-Rad) and the Mycoplasma IST 2 kit 
(bioMerieux). Both kits comprise microwells containing different 
concentrations of an antibiotic. Antibiotics used for resistance profiling in the 
SIR kit include: doxycycline (4 µg/ml and 8 µg/ml), tetracycline (4 µg/ml and 8 
µg/ml), azithromycin (2 µg/ml and 4 µg/ml), josamycin (2 µg/ml and 8 µg/ml), 
erythromycin (1 µg/ml and 4 µg/ml), ofloxacin (1 µg/ml and 4 µg/ml), 
clindamycin (2 µg/ml) and pristinamycin (8 µg/ml). If 
mycoplasmas/ureaplasmas inoculated into the antibiotic containing wells are 
susceptible to an antibiotic present, growth will be inhibited and the broth will 
remain yellow. M. hominis is intrinsically-resistant to erythromycin and 
azithromycin, Ureaplasma spp. are intrinsically-resistant to clindamycin while 
josamycin is active against both M. hominis and ureaplasmas. Tetracycline 
and doxycycline are also assessed as there have been reports of low-level 
resistance, although frequency/rate of resistance tends to vary according to 
country and levels of antibiotic exposure. Ofloxacin is reported to be active 
against M. hominis and ureaplasmas but resistance frequencies to date are 
not well known (SIR kit manual; Bio-Rad). The SIR kit has been validated by 
laboratories in France and used in preliminary antibiotic resistance screening 
tests (Bebear et al., 2003; Degrange et al., 2008). 
 
The Mycoplasma IST 2 kit is similar to the SIR kit, however, MycoIST2 uses 
different antibiotics with clarithromycin and ciprofloxacin at concentrations 1 
and 4 µg/ml, and 1 and 2 µg/ml respectively, while azithromycin 
concentrations are 0.12 and 4 µg/ml. There have been contrasting reports 
concerning antibiotic resistance profiles when using the MycoIST2 kit 
(Smayevsky et al., 1995; Kenny and Cartwright, 2001) and false positive 
results have been obtained (Biernat-Sudolska et al., 2006). 
 
Antibiotic susceptibility testing for M. pneumoniae is not routinely performed 
as resistant isolates are considered rare and results are only available after a 
prolonged period due to the fastidious nature of M. pneumoniae (Bebear, 
2008). 
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Minimum inhibitory concentration (MIC) ranges for various antimicrobials 
against Mycoplasma spp. and Ureaplasma spp. have been reported (Table 
1.1) (Bebear and Kempf, 2005). 
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Table 1.1: MIC ranges (µg/ml) for various antimicrobials against Mycoplasma spp. and  
Ureaplasma spp. (Bebear and Kempf, 2005). 
 
 
b: Susceptible strains    
#: Bebear et al. (2008) reported ofloxacin MIC range to be 0.5-8 µg/ml for Ureaplasma spp;  
 
 
 
 # 
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1.5 ANTIMICROBIAL DRUG RESISTANCE 
 
Resistance to an antibiotic can originate in different ways: (i) resistance due to 
natural genetic makeup, resulting in all bacteria belonging to that species 
being resistant (intrinsic resistance); (ii) resistance developed by mutation(s) 
in an antimicrobial target region and (iii) resistant gene/gene regions acquired 
from another microorganism, in cases ii and iii resistance is limited to a 
particular isolate/clone. Genital mycoplasmas and ureaplasmas are 
intrinsically resistant to certain members of the MLSK-group as described in 
section 1.2. Target alterations associated with quinolone and macrolide 
resistance development, and transposon located tetM genes have been 
described in mycoplasmas and ureaplasmas (Bebear and Kempf, 2005). 
 
Fluoroquinolones act by inhibiting DNA replicating enzymes, gyrase and 
topoisomerase IV. Mutations in the quinolone resistance determining regions 
(QRDR’s) of genes encoding gyrase subunits (gyrA and gyrB), and 
topoisomerase IV genes (parC and parE) have been correlated with quinolone 
MICs to determine which mutations/amino acid substitutions contribute to 
resistance development in ureaplasmas (Bebear et al., 1997; Bebear et al., 
1999; Bebear et al., 2003).  
 
Until 2006, mutations resulting in amino acid substitutions at Ser83Leu and 
Asp87Lys in ParC and a triple substitution of Asp112Glu in GyrA protein along 
with Ala125Thr and Ala136Thr in ParC had all been suggested to be 
associated with fluoroquinolone resistance development in Ureaplasma spp. 
(Bebear et al., 2000; Zhang et al., 2002; Bebear et al., 2003). However, 
recently Beeton et al. (2009a), attributed the triple mutations to species-
specific polymorphisms found in all Ureaplasma serovars and therefore not 
considered to be associated with a resistance phenotype. 
 
GyrA, gyrB, parC and parE mutations in 13 fluoroquinolone-resistant clinical 
isolates of U. parvum from two research groups were compared by Duffy et al. 
(2006), the most frequently observed amino acid replacements were 
Asp112Glu in GyrA and Ser83Leu in ParC which was seen in tandem for 
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twelve isolates. An American isolate exhibiting an ofloxacin MIC of 128 µg/ml 
was found to contain the Ser83Leu substitution in ParC but the only GyrA 
mutation noted was Gln103Lys (Duffy et al., 2006). Beeton et al. (2009a), on 
conducting a similar comparative study to Duffy et al. (2006), that now 
incorporated reports from six groups and comprised 32 resistant isolates, 
drew attention only to the Ser83Leu substitution in ParC which was found in 
19/32 isolates. On adding a study isolate with a ciprofloxacin MIC 8 µg/ml 
which had a single ParC substitution Asp82Asn Beeton et al. (2009a), 
concluded that only mutations within an 8-amino acid region of the most 
common ParC substitution Ser83Leu should be considered to be associated 
with quinolone resistance. 
 
The active efflux of fluoroquinolones is mediated by endogenous multidrug 
resistance (MDR) efflux pumps, increased expression of which can develop a 
MDR resistance phenotype. Raherison et al. (2002), reported an active efflux 
system, in ethidium bromide selected strains of M. hominis that exhibited a 
MDR resistance phenotype with increased MICs to ciprofloxacin. Two genes 
(md1 and md2) coding for putative multidrug resistance ABC transporters 
were identified and that the resistant strains exhibited higher expression levels 
of proteins involved in the membrane pump. To-date resistance to 
fluoroquinolones has been reported among human genital Mycoplasma and 
Ureaplasma species (Bebear and Kempf, 2005; Duffy et al., 2006; Xie and 
Zhang, 2006). Characterisation of in vitro-selected mutants of U. parvum that 
were resistant to macrolides revealed no significant difference in MICs, with or 
without reserpine indicating the absence of a putative efflux mechanism 
(Pereye et al., 2007a). 
 
The methyltransferase enzyme (Erm family) or enzymes modifying macrolides 
have not been identified in mycoplasmas/ureaplasmas (Bebear and Kempf, 
2005). Strains exhibiting low, but elevated levels (i.e. greater than reported 
susceptibility MICs yet lower than resistant MICs) of macrolide resistance 
have been found not to contain mutations in the 23S rRNA encoding operon 
or L22 and L4 proteins. Erythromycin and clarithromycin resistance in 
Ureaplasma spp. has recently been found to include novel point mutations in 
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the L4 protein, attributed to a six base pair deletion corresponding to two 
deleted amino acids arginine and glutamine at residue numbers 66 and 67 
(Beeton et al., 2009b). It has also been suggested that transition mutations in 
23S rRNA could account for macrolide resistance development in U. 
urealyticum (Pereyre et al., 2007a; Dongya et al., 2008). Macrolide and 
ketolide resistance is thought to be predominantly centred in domain V of 23S 
rRNA, involving specific G2056U, G2057U and A2058G transition mutations 
(Pereyre et al., 2007a). A 23S rRNA operon investigation on roxithromycin 
and azithromycin resistance found a C2243N transition mutation appeared to 
facilitate resistance to both macrolides, with A2149C and A2181T mutations 
associated with roxithromycin resistance only (Dongya et al., 2008). Pereyre 
et al. (2007a and 2007b), have also proposed that several mutations on both 
rRNA subunits and ribosome protein components are prerequisites for full 
expression of high-level macrolide resistance. The increasing prevalence of 
macrolide-resistant strains of M. pneumoniae has become a significant clinical 
issue in paediatric patients (Matsubara et al., 2009) and has been associated 
with prolonged severe respiratory infection in children (Li et al., 2009). 
 
Concerning acquisition of resistance genes/gene regions from other bacteria, 
only cryptic plasmids have been found in Mollicutes of which none have been 
described in species that colonise/infect humans (Bebear and Kempf, 2005). 
The extent to which tetracycline resistance occurs in genital mycoplasmas/ 
ureaplasmas varies geographically and according to prior antimicrobial 
exposure. The tetM gene has been found in the Tn916-Tn1545 family of 
conjugative transposons in both Streptococcus spp. (Su et al., 1992) and in 
M. hominis (Bebear and Kempf, 2005). The mechanism by which the TetM 
protein functions is to cover a ribosomal site that would otherwise enable 
tetracycline to bind and prevent translation. The tetM gene has DNA regions 
homologous to those of elongation factors EF-G and EF-Tu and thus the TetM 
protein protects the ribosome and allows for the continuation of translation to 
occur (Bebear and Kempf, 2005).  
 
Tetracycline resistance in clinical isolates of Ureaplasma spp. and M. hominis 
have been reported in Singapore (Ngan et al., 2004), France (Degrange et al., 
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2008) and United Kingdom (Beeton et al., 2009b). Tetracycline-resistant 
strains that are concurrently resistant to doxycycline have been described 
(Blanchard et al., 1992 and Beeton et al., 2009b). Such strains could influence 
the prevalence of mycoplasmas/ureaplasmas in countries that include 
doxycycline in sexually transmitted infection syndromic management 
regimens. 
 
 
 
1.6 POTENTIAL FOR INTERGENERIC TRANSFER OF ANTIBIOTIC 
 RESISTANCE GENES 
 
As natural exchange of chromosomal DNA between cells of mycoplasmas 
has only been proposed by Teachman et al., (2002), it is thought that 
mycoplasmas/ ureaplasmas probably do not acquire DNA by conventional 
transformation processes. The lack of a cell wall in mycoplasmas/ 
ureaplasmas would be expected to facilitate the introduction of exogenous 
DNA into the cells that may well involve transient fusion of the cell 
membranes at the zone of contact (Razin et al., 1998). The very small 
genomes of mycoplasmas/ureaplasmas lack a substantial part of standard 
recombination mechanisms available in larger bacterial genomes, however, 
they do contain large numbers of repeat DNA sequences considered vital for 
adaptation and chronic colonisation of their hosts (Rocha et al., 2005). 
 
Although mycoplasmal phages are known to exist, transduction has not been 
described. Several mycoplasmas have been shown to acquire the conjugative 
transposon Tn916 by mating with an enterococcal donor, but conjugal transfer 
of any genetic element including Tn916 from a mycoplasmal donor has not 
been described. Circumstantial evidence suggests that horizontal gene 
exchange has occurred between species of Mycoplasma with the IS1221 
insertion sequence having been found in M. hyorhinis, M. hyopneumoniae 
and M. flocculare (Teachman et al., 2002). 
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The possibility of exchange of DNA between mycoplasmas and other 
pathogenic infectious agents within the urogenital tract, such as Neisseria 
gonorrhoeae may contribute to gene transfer, which may promote antibiotic 
resistance in such pathogens. 
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1.7 SCOPE AND OBJECTIVES 
 
The molecular basis of Mycoplasma and Ureaplasma pathogenicity remains 
largely elusive. Due to conflicting reports from around the world concerning 
the pathogenic nature of mycoplasmas and ureaplasmas, it is important to 
clarify the situation as it pertains to South Africa where there are high 
incidences of sexually transmitted diseases and HIV. Resistance to 
quinolones, tetracyclines and macrolides have been reported in mycoplasmas 
and ureaplasmas, however, ongoing surveillance of antibiotic resistance 
development and potential consequences is lacking in South Africa. 
 
Objectives: 
 
1. To validate both conventional culture and molecular methods 
used for the detection of Mycoplasma spp. and Ureaplasma spp. 
from clinical specimens. 
2. To investigate the prevalence of genital mycoplasmas, 
ureaplasmas and Chlamydia on women attending their first 
prenatal visit, in conjunction with preterm labour or HIV status. 
3. To determine the prevalence of community-acquired atypical 
pneumonias in adults (M. pneumoniae and P. jiroveci) and 
neonates (mycoplasmas, ureaplasmas and C. trachomatis). 
4. To determine antibiotic susceptibility profiles of clinical isolates of 
U. parvum and U. urealyticum, and detect target gene 
mutations/acquisitions responsible for resistance development. 
5. To investigate, as tetracycline resistance genes (tetM) are 
transposon located, inter-generic resistance gene transfer 
potential to N. gonorrhoeae. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
2.1 GENITAL SETTING: PATIENTS AND ENDOCERVICAL SPECIMENS 
 
Consenting pregnant women participated in these studies for which ethics 
approval was obtained from the Committee for Human Research, 
Stellenbosch University, [Reference numbers: 2001/C067 (2003 study) and 
N04/02/038 (2005 study)]. 
 
Extended mycoplasma and ureaplasma prevalence studies (2003 and 2005); 
2003: Specimens were collected from the first 199 women attending the 
Bishop Lavis Midwife Obstetric Unit in 2003 (Odendaal et al., 2006). Preterm 
delivery was defined for women delivering before 37 weeks gestation. The 
HIV status of the women was not obtained. 
2005: For the Mycoplasma spp., Ureaplasma spp., Chlamydia trachomatis 
and HIV, co-infection/co-colonisation study; 219 women attending the 
Obstetrics Unit, Tygerberg Hospital were screened in 2005. The HIV Abbott 
Determine® HIV-1/2 rapid test was used and positive tests at the Obstetrics 
Unit were confirmed by ELISA performed at the Virology Laboratory at the 
Faculty of Health Sciences. The HIV results were recorded anonymously to 
laboratory reference numbers. 
 
For the ureaplasma antibiotic resistance study, 191 women attending the 
Obstetrics Unit, Tygerberg Hospital were screened in 2006. 
 
All specimens were taken by nurses, independently to those for diagnostic 
investigations. Specimens were endocervical swabs (Dacron) that were 
transferred onto Microbank beads (Davies Diagnostics) by swabs being 
expressed into broth in Microbank tubes and stored at -80oC within 30 min of 
specimen collection. 
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2.2 RESPIRATORY SETTING: PATIENTS AND SPECIMENS 
 
Approval to conduct the study was obtained from the Human Ethics 
Committee, Nelson Mandela Metropolitan University (Reference number: 
H06SB005). 
 
2.2.1 Adult pneumonia 
 
Consenting adult patients (102) with pneumonia, or symptoms of pneumonia, 
admitted to the general ward of Dora Nginza (101 specimens collected) and 
Livingstone Hospitals (one specimen collected) during the period 2006 – 
2008, participated in the study. X-Rays, HIV status, sputum and blood 
samples for culture requested by doctors, were forwarded to the National 
Health Laboratory Services (NHLS), Port Elizabeth. National 
recommendations for diagnosis of M. tuberculosis were conducted: two sputa 
samples were sent for Ziehl-Neelsen-microscopy, if one was positive for acid 
fast bacilli, then X-rays were performed; if the two samples were negative, 
then a third sputum sample was taken. HIV status was determined employing 
ELISA tests performed at NHLS, Port Elizabeth. HIV status and routine 
microbiological data recorded in patients’ files was extracted by Dr GS Ocana. 
Sputum samples independently collected for study purposes were 
immediately stored at -80oC. Adult samples were collected whenever doctors 
suspected that adult patients might have pneumocystis pneumonia.  
 
2.2.2 Neonatal pneumonia 
 
Following parent consent, neonates (age < 1 month) with respiratory problems 
admitted to Dora Nginza Hospital Neonatal Intensive Care Unit (NICU), were 
included in the study, duration 2007 to 2008. Sixty-nine endotracheal aspirate 
specimens were collected by the neonatal ICU nurse and immediately stored 
at -80ºC. Neonate samples were collected whenever paediatricians at the 
NICU suspected that neonates had atypical pneumonia. 
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2.3 CULTURE: CONVENTIONAL MEDIA 
 
American Type Culture Collection (ATCC) strains that were purchased and 
used for media quality control were: M. hominis (ATCC 14027), U. urealyticum 
(ATCC 27618), U. parvum (ATCC 27815) and M. penetrans (ATCC 55252) 
and M. pneumoniae (ATCC 29343). 
 
Efforts were made to isolate and culture Mycoplasma sp. and Ureaplasma sp. 
from both endocervical swabs and sputa. Approximately 100 μl of 
endocervical swab specimen (and two microbank beads) were inoculated into 
media as specified by the ATCC for each of the micro-organisms as described 
below. Broths/cultures were incubated at 37oC, ATCC controls for 3 days and 
clinical samples to 10 days under aerobic conditions. A8 plates both 
commercially available (bioMerieux) and made onsite at NMMU according to 
the method described by Duffy and Waites, (2008), (IOM Workshop, China) 
were also used for the culture of M. hominis, U. parvum and U. urealyticum 
with incubation at 37oC in a candle extinction jar for 7 - 10 days. The media 
used for each species is described in more detail below. 
 
2.3.1 M. hominis 
#243 ATCC broth medium: Basal medium [17.5 g heart infusion broth, 700 ml 
distilled water] was autoclaved followed by aseptic addition of filter sterilised 
solutions [200 ml horse serum (heat inactivated), 100 ml yeast extract solution 
and 1000 U/ml benzyl penicillin]. 
 
2.3.2 U. urealyticum 
#1331 ATCC broth medium: Basal medium [14.7 g PPLO broth, 700 ml 
distilled water] pH 6 adjustment with HCl was autoclaved followed by aseptic 
addition of filter sterilised solutions [200 ml horse serum, 100 ml yeast extract 
solution, 0.1 g L-cysteine HCL, 0.5 g urea, 5 ml Isovitalex enrichment, 10 mg 
phenol red and 1000 U/ml benzyl penicillin]. 
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2.3.3 U. parvum 
#2616 ATCC broth medium: Basal medium [3.5 g PPLO broth, 10 g 
pancreatic digest of casein (tryptone), 5 g pancreatic digest of gelatine 
(peptone), 500 ml distilled water] was autoclaved followed by aseptic addition 
of filter sterilised solutions [50 ml 10X CMRL-1066 medium, 35 ml yeast 
extract solution, 20 ml yeastolate [10% (w/v)], 170 ml foetal bovine serum, 20 
ml of 0.1% phenol red solution, 1 g urea, 205 ml distilled water]. 
 
2.3.4 M. penetrans 
#988 ATCC (Spiroplasma) broth medium: Basal medium [5.5 g PPLO broth, 5 
g tryptone, 2.5 g glucose, 307.5 ml distilled water] was autoclaved followed by 
aseptic addition of filter sterilised solutions [25 ml 10X CMRL-1066 medium, 
17.5 ml yeast extract solution, 50 ml 2% (w/v) yeastolate, 85 ml foetal bovine 
serum, 10 ml 0.1% (w/v) phenol red solution and 1000 U/ml benzyl penicillin]. 
 
2.3.5 M. pneumoniae 
#988 ATCC (Spiroplasma) broth medium (Section 2.3.4). 
Culture: Approximately 100 μl of the sputa specimens were inoculated into 
#988 ATCC (Spiroplasma) broth. Upon a colour change from red to yellow, 
sub-cultures were made directly onto #988 ATCC Spiroplasma agar (medium 
composition as broth with the addition of 10 g/l of agar) (Matsuoka et al., 
2004) and Modified New York City agar plates (whole blood component 
replaced with horse serum) manufactured by NHLS Port Elizabeth (Granato et 
al., 1983). Inoculated broth tubes were incubated at 37oC for 10 – 30 days 
under aerobic conditions, while agar plates were incubated at 37oC in a 
candle extinction jar for 7 - 30 days. 
 
 
2.4 CULTURE: COMMERCIAL KITS 
 
For detection of M. hominis and Ureaplasma sp., the Mycoview (Ivagen), 
Mycoplasma IST2 (bioMerieux) and Mycoplasma Duo kits (Bio-Rad) were 
used and for M. pneumoniae the Pneumofast kit (International Microbio, 
Signes, France, Progen-SA). 
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2.4.1 MycoView kit (Ivagen) 
 
The MycoView test kit was used for the identification and differential titration 
of U. urealyticum and M. hominis and antibiotic susceptibility profiles to nine 
antimicrobial agents. The principle of the test is based on specific metabolic 
properties and natural resistance: U. urealyticum (hydrolysis of urea and 
resistance to lincomycin); M. hominis (hydrolysis of arginine and resistance to 
erythromycin). Growth was indicated by a change in colour of pH indicator 
from yellow-orange to red or pink. The MycoView kit comprises the following: 
transport broth (2 ml), culture medium (freeze dried medium), MycoView strip 
(2 strips of 12 test-wells, sealed in an aluminium pouch, with desiccant), 
incubation rack for 4 strips, with a lid and paraffin. The format of the 
MycoView strip is shown in Fig. 2.1. 
Approximately 100 μl of endocervical swab specimen with two microbank 
beads were inoculated into a vial of transport broth. A vial of culture medium 
was regenerated with one inoculated transport broth. The regenerated 
medium which contained the inoculum was gently mixed 4 to 5 times with a 
pipette before inoculating the MycoView strip. Twelve wells of the strip were 
inoculated with 100 µl of culture followed by one drop of paraffin to each well. 
The wells were sealed with film, placed in the rack with the lid closed and 
incubated at 37oC for 48-72 h. All wells were expected to be limpid as a turbid 
appearance was indicative of bacterial or yeast contamination. Urogenital 
mycoplasmal/ureaplasmal growth was confirmed by a change in colour of the 
medium from yellow to red/pink. 
 
 
Figure 2.1: MycoView strip format (Ivagen kit manual). 
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2.4.2 Mycoplasma IST2 (bioMerieux) 
 
The Mycoplasma IST2 kit combines a selective culture broth with a strip 
containing 22 tests. A positive test is indicated by a change of broth colour 
from yellow to red as a result of the phenol red indicator in the broth (urea for 
U. urealyticum and arginine for M. hominis). The combination of three 
antibiotics and one antifungal agent provides selectivity, ensuring that any 
contaminating flora present in the specimen does not affect the test. The kit 
comprises the following: reagent R1 (3 ml broth); reagent R2 (1 ml lyophilised 
urea-arginine broth), mineral oil and strips that contained 22 tests. Strips are 
divided into 3 sections: identification (cupules no. 1-3); indicative enumeration 
(cupules no. 4 and 5); susceptibility tests (cupules no. 6-22) (Fig. 2.2). 
Approximately 100 μl of endocervical swab specimen (and two microbank 
beads) were inoculated into R1 solution which was combined with a vial of R2 
and vortexed until the lyophilised pellet was completely dissolved. Of the 
combined R1/ R2 solution 55 μl was dispensed into each of the 22 test 
cupules on the strip followed by addition of 2 drops of mineral oil to each 
cupule and lid placed over the strip. Strips were incubated at 37oC for 24-48 h. 
 
(A) 
(B) 
(C) 
Figure 2.2: Composition of MycoIST2 strips. (A) Identification (cupules no. 1-3). (B) 
Indicative enumeration (cupules no. 4 and 5). (C) Susceptibility tests (cupules 
no. 6-22) 
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2.4.3 Mycoplasma Duo kits (Bio-Rad) 
 
The Mycoplasma Duo kit was used for the identification of U. urealyticum and 
M. hominis based on hydrolysis of urea and arginine respectively where a 
change in colour from yellow to red was a positive test. The Kit comprises 
twenty microplates: Each microplate has 6 microwells which contains 
dehydrated substrates for identification, Mycoplasma growth factors, with 
agents to inhibit the growth of concomitant polymorphic flora (Fig. 2.3); 2 ml 
vials of suspension medium, 15 ml diluent, plastic micropipettes, adhesive 
sheets. Approximately 100 μl of endocervical swab specimen and two 
microbank beads were inoculated into suspension medium. Diluent (200 μl) 
was transferred to each of the three wells of the lower row of the microplate: 
U≥104, D, and H≥104. A micropipette was then used to transfer 200 μl of 
specimen containing suspension medium into each of the 3 wells of the upper 
row of the microplate: U, X, H and 25 μl was added to well D. Using a different 
pipette contents of well D were mixed and 25 μl transferred to well U≥104 and 
25 μl transferred H≥104. The microplate was covered with an adhesive sheet 
and incubated at 37oC for 24 - 48 h. 
 
 
Figure 2.3: Presentation of Mycoplasma Duo microplate. U and U≥104: identification and 
titration of UU (containing urea). H and H≥104: identification and titration of 
MH (containing arginine). D: dilution well. X: selective mycoplasma 
enrichment: preparation of standardised inoculum for antibiotic susceptibility 
testing. 
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2.4.4 Pneumofast Kit (International Microbio, Signes, France, 
Progen-SA) 
 
The Pneumofast kit was used for isolation, identification, enumeration and 
antibiotic resistance testing of M. pneumoniae from clinical specimens. The kit 
comprises: M. pneumoniae base (MP base), M. pneumoniae supplement (MP 
supplement), M. pneumoniae agar (MP agar) and Pneumofast trays. MP 
supplement was regenerated by the addition of 1.5 ml of MP base to the MP 
supplement vial. MP agar vials were liquefied in a boiling water bath and 
allowed to cool to 55oC, and 1 ml of the regenerated MP supplement was 
introduced into the agar base and poured into a 55 mm petri dish and allowed 
to solidify. The remaining MP base was then added to the remaining MP 
supplement forming the Pneumofast broth. Two hundred microlitres of each 
sputa sample and the different dilutions of the ATCC culture, ATCC 29343 (7, 
11 and 12.5 times dilutions) were added to Pneumofast broth, and 100 μl of 
the mixture was added to each well of the Pneumofast tray, which was then 
covered with two drops of paraffin oil. Each tray was sealed within a sterile 
petri dish and incubated anaerobically at 37oC. Three drops of each of the 
biological samples were placed randomly onto an agar plate. The agar plates 
were incubated at 37oC within a candle extinction jar. The Pneumofast trays 
and agar plates were monitored daily for approximately 12 to 30 days. 
Samples resistant to ampicillin (40 µg/ml), sulfa-trimethoprim (4 µg/ml), and 
lincomycin (1 µg/ml) but were inhibited by erythromycin (8 µg/ml) were 
positively identified as M. pneumoniae. 
 
 
2.5 CULTURE: ARGININE AND U9 BROTHS (BIO-RAD) 
 
Commercially made media; U9 and arginine broths were also used to culture 
M. hominis and Ureaplasma spp. Sterile distilled water (2 ml) was added to 
each ampoule to reconstitute the lyophilised broths (U9 or arginine). The 
reconstituted broths were transferred to sterile eppendorfs and used 
immediately. To six wells of a microtitre plate row, 180 µl of U9 broth or 
arginine broth was transferred. Endocervical specimens (20 µl) were then 
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transferred to the first well of each broth row (U9 and arginine). The contents 
of the first well were mixed with a pipette and 20 µl from the first well was 
transferred into the second well and serial 10-1 dilutions conducted. The 
microtiter plates were then sealed with aluminium sealing tape and incubated 
at 37oC for 24 to 96 h. A colour change in the wells from yellow to red-pink 
indicated the presence of M. hominis (arginine broth) and U. urealyticum (U9 
broth). 
 
 
2.6 DNA EXTRACTION: PCR DETECTION OF MYCOPLASMA SPP. 
AND UREAPLASMA SPP. 
 
2.6.1 Endocervical specimens 
DNA was extracted from 200 μl of endocervical swab specimens (microbank 
bead broth) employing the High Pure PCR Template Preparation Kit (Roche) 
as for the isolation of nucleic acids from whole blood, buffy coat, or cultured 
cells as described by the manufacturer. For ATCC control cultures and 
cultures used in Chapter six (detection of antibiotic resistance genes), 200 μl 
of broth culture was centrifuged at 3000 xg for 5 min, and the resulting pellet 
re-suspended in 200 μl PBS with DNA extracted using the Roche High Pure 
PCR Template as for the isolation of nucleic acids from bacteria. 
 
2.6.2 Sputa specimens 
2.6.2.1 P. jiroveci 
For P. jiroveci approximately 200 μl of sputa was treated with an equal volume 
of 0.1 M 1,4-dithiothreitol, (Roche), vortexed and incubated at 37oC for 30 
min, until liquefied. The suspension was centrifuged at 3000 xg for 15 min and 
the pellet re-suspended in 500 μl sterile deionised water. P. jiroveci control 
DNA that had been extracted from paraffin embedded lung histological 
sections confirmed as PcP positive by methanamine silver staining and PCR 
mitochondrial large subunit ribosomal RNA (mtLSUrRNA), dihydropteroate 
synthase (DHPS), dihydrofolate reductase (DHFR) genes, were kindly 
supplied by FJL Robberts et al. (2007). 
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2.6.2.2 M. pneumoniae 
Approximately 200 μl, of the sputa specimens, were liquefied with an equal 
volume of 3% N-acetyl cysteine, (NALC, Merck) and incubated at 37oC for 15 
to 30 min (Ursi et al., 2003; Qasem et al., 2002) followed by an additional 10 
min at 65oC, then 15 min incubation at 100oC to ensure that any tubercle 
bacilli or other respiratory pathogens present had been inactivated prior to 
DNA extraction (Pitcher et al., 2006). DNA was extracted from 200 μl of each 
pre-treated respiratory specimen using the Roche High Pure PCR Template 
Preparation Kit as for the isolation of nucleic acids from whole blood, buffy 
coat, or cultured cells as described by the manufacturer. For ATCC control 
cultures, 200 μl of broth culture sample was centrifuged at 3000 xg for 5 min, 
and the resulting pellet re-suspended in 200 μl PBS with DNA extracted using 
the Roche High Pure PCR Template as for the isolation of nucleic acids from 
bacteria. 
 
2.6.3 Endotracheal aspirates (neonates) 
The endotracheal aspirate tube was flushed with sterile PBS and 200 μl of the 
endotracheal aspirate suspension liquefied with an equal amount of 3% (w/v) 
N-acetyl Cysteine (NALC, Merck) and treated as described above for M. 
pneumoniae in section 2.7.2.2. 
 
 
2.7 PCR DETECTION 
 
2.7.1 Mycoplasma detection kit (Takara) 
PCR detection of M. hominis, M. fermentans and Ureaplasma spp. was 
performed using a Mycoplasma PCR detection kit (Takara Bio Inc., Japan). 
Primers (F1 and R1): amplification of 16S-23S rRNA spacer region, products; 
370 bp fragment M. hominis, 482 bp fragment Ureaplasma spp. and 491 bp 
fragment M. fermentans. Designed nested primers F2 and R2: target highly 
conserved spacer region and 23S gene, products; 148 bp fragment M. 
hominis, 154 bp fragment Ureaplasma spp. and 195 bp fragment M. 
fermentans. Amplification was performed in a total volume of 50 µl. The 
reaction mixture for the first PCR comprised: 5 µl 10x PCR buffer, 4 µl 
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deoxynucleotide triphosphate mixture [2.5 mM of each dNTP (Takara)], 0.5 µl 
of each primer (20 pmol/µl), 1.25 units of Taq DNA polymerase (Takara 
TaqTM) and 3 µl of template DNA. The reaction mixture for the second PCR 
reaction comprised: 5 µl 10x PCR buffer, 4 µl deoxynucleotide triphosphate 
mixture [2.5 mM of each dNTP (Takara)], 0.5 µl of each primer (20 pmol/µl), 
1.25 units of Taq DNA polymerase (Takara TaqTM) and 1 µl of the first PCR 
reaction product. Amplification was performed in an iCycler PCR machine 
(Bio-Rad). Amplification: First reaction, 1 cycle at 94oC for 30 sec; 35 cycles 
denaturation 94oC for 30 sec, annealing 55oC for 2 min and elongation 72oC 
for 1 min, followed by a final elongation step at 72oC for 5 min. Second 
reaction, 30 cycles: denaturation 94oC for 30 sec, annealing 55oC for 2 min 
and elongation 72oC for 1 min, followed by a final elongation step at 72oC for 
5 min. The amplification products of the first PCR reaction were separated on 
3% (w/v) agarose gels for 1 h at 100 V in Tris-acetate EDTA buffer (40 mM 
Tris base, 5 mM sodium acetate, 1 mM EDTA, pH 8) and amplified products 
of the second PCR reaction were separated on 4% (w/v) agarose gels for 75 
min at 100 V. Ethidium bromide stained DNA products were visualised by UV 
transillumination and images captured using an Alpha ImagerTM3400 gel 
system (Alpha Innotech). A 100 bp DNA ladder (Promega) was included in 
each gel run. 
 
2.7.2 Specific primers and conditions 
All PCR reactions included positive and negative controls. Control DNA was 
extracted from: M. hominis (ATCC 14027), M. penetrans (ATCC 55252), M. 
genitalium (ATCC 33530), U. parvum (ATCC 27815) (for prevalence and 
antibiotic resistance), U. urealyticum (ATCC 27618) (for prevalence and 
antibiotic resistance), C. trachomatis (ATCC VR-887), M. pneumoniae (ATCC 
29343), and for P. jiroveci DNA was extracted from confirmed histological 
specimens (Section 2.7.2.1). All PCRs from which fragments of expected size 
were produced, were repeated for confirmation. 
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2.7.2.1   M. hominis,   M. penetrans   M. genitalium,   U. parvum,    
   U. urealyticum, C. trachomatis, P. jiroveci 
 
Specific PCR primers and conditions employed for the detection of M. 
hominis, M. penetrans, M. genitalium, U. parvum, U. urealyticum, C. 
trachomatis, P. jiroveci are given in Table 2.1. 
 
35 
 
Table 2.1: PCR primers employed in the detection of Mycoplasma spp., Ureaplasma spp., C. trachomatis and P. jiroveci. 
 
Organism 
 
Primer (F) 
             (R) 
 
Sequence (5’ - 3’) 
Size of amplified 
product (bp) 
 
Target gene 
 
Reference 
M. hominis HOM+ 
UNI- 
TGAAAGGCGCTGTAAGGCGC 
TAATCCTGTTTGCTCCCCAC  
 
589  16S rRNA Dussurget et al. (1994) 
Cordova et al. (2000) 
M. penetrans MYCPENETP 
MYCPENETN 
CATGCAAGTCGGACGAAGCA 
AGCATTTCCTCTTCTTACAA 
 
410  16s rRNA Grau et al. (1994) 
Cordova et al. (2000) 
M. genitalium MgPa-1 
MgPa-3 
AGTTGATGAAACCTTAACCCCTTGG 
CCGTTGAGGGGTTTTCCATTTTTGC 
 
281  Adhesin gene Jensen et al. (1991) 
Cordova et al. (2000) 
U. parvum UPS2c 
UPA2c 
CAGGATCATCAAGTCAATTTAG 
AACATAATGTTCCCCTTTTTATC 
420 UreA - UreB gene 
spacer region  
 
Biernat-Sudolska et al. (2006) 
Kong et al. (2000) 
U. urealyticum UUS2c 
UUA2c 
CAGGATCATCAAATCAATTCAC 
CATAATGTTCCCCTTCGTCTA 
420  UreB – UreC gene 
spacer region 
Biernat-Sudolska et al. (2006) 
Kong et al. (2000) 
C. trachomatis T1 
T2 
GGACAAATCGTATCTCGG 
GAAACCAACTCTACGCTG 
 
517  cryptic plasmid Class et al. (1991) 
M. pneumoniae F1 
R1 
CCGCGAAGAGCAATGAAAAACTCC 
TCGAGGCGGATCATTTGGGGAGGT 
375 P1 adhesin Ramirez et al. (1996) 
16SrRNA F 
16SrRNA R 
AAGGACCTGCAAGGGTTCGT 
CTCTAGCCATTACCTGCTAA 
 
277 16SrRNA Nadal et al. (2001) 
P.jiroveci 
(Nested PCR) 
pAZ102-E 
pAZ102-H 
GATGGCTGTTTCCAAGCCCA 
GTGTACGTTGCAAAGTACTC 
346 mtLSUrRNA Wakefield et al. (1996) 
 
pAZ102-X 
pAZ102-Y 
GTGAAATACAAATCGGACTAGG 
TCACTTAATATTAATTGGGGAGC 
260 
 F1  
B45 
CCTGGTATTAAACCAGTTTTGCC 
CAATTTAATAAATTTCTTTCCAAATAGCATC 
 
300 
DHPS Lane et al. (1997) 
 AHUM  
BN 
GCGCCTACACATATTATGGCCATTTTAAATC 
GGAACTTTCAACTTGGCAACCAC 
  
 FR280  
FR1038 
GCAGAAAGTAGGTACATTATTACGAGA 
AACCAGTTACCTAATCAAACTATATTGC 
 
798 
DHFR Ma et al. (1999) 
 FR242  
FR1018 
GTTTGGAATAGATTATGTTCATGGTGTACG 
GCTTCAAACCTTGTGTAACGCG 
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For U. parvum and U. urealyticum reaction mix (25 µl) comprised: 1X GoTaq 
Green master mix (Promega), 0.5 µM of each primer and 2 µl of template 
DNA. Amplification comprised: an initial step of 95oC for 5 min, followed by 40 
cycles: 92oC for 1.5 min, 55oC for 2 min, 72oC for 1.5 min and final extension 
of 72oC for 8 min (Biernat-Sudolska et al., 2006; Kong et al., 2000). For M. 
hominis, M. genitalium and M. penetrans: reaction mix (25 µl) comprised 1X 
GoTaq Green master mix (Promega), 0.5 µM of each primer specific to the 
relevant microoganism and 2 µl of template DNA. Amplification comprised: an 
initial step of 95oC for 5 min, followed by 30 cycles: 95oC for 30 sec, 58oC for 
1.5 min, 72oC for 1.5 min and final extension of 72oC for 8 min (Cordova et al., 
2000). For C. trachomatis: reaction mix (25 µl) comprised: 1X GoTaq Green 
master mix (Promega), 0.5 µM of each primer and 2 µl of template DNA. 
Amplification consisted of an initial step of 94oC for 2 min, followed by 40 
cycles: 94oC for 1 min, 42oC for 2 min, 72oC for 3 min and final extension of 
72oC for 7 min (Class et al., 1991). 
 
2.7.2.2 M. pneumoniae and P. jiroveci 
Detection of M. pneumoniae employed primers F1 and R1, which are specific 
for the P1 adhesin gene (Table 2.1) (Ramirez et al., 1996 and Buck et al., 
1992). The PCR reaction mixture comprised: 3 μl DNA template, 1.5 mM 
MgCl2, 0.5 μM of each primer, 0.2 mM of each dNTP, 0.625 units of the 
enzyme GoTaq® Flexi DNA polymerase and 5X Green GoTaq® Flexi buffer 
(Promega). Amplification of the P1 adhesin gene again included a three-step 
initial phase, comprising 94oC for 5 min, followed by 50oC for 5 min (addition 
of Taq polymerase) and 72oC for 5 min. Amplification was conducted for 35 
cycles: 94oC for 30 sec, 65oC for 30 sec and 72oC for 30 sec followed by a 
final extension phase of 10 min at 72oC. Primers 16S rRNA F and 16S rRNA 
R were used in the single 16S rRNA PCR reaction. The PCR reaction mixture 
comprised: 3 μl DNA template, 2 mM MgCl2, 1.25 μM of each primer, 0.2 mM 
of each dNTP, 0.625 units of GoTaq® Flexi DNA polymerase and 5X Green 
GoTaq® Flexi buffer (Promega). A three-step initial phase of: 94oC for 5 min, 
followed by 50oC for 5 min (addition of Taq polymerase) and 72oC for 5 min 
was used. Amplification was conducted for 40 cycles: 94oC for 1 min, 60oC for 
1 min and 72oC for 1 min followed by a final extension phase of 5 min at 72oC. 
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The PCR reaction mixture for the mtLSUrRNA method for detection of P. 
jiroveci comprised: 3 µl DNA template, 3 mM MgCl2, 1 µM of each primer, 0.4 
mM of each dNTP and 0.625 units of the enzyme GoTaq® Flexi DNA 
polymerase and 5X Green GoTaq® Flexi buffer (Promega). PCR conditions 
used included a three-step initial phase, of 94oC for 2 min, 50oC for 5 min, 
followed by the addition of Taq polymerase and 72oC for 5 min. Amplification 
primers pAZ102-E and pAZ102-H comprised: 40 cycles at 94oC for 1.5 min, 
55oC for 1.5 min and 72oC for 2 min followed by a final extension phase of 10 
min at 72oC. From the first PCR reaction, 1 µl was used for the second PCR 
reaction. Primers pAZ102-X and pAZ102-Y were used in the second PCR 
reaction: initial step, of 94oC for 5 min, followed by 10 cycles at 94oC for 1.5 
min, 55oC for 1.5 min and 72oC for 2 min, and 30 cycles at 94oC for 1.5 min, 
63oC for 1.5 min and 72oC for 2 min with a final extension phase of 10 min at 
72oC.  
The F1 and B45 primers were used in the first reaction of the DHPS nested 
PCR (Table 2.1). The PCR reaction mixture comprised: 3 μl DNA template, 
2mM MgCl2, 0.4 μM of each primer, 0.2 mM of each dNTP, 0.625 units of 
GoTaq® Flexi DNA polymerase and 5X Green GoTaq® Flexi buffer 
(Promega). DHPS amplification included a three-step initial phase: 94oC for 5 
min, followed by 52oC for 5 min (addition of Taq polymerase) and 72oC for 5 
min. Amplification included 35 cycles of: 92oC for 30 sec, 52oC for 30 sec and 
72oC for 1 min followed by a final extension phase of 5 min at 72oC. For the 
second round of amplification primers AHUM and BN and 1μl of the first round 
product were used. PCR conditions were the same as the first PCR, except 
that an initial step of 94oC for 5 min and annealing at 55oC were included.   
The DHFR PCR mixture contained 2 μl DNA template, 2mM MgCl2, 0.25 μM 
of each primer, 0.2 mM of each dNTP, 0.625 units of GoTaq® Flexi DNA 
polymerase and 5X Green GoTaq® Flexi buffer (Promega). Amplification 
included a three-step initial phase of 94oC for 5 min, followed by 52oC for 5 
min (addition of Taq polymerase) and 72oC for 5 min. Cycling parameters 
comprised 35 cycles of: 94oC for 1 min, 60oC for 2 min and 72oC for 3 min, 
with a final extension phase of 10 min at 72oC. For the second round of 
amplification 1μl of the first round product was used, and the PCR conditions 
remained the same except for an initial step of 94oC for 5 min. 
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2.8 AGAROSE GEL ELECTROPHORESIS 
 
PCR products were separated in 2% (w/v) agarose gels for 45 min at 100 V 
using Tris-acetate EDTA buffer (40 mM Tris base, 5 mM sodium acetate, 1 
mM EDTA, pH 8). Ethidium bromide (Promega) stained DNA products were 
visualised by UV transillumination and images captured using an Alpha 
ImagerTM3400 gel system (Alpha Innotech). Positive and negative controls 
and a 100 bp DNA ladder (Promega) were included in each gel run to 
determine approximate sizes of the PCR products. 
 
 
2.9 SEQUENCING PROCEDURES AND COMPARISONS 
 
PCR products (for prevalence and antibiotic resistance chapters) were 
prepared for sequencing using Wizard SV gel and PCR clean-up system 
(Promega) according to the manufacturer’s instructions. For clean-up of a 
PCR product an equal volume of membrane binding solution (4.5 M guanidine 
isothiocyanate and 0.5 M potassium acetate, pH 5) was added to the PCR 
reaction mixture. The binding of the DNA, washing and elution steps were 
followed according to the suppliers instructions. Purified DNA samples were 
sequenced at the Central Analytical Facility, University of Stellenbosch. 
Sequence analyses were performed using Chromas 1.45, Bioedit 7.0.5 and 
Geneious 3.8.5, and sequences compared to regions of relevant target genes 
from micro-organisms deposited in GenBank. 
 
2.9.1 Prevalence studies 
For identification and detection of Mycoplasma spp. and Ureaplasma spp. 
PCR products were compared to known sequences on GenBank. M. hominis: 
GenBank accession number M96660 (Blanchard et al., 1993). U. parvum: 
GenBank accession number AF085729 (Biernat-Sudolska et al., 2006; Kong 
et al., 2000; Kong et al., 1999). U. urealyticum: (GenBank accession number 
AF085729). P. jiroveci: GenBank accession number: mtLSUrRNA M58605 
(Sinclair et al., 1991). M. pneumoniae: GenBank accession number: M18639 
(Su et al., 1987). 
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2.9.2 Antibiotic resistance genes 
Predicted PCR products from ATCC control cultures and sequences obtained 
from clinical strains were compared to corresponding regions obtained 
through BLAST search for QRDR regions of U. parvum (GenBank accession 
number: CP000942.1), U. urealyticum (GenBank accession number: 
AAYN02000002.1), Streptococcus pneumoniae tetM (GenBank accession 
number: X90939.1) and N. gonorrhoea tetM (GenBank accession number: 
L12241). 
 
 
2.10 STATISTICAL ANALYSIS 
 
Statistical analysis was performed employing the program Statistica (version 
8.0) and Pearson chi square and p- values determined. Sensitivity and 
specificity calculations: Sensitivity = [(no. True positives) / (no. true positives + 
no. false negatives)] x 100 = %; Specificity = [(no. True negatives) / (no. true 
negatives + no. false positives)] x 100 = %. 
 
 
2.11 ANTIBIOTIC SUSCEPTIBILITY TESTS 
 
2.11.1 SIR Mycoplasma kit: antibiogram for urogenital Mycoplasma (Bio-
Rad) 
Antimicrobial screening was performed according to instructions supplied in 
the product insert. A 24 h subculture from U9 broth stock (previously grown as 
described in section 2.5) was used. The expected titre obtained was 106 – 107 
colour changing units/ml according to the published recommendations and the 
SIR kit instructions. Thus, 20 µl of a 24 h culture in U9 broth medium was 
diluted with 1.8 ml of U9 broth (1/100 dilution). A standard inoculum of 100 µl 
(1/100 dilution of the pre-culture, in U9 broth) was aliquoted into each well of 
the SIR microplate. The microplate was covered with sealing film and 
incubated at 37ºC for 48 h. 
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2.11.2. Microbroth Dilution 
Minimum inhibitory concentrations (MIC) of antibiotics were determined by 
microbroth dilution tests as described by Bebear and Robertson (1996) and 
Waites et al. (2001). Antibiotic free broth was used for microbroth dilution tests 
for U. urealyticum ATCC #1331 broth (Section 2.3.2) and for U. parvum ATCC 
#2616 broth (Section 2.3.3). MICs to ofloxacin (Sigma), erythromycin (Sigma), 
azithromycin (Sigma) and tetracycline (Sigma) antibiotics were performed. All 
antibiotics were prepared at stock concentrations of 1 mg/ml in relevant 
diluents (either NaOH or ethanol) as specified by the supplier. For the MIC 
protocol, 100 µl of appropriate ATCC broth was added to wells 2 – 8. To wells 
1 and 2, 100µl antibiotic at 64 µg/ml was added. Doubling dilutions were then 
performed across wells 2 to 8. The inoculum 100 µl per well was derived from 
combining 50 µl from the last positive growth well from resuscitation in the 
appropriate ATCC broth with 1 ml ATCC broth. Controls comprised: well 9: 
positive control (100 µl inoculum + 100 µl ATCC broth), well 10: antibiotic 
control (100 µl antibiotic containing media + 100 µl ATCC broth); well 11: 
negative control (200 µl ATCC broth). 
 
 
2.12 DETECTION OF TARGET GENE MUTATIONS OR GENE 
ACQUISITIONS IN ANTIBIOTIC-RESISTANT UREAPLASMAS 
 
2.12.1. DNA Extraction and plasmid screening 
U. parvum and U. urealyticum DNA was extracted from 200 µl of U9 broth 
culture and N. gonorrhoeae DNA from 10 colonies grown on chocolate agar 
that were suspended in 200 µl of sterile water, using a High Pure PCR 
Template preparation kit (Roche) as for the isolation of nucleic acids from 
bacteria as described by the manufacturer. For N. gonorrhoeae, cells were 
additionally treated with 5 µl of 10 mg/ml lysozyme in 10 mM tris-HCl buffer at 
pH 8 for 15 min at 37ºC prior to addition of binding buffer.  
 
All clinical strains of Ureaplasma spp. which were resistant to tetracycline 
were screened for plasmids using the Pure Yield plasmid miniprep isolation kit 
(Promega). A tetracycline-resistant N. gonorrhoeae strain (A11) that carried a 
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tetM gene was used as a positive control and was kindly provided by Mari de 
Jongh, University of Limpopo. 
 
2.12.2. PCR amplification of genes associated with antibiotic  
  resistance 
For the detection of resistant gene target alterations/acquisitions and 
transposon regions, PCR conditions and specific primers employed are given 
in Tables 2.2 – 2.6. In addition, tetracycline -susceptible and -intermediate 
resistant clinical stains of U. parvum or U. urealyticum were screened for tetM 
and int-Tn genes. PCR products were separated on agarose gels as 
described in section 2.8 and sequencing performed with comparisons as 
described in section 2.9. 
 
 
 
 
Table 2.2:  Primers and PCR conditions employed for the amplification of QRDR of gyrase 
and topoisomerase IV genes in U. urealyticum and U. parvum (Bebear et al., 2000). 
 
Gene  
 
Primer  Sequence  Size (bp) 
gyrA gyrA-1 5’-TTGCTGCTTTCGAAAACGG-3’ 320 
 gyrA-2 5’-CTGATGGTAAAACACTTGG-3’  
    
gyrB gyrB-3 5’-CCTGGTAAATTAGCTGACTG-3’ 300 
 gyrB-4 5’-TTCGAATATGACTGCCATC-3’  
    
parC parC-5 5’-ACGCAATGAGTGAATTAGG-3’ 300 
 parC-6 5’-CACTATCATCAAAGTTTGGAC-3’  
    
parE parE-7 5’-ATGGGCGGAAAATTAACGC-3’ 300 
 parE-8 5’-CTTGGATGTGACTACCATCG-3’  
    
PCR conditions 
(Bebear et al., 1997) 
Amplification in final volume of 25 µl. 
Denaturation: 5-10 min @ 92ºC 
40 cycles:   1 min @ 92ºC 
    1 min @ 57ºC 
    2 min @ 72ºC 
Final extension: 10 min @ 72ºC 
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Table 2.3:  Primers and PCR conditions employed for the amplification of int-Tn gene for 
encoding the protein required for movement of Tn1545-like transposon of Ureaplasma spp. 
(de Barbeyrac et al., 1996). 
 
Gene  
 
Primer  Sequence  Size (bp) 
int-Tn Int 1 5’-TGACACTCTGCCAGCTTTAC-3’ 579 
 Int 2 5’-CCATAGGAACTTGACGTTGG-3’  
    
PCR conditions 
(de Barbeyrac et al., 1996) 
Amplification in final volume of 25 µl. 
Denaturation:      5 min @ 95ºC 
35 cycles:   1 min @ 95ºC 
    1 min @ 60ºC 
    1 min @ 72ºC 
Final extension: 10 min @ 72ºC 
 
 
 
Table 2.4:  Primers and PCR conditions employed for the amplification of 397 bp regions of 
tetM genes (Blanchard et al., 1992). 
Gene  
 
Primer  Sequence  Size (bp) 
tetM tetMF 5’-TTATCAACGGTTTATCAGG -3’ 397 
 tetMR 5’-CGTATATATGCAAGACG -3’  
    
PCR conditions 
(Blanchard et al., 1992) 
Amplification in final volume of 25 µl. 
Denaturation:      5 min @ 95ºC 
40 cycles:   25 sec @ 95ºC 
    1 min @ 50ºC 
    1 min @ 72ºC 
Final extension: 10 min @ 72ºC 
 
 
 
Table 2.5:  Primers and PCR conditions employed for the amplification of 1.7 kb regions of 
tetM genes (Beeton et al., 2009a). 
Gene  
 
Primer  Sequence  Size (kb) 
tetM tetMF 5’-TTATCAACGGTTTATCAGG-3’ 1.7 
 tetMR 2123 5’-GCATTTCGGACAATAGAGGGGG-3’  
    
PCR conditions 
(Beeton et al., 2009a) 
Amplification in final volume of 25 µl. 
Denaturation:      5 min @ 95ºC 
35 cycles:   1 min @ 95ºC 
    1 min @ 54ºC 
    1 min @ 72ºC 
Final extension: 7 min @ 72ºC 
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Table 2.6:  Primers and PCR conditions employed for the amplification of two operons (OP1 
and OP2) of 23S rRNA, L4 and L22 proteins of Ureaplasma spp. (Beeton et al., 2009a). 
 
Gene  
 
Primer  Sequence  Size (bp) 
23S OP1 
domain V 
MH23S-11 5’-TAACTATAACGGTCCTAAGG -3’ 1339 
 UP23S-OP1 5’-ACCACCATTCAATGTTTGAC -3’  
    
23S OP2 
domain V 
MH23S-11 5’-TAACTATAACGGTCCTAAGG -3’ 1424 
 UP23S-
OP2R2 
5’-CGTATACTTTGCCATAGTGTTGCC -3’  
    
L4 UPL4-U 5’-TCTATTGATGGTAACTTCGC -3’ 392 
 UPL4-R 5’-GTTGAAGGTGTTTCTAAATCGC -3’  
    
L22 UPL22-U 5’-TTCGCACCGTAAAGCTTCTC -3’ 458 
 UPL22-R 5’-GTTCTGGATCAACGTTTTCG -3’  
PCR conditions 
(Beeton et al., 2009a) 
Amplification in final volume of 25 µl. 
Denaturation: 5-10 min @ 92ºC 
40 cycles:   1 min @ 92ºC 
    1 min @ 56ºC (OP1 and OP2) and 60ºC (L4 and L22) 
    2 min @ 72ºC 
Final extension: 10 min @ 72ºC 
 
 
 
 
Table 2.7:  Primers designed and PCR conditions employed for the amplification of 1.3 kb 
regions of tetM genes (from base 2886-4222; Accession no.: X90939). 
 
Gene  
 
Primer  Sequence  Size (kb) 
tetM TMF1 5’-GCG TCT TGC ATA TAT ACG TCT TTA T-3’ 1.3 
 TMR1 5’-TCT GCA TTT CGG ACA ATA GAG GGG G-3’  
    
PCR conditions 
 
Amplification in final volume of 25 µl. 
Denaturation:      5 min @ 95ºC 
35 cycles:   1 min @ 95ºC 
    1 min @ 54ºC 
    1 min @ 72ºC 
Final extension: 7 min @ 72ºC 
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2.12.3 tetM sequence comparisons of Ureaplasma spp. strains from this 
study with S. pneumoniae, N. gonorrhoeae and Ureaplasma spp. 
GenBanked sequences 
 
Ureaplasma spp. tetM sequence comparisons were performed against the 
tetM sequence of N. gonorrhoeae strain 6418 (GenBank accession number: 
L12241) [USA, 1993, plasmid pOZ100] (Gascoyne-Binzi et al., 1993). The 
genes aligned were: S. pneumoniae: X90939: [Italy, 1995, Transposon 
Tn5251 (Provvedi et al., 1996); U. urealyticum SV9-Seattle: U08812 [1988, 
Transposon Tn916 doxycycline-susceptible (Sanchez-Pescador et al., 1988). 
 
 
2.13. ANTIBIOTIC RESISTANCE GENE TRANSFER 
 
N. gonorrhoeae and ureaplasma transformation experiments were performed 
employing media, conditions and recipient/donor concentrations of cells/DNA 
from which transformants have been obtained in other studies (Morse et al. 
1996; Roberts and Kenny, 1987; Chalkley and Koornof, 1990; Potgieter and 
Chalkley, 1991; Voelker and Dybvig, 1996; Teachman et al., 2002). Extended 
co-incubation strategies, with recipient growth from exponential to early 
stationary phase, were based on studies for S. pneumoniae (Chalkley and 
Koornhof, 1991). Clinical strains of N. gonorrhoeae were kindly provided by 
Mari de Jongh, University of Limpopo, Frans Radebe, NICD-NHLS, University 
of the Witwatersrand and Prof E Wasserman, NHLS, University of 
Stellenbosch. 
 
2.13.1 Co-incubation of a N. gonorrhoeae recipient strain with 
 tetracycline-resistant Ureaplasma donor DNA 
 
Antibiotic susceptible N. gonorrhoeae recipients were cultured on chocolate 
agar plates in a 5-10% CO2 atmosphere at 37oC for 36 h. Twenty-colonies of 
N. gonorrhoeae were inoculated into 2.5 ml of a modified semi defined broth 
[3.5g Columbia broth base, (Laboratories CONDA); 0.5g Glucose, (Merck); 
0.2493g Peptone special (vegetable), (Sigma); made up to 80 ml with sterile 
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distilled water and autoclaved. Sterile distilled water (14 ml), and the following 
filter-sterilized components were added aseptically: 4 ml Yeast extract, 
(Merck) (25% w/v); 2 ml bovine serum albumin (Roche) (0.5 g/l); (Takei et al., 
2005; Chalkley and Koornhof., 1991). The cell suspension was mixed and 
then divided into two 1.25 ml aliquots in microcentrifuge tubes. A third tube 
containing 1.25 ml of broth was included as a broth medium sterility control. 
The three tubes were incubated at 37oC in a heating block for 3 h. At this time, 
10 µl of culture from the two tubes containing the recipient (N. gonorrhoeae) 
was removed and serial hundred-fold dilutions were prepared for plate counts 
on chocolate agar. Transformation experiment: to tube 1 containing the 
recipient culture, 10 µl of DNA extracted from a tetracycline-resistant 
Ureaplasma (which had been tested for sterility) was added; Culture control: 
to tube 2 containing recipient culture 10 µl of sterile water was added; Broth 
control: to tube 3 containing broth 10 µl of sterile water was added. All tubes 
were then incubated for 2 h after which 10 µl of culture from the tubes 1 and 2 
was removed and serial hundred-fold dilutions were prepared for plate counts. 
Fresh media 1.2 ml was then added to all tubes and incubation continued for 
an additional 1 h. After this period, 10 µl of culture from the tubes 1 and 2 was 
removed and serial hundred-fold dilutions were prepared for plate counts. The 
culture from tube 1 was examined for tetracycline-resistant transformants by 
the Etests (AB Biodisk, Solna, Sweden) method 100 µl of culture using 
chocolate agar plates followed by incubation in a 5-10% CO2 atmosphere at 
37oC for 36 h. To test for any spontaneous tetracycline-resistant mutations/ 
contaminants an Etest was performed on 100 µl of culture from tube 2. To 
confirm the broth was not contaminated, 50 µl of medium from tube 3 was 
spread across a chocolate agar plate with incubation in a 5-10% CO2 
atmosphere at 37oC for 36 h. In the event confirmatory testing was required, 
to the remaining culture in tubes 1 and 2 sterile glycerol was added [final 
concentration 10% (v/v)] and tubes stored at -80oC. 
 
 
 
 
 46
2.13.2 Co-incubation of N. gonorrhoeae recipients with tetracycline 
resistant U. parvum and U. urealyticum donors (culture+culture) 
 
Two susceptible N. gonorrhoeae strains were resuscitated on chocolate agar 
for 36 h at 37ºC. Thirty colonies were inoculated into 3.75 ml of modified semi 
defined medium (Section 2.14.1) in Schott bottles. The suspension was mixed 
and divided into 3x 1.25 ml aliquots in microfuge tubes that were incubated for 
3 h at 37ºC on a heating block. Dilution plate counts were performed after the 
3 h incubation period to establish cell numbers of N. gonorrhoeae. Thereafter, 
900 µl of N. gonorrhoeae recipient culture was added to 100 µl tetracycline-
resistant U. parvum or U. urealyticum (donor cultures) and cells left to 
settle/contact at 37ºC for a further 3 h. After this period, 100 µl of 10% (v/v) 
glycerol was added to the culture which was then carefully mixed and stored 
overnight at -80ºC. On removal from 24 h storage, tubes were incubated at 
37ºC for 30 min and then centrifuged for 15 min at 7 000 xg. The supernatant 
was removed, and pellet resuspended in 500 µl fresh modified semi defined 
medium containing 8 µg/ml tetracycline. The resuspended pellet was then 
incubated for 4 h at 37ºC. To recover transformants, 100 µl of medium was 
spread across chocolate agar plates (2x 50 µl) and 20 µl streak plated on a 
chocolate agar with incubation in a candle extinction jar at 37oC for 48 h. 
 
2.13.3 Co-incubation of U. parvum and U. urealyticum recipients with 
tetracycline-resistant U. parvum and U. urealyticum donors 
(culture+culture or culture+DNA) 
 
Four susceptible Ureaplasma recipients were used (2 U. parvum and 2 U. 
urealyticum) with grown in their specific media, for U. urealyticum ATCC 
#1331 broth and for U. parvum ATCC #2616 broth (Sections 2.3.2 and 2.3.3) 
for 20 h when cell concentrations were equivalent to approximately 107 
cells/ml. Donor cells/DNA comprised: exponential phase cultures of one U. 
urealyticum and three U.parvum tetracycline-resistant strains; N. gonorrhoeae 
plasmid DNA containing tetM; DNA extracted from the one U. urealyticum and 
three U. parvum strains used in culture+culture experiments. For culture to 
culture transfer and DNA to culture transfer, 1/10 dilutions of donors were 
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used and for plasmid donor 1/15 dilution used. After addition of donor 
cells/DNA to a recipient incubation was conducted for 6 h at 37ºC. Broth from 
tubes showing positive growth was used to determine tetracycline MICs by 
microbroth dilution (Section 2.12.2). Depending on MIC results, possible 
tetracycline-resistant transformant/recombinant cells were species identified 
and DNA extracted for PCR detection of tetM as described in section 2.13.2. 
 
2.13.4 Electroporation: N. gonorrhoeae recipient 
 
For N. gonorrhoeae electroporation, cell preparation and pulse conditions 
were based on procedures that have been found to be appropriate for N. 
gonorrhoeae and E. coli (Biorad Gene Pulser user guide; Genco et al. 2002; 
Sambrook et al. 1989; Shigekawa and Dower, 1988). Thirty colonies from a 
36 h N. gonorrhoeae culture grown on chocolate agar plates were inoculated 
into 3.75 ml semi defined medium in Schott bottles and incubated for 4 h at 
37°C. Cells were harvested by centrifugation at 5 000 xg for 10 min. The 
pellet was resuspended in 400 µl ice cold sterile distilled water, and 
centrifuged at 2500 xg for 15 min. The supernatant was removed and a further 
400 µl ice cold sterile distilled water added and cells centrifuged at 2500 xg for 
15 min. The pellet was then resuspended in 400 µl ice cold sterile 10% (v/v) 
glycerol, followed by centrifugation at 2500 xg for 15 min. This step was 
repeated. Cells were then resuspended in 250 µl ice cold sterile 10% (v/v) 
glycerol and aliquoted (5x50 µl) before storage at -80°C. Prior to 
electroporation an aliquot of cells was thawed, 5 µl of donor DNA added and 
cells transferred to chilled electroporation cuvettes (0.1 cm). Electroporation 
(Biorad Gene Pulser) conditions: 1.8kV, capacitance = 25 µFD, 200 ohms; left 
set on 125 µFD. After electroporation, the contents of the cuvette were 
transferred to a culture tube followed by the addition of 400 µl of semi defined 
media. After incubation at 37°C for 3 h, to enable recovery and expression of 
incorporated DNA, the culture was spread on chocolate agar plates for E-test 
detection of recombinant cells. 
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2.14 ELECTROPORATION AND TRANSFORMATION PROTOCOLS 
WITH ESCHERICHIA COLI  
 
2.14.1 Electroporation: E. coli strain DH5α recipient  
For E. coli DH5α electroporation, cell preparation and pulse conditions were 
based on standard procedures described for E. coli (Biorad Gene Pulser user 
guide; Sambrook et al. 1989). E. coli DH5α bacteria were grown on LB agar 
plates [10 g/l tryptone, 5 g/l yeast extract, 10g/l NaCl; pH adjusted to 7.5, 20 g 
agar, distilled water added to final volume of 1 l and autoclaved] for 24 h. 
Twenty colonies were inoculated into 4 ml LB broth [10 g/l tryptone, 5 g/l yeast 
extract, 10g/l NaCl; pH adjusted to 7.5, distilled water added to final volume of 
1 l and autoclaved] in falcon tubes. Cells were incubated for 3 h at 37°C with 
shaking (225 rpm) and harvested by centrifugation and washing with ice cold 
sterile distilled water and 10% (v/v) glycerol as described for N. gonorrhoeae 
(section 2.13.4). Cells were then resuspended in 250 µl ice cold sterile 10% 
(v/v) glycerol and aliquoted (5x50 µl) before storage at -80°C. Prior to 
electroporation aliquots of cells (E. coli DH5α) were thawed, 5 µl of donor 
DNA (whole cell from ureaplasmas); positive control: (pUC18 DNA) added 
and cells transferred to chilled electroporation cuvettes (0.1 cm). 
Electroporation (BioRad Gene Pulser) conditions: 1.8kV, capacitance = 25 
µFD, 200 ohms; left set on 125 µFD. After electroporation, the contents of the 
cuvette were transferred to a culture tube followed by the addition of 400 µl of 
LB media with incubation at 37°C for 3 h, to enable recovery and expression 
of incorporated DNA. The cells were spread on LB agar plates with ampicillin 
(100 µg/ml) for detection of transformants with pUC18 control DNA or LB agar 
plates with tetracycline (8 µg/ml) to detect any transformants containing tetM 
from Ureaplasma spp. strains. Plates were incubated at 37ºC for 16-20 h. 
 
 
2.14.2 Electroporation: E. coli DH5α recipient (transformed with pUC18) 
The E. coli DH5α-pUC18 recipient was grown on LB agar plates containing 
ampicillin for 24 h and processed as described above (2.14.1) to determine 
whether transfer of donor DNA (from Ureaplasma spp.) to E. coli DH5α with a 
plasmid carrying an antibiotic resistance gene would occur. 
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2.14.3 Transformation with E. coli JM109 competent cells 
E. coli JM109 commercially available competent cells (Promega) were used 
for transformation experiments for transfer of whole cell DNA from 
Ureaplasma spp. Control DNA (pGEM-3Z vector) was used as a positive 
control to determine whether transformation did occur. Sterile culture tubes 
(Falcon) were chilled on ice, one per transformation. Frozen competent cells 
were placed on ice for 5 min until thawed and 100 µl transferred to each 
chilled tube. DNA (10 µl) from each of the seven tetracycline-resistant 
Ureaplasma spp. was added to tubes containing 100 µl competent E. coli 
cells. For the positive control, 1 µl of pGEM-3Z vector DNA (Promega) was 
added to 100 µl competent cells. Tubes containing competent E. coli cells and 
DNA (i.e. either from Ureaplasma spp strains or control pGEM-3Z vector 
DNA) was placed on ice for 10 min followed by heat shock (42ºC water bath) 
for 45-50 seconds and immediately placed on ice for 2 min. This was followed 
by addition of 900 µl of cold (4 ºC) SOC medium [2g tryptone, 05g yeast 
extract, 1ml 1M NaCl, 0.25 ml KCl and 97 ml double distilled water and 
autoclaved, followed by addition of filter sterilised 1 ml Mg 2+ stock (1M MgCl2, 
1M MgSO4) and 1 ml 2M glucose, made up to 100 ml with sterile double 
distilled water and complete medium filter sterilised] to each transformation 
reaction that was then incubated at 37ºC for 60 min with shaking (225 rpm). 
Cells (100 µl of undiluted and 1:10 dilution) were plated on LB agar plates 
containing either ampicillin (100 µg/ml) for pGEM-3Z vector control DNA or 
tetracycline (8 µg/ml) to detect any transformants with tetM DNA from the 
ureaplasmas. Plates were incubated at 37ºC for 16-20 h. 
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CHAPTER THREE 
 
VALIDATION OF METHODS 
 
 
3.1 INTRODUCTION 
 
Conventional diagnostic microbiology can be seriously limited in cases where 
causative microorganisms are considered “difficult” to culture; these include 
genital Mycoplasma and Ureaplasma spp. and M. pneumoniae. 
 
Routine investigations on mycoplasmas and ureaplasmas are compromised not 
only by time factor to isolation but also by the complexity and expense of culture 
media that requires rigorous quality control measures. Commercial culture kit 
assays have been developed that are based on selective media and enzymatic 
colour changes and include: Mycoview (Ivagen), Mycoplasma IST2 (bioMerieux), 
and Mycoplasma Duo (Bio-Rad) (Cheah et al., 2005; Smayevsky et al., 1995; 
Kenny and Cartwright, 2001; Biernat-Sudolska et al., 2006; Evans et al., 2007). 
These assays designed for the detection of M. hominis, U. parvum and U. 
urealyticum have not been used widely or have limited availability (Evans et al., 
2007). The Pneumofast kit a commercial culture detection kit for M. pneumoniae 
has been recommended for identification and antibiotic susceptibility 
determinations (Madani and Al-Ghamdi, 2001). 
 
The introduction of molecular biological tools in diagnostic microbiology has 
made for a more informed understanding of infection, transmission and survival 
of pathogenic microorganisms that are either non-culturable or difficult to culture. 
Polymerase chain reaction techniques such as conventional and real-time, 
multiplex PCR (Waites and Talkington, 2005); and the commercial Takara 
Mycoplasma PCR detection kit have been fine tuned, incorporating high copy 
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number/specific gene amplifications for rapid and accurate detection and 
identification. 
 
Evaluation of detection methods and specific confirmatory tests/verifications that 
were performed in the identification of Mycoplasma spp. and Ureaplasma spp. 
are described in this chapter so as not to detract from results presented on 
prevalence and antibiotic susceptibilities in Chapters 4 - 6. 
 
 
3.2 RESULTS 
 
3.2.1 Comparison of conventional culture methods, commercial detection 
kits and PCR (Takara PCR detection kit and publication 
recommended primers) 
 
Specimens that showed growth in #243 ATCC and arginine (Bio-Rad) broths 
were after DNA extraction from broth culture, confirmed by Takara-PCR to be M. 
hominis. No subsequent growth of M. hominis on solid media was achieved. All 
specimens for which a positive culture in U9 broth (Bio-Rad) [Fig. 3.1(A)] was 
obtained were PCR positive for U. urealyticum and/or U. parvum using 
publication recommended primers (Table 2.1). Positive culture results from 
#1331 ATCC and #2616 ATCC broth media [Fig. 3.1(B)], were also PCR positive 
for U. urealyticum or U. parvum respectively. On subculture to solid media only a 
sparse growth of Ureaplasma spp. was observed. 
 
Initially, the first 14 specimens were screened by all four kits: Mycoview, Myco 
IST2 (Fig. 3.2), Mycoplasma Duo (Fig. 3.3) and Takara-PCR. 
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Figure 3.1: A: U9 Broth microwell culture. B: #1331 ATCC broth culture. Red wells 
indicate positive Ureaplasma spp. and yellow wells represent negative culture. 
 
 
 
Figure 3.2: MycoIST2 test strip. A positive U. urealyticum is indicated by a pink colour 
change while a negative result is yellow. 
 
 
 
 
Figure 3.3: 
 
MycoDuo kit. A: Negative result for Ureaplasma spp. and M. hominis; B: 
Positive Ureaplasma spp. and M. hominis; C: Positive Ureaplasma spp. – high 
titre; D: Positive Ureaplasma spp. – low titre. 
Positive 
Negative control 
Positive 
Negative control 
A B 
Positive 
Negative 
A D B C 
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On comparing the Takara kit with Mycoview and Mycoplasma Duo kits, Takara 
provided 100% sensitivity and specificity (Table 3.1). When Takara PCR was 
compared with specific broth media, sensitivity of Takara was only 27% for 
Ureaplasma spp. (Table 3.2). However, on comparison with specific primers 
(Table 3.3), sensitivity was 100% for Ureaplasma spp., showing that broth 
cultures were producing false positive results. Concerning Ureaplasma spp., 
Takara kit did not differentiate between U. urealyticum and U. parvum. 
Performance of Takara with PCR based on publication recommended primers 
(after new classification of ureaplasmas into U. urealyticum and U. parvum) 
provided excellent comparisons for M. hominis with good sensitivity and 
reasonable specificity for ureaplasmas (Table 3.3). 
 
 
Table 3.1: Comparison of detection kits for the identification of M. hominis and Ureaplasma 
spp. on 14 specimens. 
Test kit M. hominis Ureaplasma 
spp  
M. hominis + 
Ureaplasma 
spp. 
Negative Sensitivity 
(%) 
Specificity 
(%) 
Takara-PCR 5 1 1 7 100 100 
Mycoview 2 5 1 6 100 60 
Myco IST2 1 2 0 11 33 87 
Mycoplasma Duo 1 6 1 6 100 55 
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Table 3.2: Comparison of culture with Takara-PCR on 20 specimens. 
 
Test kit M. hominis U. 
urealyticum/ 
U. parvum 
M. hominis 
+ 
Ureaplasma 
spp. 
Negative Sensitivity 
(%) 
Specificity 
(%) 
#243 ATCC 
broth (Mh) 
8 N/A  12 73 100 
Arginine broth 
(Mh) 
5 N/A 1 14 50 100 
Takara-PCR 10 2 1   9 M. hominis 
17 Ureaplasma 
spp. 
100 (Mh) 
27 (U) 
100 (Mh) 
90 (U) 
U9 broth (Up 
+Uu) 
N/A 11 0 9 92 100 
#1331 ATCC 
broth (Uu) 
N/A 4 0 16 100 100 
#2616 ATCC 
broth (Up) 
N/A 8 0 12 100 100 
 
 
Table 3.3: Comparison of MycoIST2 with Takara-PCR and publication recommended PCR 
primers on 48 specimens. 
 
Test kit or 
PCR primers 
M. 
hominis 
U. 
urealyticum 
M. hominis + 
Ureaplasma 
spp. 
Negative Sensitivity 
(%) 
Specificity 
(%) 
Myco IST2 5 11 2 41 M. hominis  
35 Ureaplasma 
spp. 
26 (Mh) 
 
100 (U) 
100 (Mh) 
 
78 (U) 
Takara-PCR 27 8 6 15 M. hominis  
34 Ureaplasma 
spp. 
100 (Mh) 
100 (U) 
100 (Mh) 
76 (U) 
HOM+ + UNI-
(Mh) 
6 N/A 2 40 24 100 
UUS2c + UUA2c 
(Uu) 
N/A 3 0 45 100 100 
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3.2.2 PCR Detection: Genital mycoplasmas, ureaplasmas and C. 
trachomatis 
 
Control ATCC cultures were constantly employed to confirm PCR reactions and 
conditions for genital mycoplasmas, ureaplasmas and C. trachomatis; and that 
fragments of expected sizes were produced especially when no PCR products 
were evident from specimens (Figs. 3.4-3.9). In contrast to low detection rates 
employing HOM+ and UNI- primers for M. hominis on DNA extracted from 
specimens, from broth culture these primers provided for quality amplification 
products (Fig. 3.4). Clearly defined fragments were obtained with nested Takara-
PCR for the detection of M. hominis, M. fermentans and Ureaplasma spp. (Figs. 
3.8 and 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: (A): M. hominis detection employing HOM+ and UNI- primers. 
Lane 1: Promega 100 bp DNA ladder, Lane 2: M. hominis (ATCC 14027).  
(B): C. trachomatis detection employing T1 and T2 primers.  
Lane 1: Promega 100 bp DNA ladder, Lane 2: C. trachomatis (ATCC VR-887). 
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 1      2 
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         1        2                    1     2 
 1      2 
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A   B 
Figure 3.5: A: Detection of M. penetrans employing a control culture. Lanes: (1) Promega 100bp DNA ladder; 
Lanes: (2) M. penetrans ATCC control. 
B: Detection of M. genitalium employing a control culture. Lanes: (1) Promega 100bp DNA ladder; 
(2) M. genitalium ATCC control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Representative gel depicting U. parvum PCR products using primers UPA and UPS. 
Lanes 1 and 11: Promega 100 bp DNA ladder; Lane 2: Positive U. parvum ATCC 27815 
control; Lane 3: Negative control; Lanes 4 – 10: Endocervical samples. 
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Figure 3.7: Representative gel depicting U. urealyticum PCR products using primers UUA 
and UUS. Lanes 1 and 11: Molecular weight markers (Promega 50 bp DNA 
ladder); Lane 2: U. urealyticum ATCC 27618 positive control; Lanes 3 and 10: 
Negative controls; Lanes 4 – 9: Endocervical samples. 
 
 
 
 
 
 
 
 
 
Figure 3.8: Representative gel depicting first reaction products employing Takara-PCR. 
Lanes: (1) Promega 50 bp DNA ladder; (2) Ureaplasma spp. (482 bp); (4) M. 
fermentans (491 bp); (5) Ureaplasma spp. (482 bp); (6, 7) M. hominis; (8) 
negative control; (9) positive M. hominis (370 bp) control. 
A 
   1      2      3       4       5       6     7      8      9      10     11   
50bp 
1350bp 
400bp 
420bp 
1       2       3      4       5       6      7      8        9     
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Figure 3.9: Representative gel depicting second reaction products employing Takara-PCR. 
Lanes: (1) Promega 50 bp molecular weight marker; (2) Ureaplasma spp. (154 
bp); (3, 4) M. fermentans (195 bp); (5) M. hominis (148 bp); (6) Ureaplasma spp.; 
(7) M. hominis (148 bp); (8) negative control; (9) positive M. hominis control. 
 
 
3.2.3 PCR Detection: M. pneumoniae 
 
Growth of M. pneumoniae was not evident from any of the clinical respiratory 
specimens either on Modified New York City (MNYC) agar plates or by the 
Pneumofast kit. M. pneumoniae ATCC® 29343TM showed growth in #988 ATCC 
broth with a characteristic colour change from red-brown to yellow after 21 days 
of incubation (Fig. 3.10).  
The Pneumofast kit was also tested using the control M. pneumoniae ATCC® 
29343TM but after 30 days of incubation a broth colour change to from red to 
orange and not yellow was recorded, which according to kit criteria is an 
inconclusive result (Fig. 3.11). 
 
 
 
 
 
 
1       2       3      4       5       6      7      8        9    
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Employing both P1 adhesin and 16S rRNA PCR primers, M. pneumoniae was 
detected in one sputum sample (Chapter 5). However, this sample could not be 
Figure 3.10: Characteristic ATCC #988 broth colour change from red-brown to yellow due to growth of 
M. pneumoniae ATCC 29343. Tube 1: Negative control; Tube 2: M. pneumoniae ATCC 
29343 (1:7 dilution); Tube 3: M. pneumoniae ATCC 29343 (1: 12.5 Dilution). 
Figure 3.11: Detection of M. pneumoniae using the Pneumofast kit. (A) Negative      (B) False positive 
and (C) M. pneumoniae ATCC 29343 Pneumofast Tray after 30 days. 
              1                  2                  3 
A B C 
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sequenced as there was insufficient DNA and all attempts to repeated PCR and 
re-extraction failed. In addition, the patient’s details were not available at the 
hospital so the patient could not be traced either for clinical follow-up or for a 
further specimen to be taken. 
 
Sequence confirmation was performed on the M. pneumoniae ATCC 29343 
control culture to confirm a P1 adhesin gene PCR product under primers and 
conditions employed (Fig. 3.12). Sequence alignment and comparison with the 
Genbank referenced P1 adhesin gene (GenBank accession no: M18639) 
confirmed the PCR fragment of M. pneumoniae ATCC 29343 (Fig.3.13) (Su et 
al., 1987). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Detection of M. pneumoniae employing P1 adhesin gene primers. Lanes 1 and 12: 
Promega 100 bp DNA ladder; Lanes 3 and 11: Negative controls; Lanes 4 – 10: Sputa 
samples (1-7); Lane 2: Positive M. pneumoniae ATCC 29343 control. 
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3.2.4 SIR Mycoplasma kit and MIC determinations 
 
Specimens in which U. parvum and/or U. urealyticum had been detected by 
PCR, were cultured in U9 broth and ATCC recommended media and screened 
for antimicrobial susceptibility using the SIR kit (Fig. 3.14). As the SIR kit is 
unable to differentiate between U. urealyticum and U. parvum and tests only two 
concentrations of an antibiotic, MICs were also determined using the microbroth 
dilution method (Fig. 3.15). Ureaplasma cultures were constantly checked for any 
signs of contamination, not only by media clarity but also by plating onto 
chocolate agar plates with incubation at 37oC in a candle extinction jar for 48 
hours. No contamination was detected. 
 
 
 
Figure 3.13: DNA sequence of a 226 bp amplified DNA portion of the P1 adhesin gene from M. pneumoniae 
ATCC 29343 compared to GenBank accession no: M18639 (Su et al., 1987).  
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Figure 3.14: Antimicrobial susceptibility testing of U. parvum strain (Up-402) using the SIR kit. 
Pink wells indicated that growth had occurred in the presence of an antimicrobial 
agent and results recorded as intermediate resistance/resistant, while yellow wells 
indicated no growth and susceptibility to an antibiotic. For intermediate resistance, 
only the well with low concentration of antibiotic turned pink. For resistance, wells 
containing both high and low concentration of antibiotics turned pink. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: MIC determinations of ureaplasmas using the microbroth dilution method. 
 
 
 
 
 
 
Ofloxacin intermediate 
resistance (1 μg/ml)  
 
Clindamycin positive (2 μg/ml) 
(ureaplasmas naturally resistant to this 
antibiotic) 
 
Erythromycin intermediate 
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Antibiotic concentrations (μg/ml)
2 48 1 0.5 0.25 0.125 P A N 
Controls: Positive (P), Antibiotic (A), 
Negative (N) 
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3.3 DISCUSSION 
 
Mycoplasmas and ureaplasmas are fastidious, difficult to culture as they are very 
susceptible to adverse environmental conditions including desiccation, osmotic 
change, toxic metabolites and fluctuations in temperature (Duffy and Waites, 
2008). Poor recovery of Ureaplasma spp. from clinical samples has been 
documented (Waites et al., 2001). 
 
For both gynaecological studies endocervical specimens were eluted by a nurse 
into microbanks that were stored at -80oC within 30 minutes. Freeze thaw 
procedures were kept to a minimum. A major challenge during the project was 
obtaining repeat culture and DNA when initial tests showed insufficient PCR 
product for sequence confirmation. Of six culture positive presumptive M. 
hominis strains obtained from 2005, endocervical specimens, two were 
susceptible to all antibiotics tested and four strains were resistant to tetracycline 
and intermediately-resistant to doxycycline. Unfortunately on trying to repeat 
susceptibility testing and M. hominis confirmation no further cultures were 
obtainable from the specimens. 
 
Ethics, sample quality and storage and patient information were certainly high on 
the agenda as studies proceeded. The gynaecological study that was conducted 
in 2003 (prior to PhD investigations being initiated) was formulated to investigate 
the effect of Chlamydia carriage on preterm labour. After analysing mycoplasma 
and ureaplasma prevalence on these specimens, information on the HIV status 
of patients was not available. In order to investigate mycoplasma/ureaplasma 
prevalence in conjunction with HIV, ethics was approved and an independent 
nurse was contracted to handle all specimens which were taken in a controlled 
clinic environment to ensure that the quality/standard of specimens and patient’s 
histories were not compromised. Whilst the majority of patients were willing to 
give consent during 2005, by 2006 there was a change in attitude and it become 
progressively more difficult to obtain specimens. 
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In contrast, the quality/standard of specimens and patient’s histories in PE 
Hospitals presented a major challenge to expanding findings of the respiratory 
study. The neonate endotracheal aspirate specimens obtained from the hospital 
were of a poor quality (i.e. some were contaminated with blood). Due to very 
small specimen volumes, samples had to be flushed out of the endotracheal 
tubes with sterile water which resulted in sample dilution. Due to circumstances 
at the hospital, it was not possible for specimens to be transferred into transport 
media prior to collection and delivery to NMMU for analysis, which may have 
contributed to negative culture results. These circumstances included refusal of 
nurses to transfer specimens into media before storage and transport to NMMU 
for analysis. There were insufficient funds to employ a private nurse in Port 
Elizabeth hospitals for collection of specimens. Staff at the hospital were 
reluctant to participate in research projects because of their increased workload. 
In an effort to remedy the situation the nurses had agreed to store the specimen 
in a freezer and contact the researcher as soon as a specimen was available. 
The researcher collected the specimen within an hour of being contacted by the 
hospital. 
 
M. hominis was not detected in endotracheal aspirate samples as has been 
reported in the majority of other studies (Waites et al., 2005). Unfortunately and 
certainly for the two neonates in which U. parvum was detected, all attempts to 
obtain information from NICU patient files at the Dora Nginza, on co-infections 
like HIV, TB, treatment or the type of delivery were unsuccessful. 
 
All cultures were constantly checked for contamination and PCR conducted for 
genus (mycoplasma vs ureaplasma) verification. 
 
The majority of PCR positive endocervical specimens collected in 2006 were 
positive for growth of Ureaplasma spp. using commercially prepared U9 broth. 
There was no contamination in any microtiter plate wells indicating that U9 broth 
can be considered a suitable medium for the culture of Ureaplasma spp. prior to 
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antibiotic susceptibility screening tests. The ATCC recommended broths were 
specific in differentiating between U. parvum and U. urealyticum while it should 
be noted that commercial U9 broth does allow growth of both U. urealyticum and 
U. parvum. 
 
The MycoDuo kit results seem to be in agreement with Evans et al. (2007), 
whereby the MycoDuo kit showed a higher detection rate (52%) than culture on 
A7 agar plates (36%). However, the results of this study were contrary to Cheah 
et al. (2005), which showed an overall agreement of 96% between PCR and 
Mycoplasma Duo Kit for the detection of Ureaplasma spp. in endotracheal 
aspirates from neonates. 
 
The MycoIST2 kit allows for the detection of Ureaplasma spp. and M. hominis as 
well as antibiotic susceptibility testing but a high rate of contamination by other 
microorganisms from the specimens produced inconclusive results. There have 
been contrasting reports concerning antibiotic resistance profiles when using the 
MycoIST2 kit (Smayevsky et al., 1995; Kenny and Cartwright, 2001). Four 
positive cultures that were inhibited by ciprofloxacin 1 µg/ml using the MycoIST2 
kit were on MIC testing found to be inhibited by 2 μg/ml ciprofloxacin (Smayevsky 
et al., 1995). In addition, false positive results have been reported due to the 
presence of other bacteria (e.g. Proteus, Klebsiella) that are capable of 
hydrolysing urea (Biernat-Sudolska et al., 2006). 
 
Granato et al. (1983), reported that MNYC medium was better suited for 
supporting M. pneumoniae growth from clinical specimens than the ATCC 988 
medium, as it provided for rapid and specific growth. However, in the current 
investigation neither MNYC/ATCC 988 agar plates supported growth of a M. 
pneumoniae from a respiratory specimen that was isolated in ATCC broth 
medium. The Pneumofast kit has been specifically designed for the identification 
of M. pneumoniae from clinical respiratory specimens. Madani and Al-Ghamdi 
(2001), incubated an ATCC control for 30 days after which a positive result was 
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recorded. However, after 30 days of incubation the M. pneumoniae ATCC 29343 
control in the present study only exhibited an orange colour which is considered 
inconclusive. Waris et al. (1998), have reported that use of the Pneumofast kit for 
the detection of M. pneumoniae from PCR positive specimens was significantly 
low, with only 1/20 PCR positive samples being test positive by the Pneumofast 
kit. Limitations of the Pneumofast method that have been shown to affect results 
include sample quality and viability levels of M. pneumoniae present within the 
samples. 
 
Antimicrobial susceptibility testing methods of mycoplasmas and ureaplasmas 
which has been in constant flux was semi-consolidated at the 17th IOM Congress 
and Mycoplasma Techniques Workshop July 2008, however, even after this 
international interactive meeting some groups are still reluctant to fully define 
MIC methodologies and media compositions. The SIR kit for antibiotic 
susceptibility screening was seen to be an efficient method and has been 
validated by laboratories in Bordeaux, France and used in preliminary antibiotic 
resistance screening tests (Bebear et al., 2003; Degrange et al., 2008). 
 
The project did encounter problems due to the prolonged time frame (part-time 
PhD), with some contributing factors par for the course and others unforeseen. 
The prolonged time frame meant constantly being aware of updates of changing 
media, methodologies concerning detection especially Ureaplasma speciation 
division which required all genital specimens collected in 2003 to be re-analysed 
for U. parvum; and antibiotic susceptibility determination preferences of different 
international groups. It must be said that information finally presented in the 
thesis benefited from repositioning with extensive comparative and confirmatory 
aspects incorporated. 
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CHAPTER FOUR 
 
PREVALENCE OF GENITAL MYCOPLASMAS, UREAPLASMAS 
AND CHLAMYDIA IN PREGNANCY 
 
4.1 INTRODUCTION 
 
The possible role of genital mycoplasmas (Mycoplasma hominis, Mycoplasma 
fermentans, Mycoplasma penetrans, Mycoplasma genitalium), Ureaplasma 
urealyticum, Ureaplasma parvum and Chlamydia trachomatis on the outcome 
of pregnancy is a topic of great interest and debate and has not been 
satisfactorily resolved. Studies of women from whom ureaplasmas and M. 
hominis were isolated from the endometrium, placenta or midtrimester 
amniotic fluid have shown a consistent association with premature rupture of 
membranes and spontaneous abortion, (Grattard et al., 1995; Kafetzis et al., 
2004; Nguyen et al., 2004; Perni et al., 2004; Witt et al., 2005). Other reports 
have found associations between U. urealyticum in amniotic fluid (Yoon et al., 
1998; Gerber et al., 2003), cervix (Mitsunari et al., 2005) and vaginal 
colonisation with bacterial vaginosis (Vogel et al., 2006) to contribute to 
adverse outcomes on pregnancy. In addition, vaginal colonisation with the 
newly classified U. parvum has been seen to be associated with late abortion 
or early preterm birth (Kataoka et al., 2006). Although M. penetrans, M. 
fermentans and M. genitalium have received less attention a) M. penetrans 
has been isolated from the urogenital tracts of individuals with HIV infection 
(Hussain et al., 1999), b) M. fermentans has been reported to be an 
opportunist in HIV infection, (Ainsworth et al., 2001; Waites and Talkington, 
2005) and c) M. genitalium has been associated with pelvic inflammatory 
disease (Taylor-Robinson, 2002; Haggerty et al., 2006), and acute 
endometritis in women in Kenya (Cohen et al., 2002), but was not seen to 
affect pregnancy outcomes in women of Guinea-Bissau (Labbe et al., 2002). 
However, as to whether M. penetrans, M. fermentans and M. genitalium 
present significant risk factors in pregnancy outcome remains unclear (Taylor-
Robinson, 2007). 
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Spontaneous preterm labour is a major cause of neonatal mortality with a 
prevalence of 20.3% in the Tygerberg area, accounting for 40% of neonatal 
deaths (Pattinson and van Zyl, 1991; Odendaal et al., 2002). In a previous 
study at the Tygerberg Hospital, an association between preterm birth and M. 
hominis and C. trachomatis infection was found (Odendaal et al., 2002). 
Furthermore, a subsequent study reported an association between C. 
trachomatis, lower body mass index (BMI) and younger maternal age with 
preterm delivery (Odendaal et al., 2006).  
 
A study was designed (including patients enrolled at two time periods, refer to 
section 2.1) to extend findings on C. trachomatis pertaining to preterm delivery 
by Odendaal et al. (2006), by including mycoplasma and ureaplasma 
prevalence data and to ascertain whether a positive HIV status lends to 
increased colonisation rates.  
 
 
4.2 RESULTS 
 
4.2.1 Mycoplasmas, Ureaplasma spp. and C. trachomatis according to 
women’s age groups 
 
In 2003, 45% of women sequentially screened were aged 14–20 years, 
however, in 2005 only 6% were in this age group (Table 4.1). Conversely in 
2003, 13% of women were older than 30 years yet in 2005, 36% were in this 
age group. The number of specimens in which no detection was recorded 
increased from 16.5% in 2003 to 48% in 2005. Colonisation was seen to be 
highest in the 14–20 year group from 2003. When compared with the 14-25 
age group prevalence of Ureaplasma spp. tended to be higher in women ≥26 
years while C. trachomatis and M. hominis tended to be lower in women ≥26 
years. In women aged ≥21 years, although co-colonisation remained at 13% 
there was a shift from co-colonisation with M. hominis and Ureaplasma spp. in 
2003 to other dual/triple combinations in 2005. 
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Table 4.1: Prevalence of mycoplasmas, Ureaplasma spp. and C. trachomatis according to women’s age groups during 2003 and 2005. 
 
 Age groups (Years) Totals  
Micro-organism detected 14 - 20 21 - 25 26 – 30 >30 (No.) (%) 
 2003 2005 2003 2005 2003 2005 2003 2005 2003 2005 2003 2005 
M. hominis 43 3 28 19 13 13 12 16 96 51 48 23 
M. fermentans 1    1    2  1  
Ureaplasma spp.  13  6 2 8 6 4 5 31 13 15.5 6 
C. trachomatis 2 3 2 3  10 1 5 5 21 3 10 
M. hominis + Ureaplasma spp.  4 1 2 1 6 1 2 5 14 8 7 4 
M. hominis + C. trachomatis  9  2 5  4 1 3 12 12 6 5.5 
M. fermentans  + C. trachomatis  1        1  0.5  
Ureaplasma spp. + C. trachomatis  3   2  1   3 3 1.5 1.5 
M. hominis + Ureaplasma spp. + C. trachomatis  1  1 2  0  3 2 5 1 2 
No detection 12 6 7 26 8 32 6 42 33 106 16.5 48 
Totals 89 13 48 60 36 67 26 79 199 219   
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4.2.3 Mycoplasma spp. and Ureaplasma spp. colonisation and preterm 
deliveries (2003 study) 
 
There were no significant differences in the presence of M. hominis (55% and 63%; 
p = 0.22720), U. urealyticum (25% and 25%; p=0.70340) and U. parvum (50% and 
36.9%; p= 0.43157) in women that delivered preterm and full term (Table 4.2).  
 
Table 4.2: Comparisons of Mycoplasma and Ureaplasma colonisation with preterm and full term 
deliveries (2003 study). 
 
Micro-organism 
detected 
Preterm (20 women) Full term (179 women) 
No. % No. % 
M. hominis 11 55 113 63 
M. fermentans 1 5 2 1 
U. urealyticum 5 25 45 25 
U. parvum 10 50 66 36.9 
 
 
 
4.2.4 M. hominis, Ureaplasma spp. and C. trachomatis colonisation and HIV 
status (2005 study) 
 
Comparisons of colonisation with HIV status are shown in Table 4.3. The 20 samples 
in the HIV positive group were also screened for the presence of U. parvum and only 
3 specimens were positive (15%). M. penetrans and M. genitalium were not detected 
in the preterm or the HIV positive groups. 
 
 
Table 4.3: Comparisons of M. hominis, Ureaplasma spp. and C. trachomatis colonisation with 
HIV status (2005 study). 
 
Micro-organism 
detected 
HIV positive (20 women) HIV negative (199 women) 
No. % No. % 
M. hominis 5 25 71 36 
Ureaplasma 
spp. 
2 10 27 14 
C. trachomatis 4 20 37 19 
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4.3 DISCUSSION 
 
The number of women in the sexually transmitted infection (STI) high risk group in 
South Africa 14-20 years age group (Rours et al., 2006a and 2006b), in 2003, was 
89 whereas in 2005, only 13 women were in this age group. The 2003 study 
focussed on low adverse pregnancy outcome risk women, attending an antenatal 
clinic located near the Tygerberg hospital, while the 2005 study was conducted on 
women (high risk) referred to the obstetric unit at the Tygerberg hospital. In 2005, in 
order to capture prevalence in conjunction with HIV status and to conform to high 
ethical standards, specimens from women attending for gynaecological examination 
at Tygerberg hospital were studied. In addition, in 2003, there was controversy of 
HIV testing/consent issues whereas by 2005, community initiatives by activist groups 
and government had increased awareness to the consequences of sexual 
behaviour, promoted condom usage and HIV testing, condemned rape and legalised 
abortion.  
 
It is acknowledged that there were limitations within the study design. The study is 
mainly laboratory based due to practicalities of carrying out a PhD study part-time, 
the candidate residing in Port Elizabeth. There is a lack of enriching clinical aspects 
as no detailed patient epidemiological, clinical history and clinical examination details 
were available. Despite the lack of opportunity to collect the clinical information, or 
data on the number of sexual partners, use of condoms, other STIs etc., number of 
cases missed during the collection periods or how representative the sample group 
is; this study was an ‘initial step’ in exploring the prevalence of Mycoplasmas and 
Ureaplasmas in pregnant women in SA. Other South African researchers have 
investigated M. genitalium (Black et al., 2008; Lewis et al., 2008) and M. hominis 
(Ballard et al., 2002; Odendaal et al., 2002) but using different categories of sample 
groups and methods compared to those used in this study.  
 
Colonisation with M. hominis, Ureaplasma spp. and C. trachomatis appeared to be 
age related. Similar findings have been documented in South Africa (Rours et al., 
2006) and other parts of the world (Baczynska et al., 2008) where chlamydial 
infection was the most prevalent STI in women less than 20 years. Syndromic 
management protocols for vaginal discharge in South Africa do consider C. 
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trachomatis hence a reduction of chlamydial carriage in older women would be 
expected in that they would have more readily (reduced stigma attachment/previous 
pregnancy) attended clinics. From 2003 to 2005, there was a general decline across 
all age groups in the prevalence of single colonisation with M. hominis or 
Ureaplasma spp. It is unclear with prevalence data from only two time frames and in 
the absence of antibiotic resistance development investigations, as to why there was 
a lower prevalence of M. hominis yet higher trend for Ureaplasma spp. in women 
≥26 years of age and a shift in co-colonisation types.  
 
The study did not find an association between M. hominis and Ureaplasma spp. with 
preterm labour. This is contrary to the findings of other research groups (Grattard et 
al., 1995; Cultrera et al., 1998; Donders et al., 2000; Perni et al., 2004; Edwards et 
al., 2006; Kataoka et al., 2006). Grattard et al., (1995) screened 208 women 
(cervico-vaginal swabs) and their neonates (aspirates) and reported (using MycoFast 
All-In test kit) M. hominis in 11% of women and 1% of neonates respectively while U. 
urealyticum was detected in 47.6% women and 19.2% neonates respectively. U. 
urealyticum detection by PCR was suggested to be associated with HIV infection in 
12 out of 84 patients (Cultrera et al., 1998). In 228 women (28 preterm births; 21 
early pregnancy losses), 14 weeks gestation, M. hominis and U. urealyticum 
remained associated with an increased risk of miscarriage (Donders et al., 2000). 
The detection of U. urealyticum or M. hominis in midtrimester amniotic fluids by PCR 
was shown to be a potential risk factor for subsequent preterm premature rupture of 
membranes as all women with premature rupture of membranes tested positive for 
either U. urealyticum or M. hominis (Perni et al., 2004).  
 
Conflicting findings have been reported as to whether U. urealyticum (Kim et al., 
2003) or U. parvum (Kataoka et al., 2006) be considered the most important 
pathogen. U. parvum was more frequently isolated from amniotic fluid of preterm 
gestations than U. urealyticum in a sample population of 77 women (gestational age 
< 37 weeks) (Kim et al., 2003). In a prospective cohort study of 877 women, vaginal 
colonisation with U. parvum by PCR-based methods was associated with late 
abortion or early preterm birth (Kataoka et al., 2006). Studies that were limited to 
sampling the lower genital tract of women have yielded inconclusive results, mainly 
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because not all women who are colonised in the lower tract will develop infection in 
the upper tract (Waites et al., 2005). 
 
In the present study, there was no significant association with U. parvum and 
preterm delivery which is in agreement with other reports (Aaltone et al., 2002; 
Matovina et al., 2004; Gonzalez Bosquet et al., 2006). However, failure to establish a 
statistically significant relationship may have been due to the small sample size of 
the preterm group (Govender et al., 2009). Kacerovsky et al., (2009) found that the 
prevalence of cervical colonisation by U. urealyticum was 68% (152/225) and M. 
hominis was 28% (63/225) in patients with preterm premature rupture of 
membranes. In the control group U. urealyticum was found in 17% (38/225) and M. 
hominis in 15% (35/225) pregnant women. 
 
M. genitalium and M. penetrans were not detected, which is in agreement with others 
findings on M. genitalium in preterm labour (Lu et al., 2001; Casin et al., 2002; Labbe 
et al., 2002). Comparisons of colonisation with HIV status also showed no 
association (p=0.36063) between M. hominis, Ureaplasma spp.; C. trachomatis and 
HIV infection (Govender et al., 2009), contradictory to a study by Cordova et al. 
(2000) that found M. penetrans was seen to occur more frequently in HIV infected 
individuals. Recent reports have associated M. genitalium from endocervical swabs 
and HIV infection/sereopositivity and vaginal discharge syndrome (Napierala and 
Weiss, 2009; Venter et al., 2009). 
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CHAPTER FIVE 
 
PREVALENCE OF MYCOPLASMAS AND UREAPLASMAS IN 
ADULTS AND NEONATES PRESENTING WITH PNEUMONIA AT 
HOSPITALS IN THE PORT ELIZABETH REGION 
 
 
5.1 INTRODUCTION 
 
Mycoplasma pneumoniae is a common cause of acute upper and lower respiratory 
tract infections particularly in children, young adults and the elderly; and community-
acquired pneumonia which often results in hospitalisation due to the severity of the 
illness (Madani and Al-Ghamdi, 2001; Waites and Talkington, 2004). Pneumocystis 
jiroveci an opportunistic fungus, is the causative agent of Pneumocystis pneumonia 
(PcP) in humans, and is an important cause of morbidity and mortality among 
immunocompromised persons, AIDS related or patients receiving prolonged 
corticosteroid or intensive immunosuppressive therapies (Pinlaor et al. 2004, 
Arcenas et al. 2006, Kong et al. 2007 and Van Oosterhout et al. 2007). 
 
M. hominis, U. urealyticum and U. parvum infections of the newborn have been 
associated with pneumonia, bacteraemia, chronic lung disease (CLD) and central 
nervous system (CNS) invasion (Waites et al, 2005; Schelonka and Waites, 2007). 
Chlamydia trachomatis (serotypes D – K) have been implicated in neonatal disease, 
including conjunctivitis and pneumonia of the newborn (Darville, 2005; Rours et al., 
2006b). 
 
As delayed treatment of pneumonia increases the risk of morbidity/mortality, rapid 
and accurate identification is crucial to the establishment of informed prognosis and 
facilitation of early appropriate treatment (Khanna et al., 2005). 
 
By 2006, provincial hospitals in Port Elizabeth had noted that the incidence of HIV in 
patients presenting with pneumonia had increased, yet there was no regional 
information on the extent of concomitant M. pneumoniae (as mentioned in section 
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1.1.4 of Chapter one) or P. jiroveci. The respiratory component of the study was 
conducted in an effort to determine prevalence of M. pneumoniae in Port Elizabeth 
hospitals and at the request of doctors at the hospitals who had observed an 
increase in pneumocystis pneumonia cases; simultaneous P. jiroveci detection was 
also performed and hence included in the thesis. PCR assays have been found to be 
very effective in detecting and improving diagnosis of P. jiroveci, (Durand-Joly et al. 
2005; Gupta et al. 2007) and M. pneumoniae, (Abele-Horn et al. 1998; Daxboeck et 
al. 2003) and were employed to investigate the prevalence of P. jiroveci and M. 
pneumoniae in patients admitted with pneumonia to two hospitals in Port Elizabeth.  
 
By 2007, an increase in mortality rate in neonates presenting with pneumonia at the 
Dora Nginza hospital Neonatal Intensive Care Unit (NICU) in Port Elizabeth raised 
treatment management concerns. Investigations were therefore requested and 
conducted on the prevalence of atypical pneumonia pathogens such as U. 
urealyticum, U. parvum and M. hominis in neonates. 
 
 
 
5.2 RESULTS 
 
5.2.1 Demographics of patient population 
5.2.1.1 Pneumonia in adults and detection of M. pneumoniae and P. 
jiroveci 
 
The 102 community-acquired pneumonia patients, came from 19 suburbs 
surrounding the Dora Nginza and Livingstone Hospitals [Fig. 5.9 (A) and (B)]. A 
substantial number of samples were obtained between March, May and August 
(2006-2008), but there was a decrease in collection during June and July (2006-
2008). The national nurses strike held in 2007, resulted in no samples being 
collected for both March and April. Patients were admitted and treated with 
cefuroxime if there were no contraindications or alternatively penicillin/gentamycin/ 
erythromycin. 
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Of the 102 patients for whom gender information was available, 85 were female, 
while 17 were males. The majority of pneumonia cases were seen in the 21-40 years 
age groups, comprising of 73 patients, with P. jiroveci detected in 40 patients. The 
high prevalence of P. jiroveci in women (46/85) was consistent with their high risk 
profile. Overall, P. jiroveci was detected in 54/102 patients; 41 patients were HIV-
positive, 3 were HIV-negative and the HIV status of 10 patients was unknown. M. 
tuberculosis and P. jiroveci were present together in 12 HIV-positive patients and 1 
HIV-negative patient (Table 5.1). P. jiroveci was found to be the sole causative agent 
in 25/71 HIV-positive patients, while M. tuberculosis was found alone in only 7 HIV-
positive patients. Although closely linked with HIV infection, P. jiroveci was not 
necessarily co-associated with M. tuberculosis. Patient history and case information 
were provided by the hospitals and many patients with P. jiroveci pneumonia were 
found to have other infections. Some of the common co-infections (where patient 
history was available) included: PcP, TB and HIV (10.78%); PcP and HIV (24.51%) 
with 20.59% of HIV-positive samples being PcP negative. Both of the young females 
(<15 years) were HIV positive and one had associated P. jiroveci colonisation. M. 
pneumoniae was detected in one patient by 16SrRNA and P1 adhesin gene PCR but 
Figure 5.1: Locations from which samples were obtained. (A) 19 suburbs within Port Elizabeth and 
(B) Hospitals in relation to these suburbs. 
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unfortunately HIV status was not known. There was no information on how many 
patients were receiving Bactrim prophylaxis (which was recommended for all HIV 
infected patients, along with vitamins, during the time of the study). 
 
 
 
 
Table 5.1:   Patient history and the presence or absence of P. jiroveci (PcP) from sputa samples. 
 Number of patients (%) 
Total (n) = 102a 
PcP positive and HIV positive 25 (24.51)  
PcP positive, HIV positive and TB positive 11 (10.78) 
PcP negative, HIV positive and TB positive 7 (6.86) 
PcP negative and HIV positive 21 (20.59) 
PcP positive and HIV negative 2 (1.96)b 
PcP positive, HIV negative and TB positive 1 (0.98)b 
PcP positive and TB positive, HIV status unknown 1 (0.98) 
PcP positive, HIV positive and previous TB 1 (0.98) 
PcP positive, HIV positive and diabetes 1 (0.98) 
PcP positive, HIV positive and epilepsy 1 (0.98) 
PcP positive, HIV positive and asthma 1 (0.98) 
PcP positive, HIV positive, Klebsiella pneumoniae and 
pleural effusion  
1 (0.98) 
PcP negative, HIV positive and pleural effusion 1 (0.98) 
PcP negative, HIV positive and anemia/thrombosis 1 (0.98) 
PcP positive, HIV status and co-infection history unknown 11 (10.78) 
PcP negative, HIV status and co-infection history unknown 16 (15.69) 
a: HIV positive (n) = 71, HIV negative (n) = 3, HIV status unknown = 28 
b: Not tested for HIV RNA by PCR 
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5.2.1.2 Neonatal pneumonia and detection of M. hominis, C. trachomatis 
  and Ureaplasma spp. 
 
Sixty-nine endotracheal aspirate samples from neonates were obtained from the 
Neonatal Intensive Care Unit (NICU) at Dora Nginza Hospital. Ages ranged from 1-
19 days with the majority of neonates in the study being in the 1-5 days old group 
[Fig. 5.10 (A)] from nine suburbs surrounding Dora Nginza hospital [Fig. 5.10 (B)]. 
 
 
 
 
 
 
 
 
Figure 5.2: (A)  Age groups of neonates presenting with pneumonia. 
(B)  Suburbs in Port Elizabeth from which samples were obtained. 
 
M. hominis and C. trachomatis were not detected in any of the neonate endotracheal 
aspirate specimens. Two specimens were positive for U. parvum using the UPA and 
UPS primers. These results were verified with repetition of PCR tests and products 
were sequence confirmed. Attempts to culture the two positive U. parvum neonate 
specimens on U9 broth and conventional broth (ATCC #1331 and #2616) were 
unsuccessful. The two endotracheal aspirate samples that were positive for U. 
parvum were negative for U. urealyticum. Mothers of the two neonates resided in the 
Uitenhage and Humansdorp suburbs which were regionally about 150 km apart. 
 
 
5.2.2 Detection of M. pneumoniae 
 
M. pneumoniae detection (refer to sections 2.7.2.2 and 2.8) was based on PCR 
using P1 adhesin and 16S rRNA primers. PCR products in the range of 375 bp, with 
the P1 adhesin gene, and 277 bp using 16S rRNA primers, for M. pneumoniae 
ATCC 29343 are shown in Figure 5.3. M. pneumoniae was detected in only one 
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sample by both 16S rRNA (results not shown) and P1 adhesin PCR (Fig. 5.3), 
however culture attempts failed (refer to section 3.2.6). The concentration of M. 
pneumoniae DNA from the clinical sample was very low and repeated DNA 
extraction and PCR using both P1 adhesin and 16S rRNA primers failed to provide a 
product that could be forwarded for DNA sequence confirmation. Unfortunately a 
second specimen could not be obtained, while HIV status and other important clinical 
data were also not available for this particular patient. 
 
5.2.3 Detection of P. jiroveci and DHPS/DHFR gene analysis 
 
For most sputa specimens (refer to section 2.2) using mtLSUrRNA primers a distinct 
388 bp DNA fragment, was obtained from the first round of PCR amplification [Fig. 
5.4(A)] while a 240 bp fragment was produced in the second round of PCR [Fig. 5.4 
(B)]. 
DHPS nested PCR generated a 342 bp fragment [Fig. 5.5 (A)], while PCR amplification 
using DHFR-specific primers, yielded a fragment of 798 bp [Fig. 5.5 (B)]. DHFR gene PCR 
did not produce bands for all samples even though they were positive by DHPS or 
mtSUrRNA as has been reported previously by Robberts et al., (2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Detection of M. pneumoniae employing P1 adhesin gene primers. 
Amplified fragments of 375 bp. Lanes 1 and 12: Molecular weight markers [100 bp DNA 
ladder (Promega)]; Lanes 3 and 11: Negative controls; Lanes 4 – 10: Sputa samples; 
Lane 2: Positive M. pneumoniae ATCC 29343 control. 
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Figure 5.4: Detection of P. jiroveci employing nested mtLSUrRNA PCR. 
(A) First round mtLSUrRNA PCR showing amplified fragments of 388 bp. Lanes 1 and 
12: Molecular weight markers [100 bp DNA ladder (Promega)]; Lanes 2, 10 and 11: 
Negative controls; Lanes 3 – 8: Sputa samples (1-6); Lane 9: Positive control (lung 
biopsy – PcP positive) and (B) Second round mtLSUrRNA PCR showing amplified 
fragments of 240 bp. Lanes 1 and 12: Molecular weight markers [100 bp DNA ladder 
(Promega)]; Lanes 2 and 11: Negative controls; Lanes 3 – 9: Sputa samples (1-7); Lane 
10: Positive control (P. jiroveci detected from a lung biopsy). 
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Figure 5.5: P. jiroveci DHPS and DHFR gene amplification. 
(A) Amplified fragments of 342 bp. Lanes 1 and 12: Molecular weight markers [100 bp 
DNA ladder (Promega)]; Lanes 2 and 11: Negative controls; Lanes 3 – 9: Sputa samples 
(1-7); Lane 10: Positive control (lung biopsy - 1 in 2 dilution). (B) Amplified fragments of 
798 bp. Lanes 1 and 11: Molecular weight markers [100 bp DNA ladder (Promega)]; 
Lanes 2 and 10: Negative controls; Lanes 3 – 8: Sputa samples (1-6); Lane 9: Positive 
control (P. jiroveci detected from a lung biopsy). 
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P. jiroveci sequencing results on mtLSUrRNA from specimens were compared with 
the wild type sequence of a 295 bp portion (GenBank accession no: M58605) of the 
mtLSUrRNA gene from P. jiroveci (Sinclair et al., 1991) [Fig. 5.6]. The 20 
amplification products from the DHPS nested PCR method were sequenced, and 
found to be identical to a known DHPS gene sequence (GenBank accession no: 
U66279) [Fig. 5.7] (Lane et al., 1997). Alignments of DHFR sequences from 17 PCR 
products were all identical to a DHFR gene (GenBank accession no: AF090368) 
[Fig. 5.8] (Ma et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Sequence of the amplified region of mtLSUrRNA from sputum specimens compared to P. 
jiroveci DNA sequence (GenBank accession no: M58605) (Sinclair et al., 1991). 
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Figure 5.7: Sequence of a 322 bp amplified region of the DHPS gene from sputum specimens 
compared to P. jiroveci DNA sequence (GenBank accession no: U66279) (Lane et al., 
1997). 
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Figure 5.8: Sequence of a 749 bp amplified DNA region of the DHFR gene from sputum specimens 
compared to P. jiroveci (GenBank accession no: AF090368) (Ma et al., 1999). 
 85
5.2.4 Detection of U. parvum and U. urealyticum and sequence confirmation 
 
PCR products (Fig. 5.9) obtained from two endotracheal aspirates (out of a total of 
69 specimens) were sequenced (Fig. 5.10) and comparisons made with the 5 696 bp 
urease gene of U. urealyticum and U. parvum (GenBank accession number 
AF085729) (Biernat-Sudolska et al. 2006; Kong et al. 2000; Kong et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: PCR detection of U. parvum using primers UPA and UPS. 
Neonate specimens: Lanes 1 and 12: Molecular weight marker (Promega 100 bp DNA ladder); 
Lane 2: Positive U. parvum ATCC 2616 control; Lane 3: 1:10 dilution of the positive control; 
Lanes 4 and 11: Negative controls; Lanes 5 – 7, 9: U. parvum negative endotracheal aspirate 
samples 49 – 51, 53; Lanes 8 and 10: U. parvum positive endotracheal aspirate samples 52 
and 54. 
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Figure 5.10: Sequence comparisons of PCR products derived from specimens 52 and 54 with the 
urease gene (UreA – UreB spacer region; Kong et al., 1999) from U. parvum. Shaded 
areas show point mutations that may indicate different strains of U. parvum. 
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5.3 DISCUSSION 
 
The standard diagnostic procedures employed at Port Elizabeth’s local hospitals 
involved determining the HIV and TB status of a patient, using microscopy, chest X-
rays and ELISA tests on collected sputum and blood samples. Upon completion of 
these tests, a second sputum sample may have been requested by doctors if PcP 
was suspected, based on clinical signs and symptoms, (such as a fever, non-
productive cough, shortness of breath), CD4 count, response to treatment and other 
data recorded in the patient’s file. The clinical detection protocol carried out at NHLS 
in Port Elizabeth made use of cytochemical staining procedures, for the visualisation 
of cysts and trophozoites of P. jiroveci. All sputa samples submitted to NMMU, 
Microbiology for molecular detection of P. jiroveci were based on patient history and 
clinical observation of PcP symptoms by the resident physician at the ward. 
 
The patients who participated in the study resided in predominantly poor, rural areas 
where medical assistance and resources are not widely available. Statistics have 
shown that the spread of HIV and AIDS related opportunistic infections are favoured 
due to the community lifestyle and living conditions within these areas, with reports in 
Port Elizabeth of two to three AIDS related deaths occurring per day 
(www.toolkitparticipation.nl/cases/87). Rama, (2005) showed that New Brighton, 
Kwazakhele, Motherwell, Zwide, Soweto-on-Sea and Veeplaas accounted for 
approximately 66% of the HIV-positive population in the Nelson Mandela 
Metropolitan area, whereas areas such as Bethelsdorp, Kwadwesi and Missionvale 
housed only 5.38% of the HIV-positive population.  
 
No samples were collected during March and April of 2007, due to serious staff 
shortages experienced at both provincial hospitals as a result of the national nurse’s 
strike. During this time important patient information was also lost. Unfortunately, 
these are just some of the continuous challenges that this study and clinical 
microbiology research faces within the Port Elizabeth region. Seasonal variations in 
the number of new P. jiroveci infections could be as a direct result of an increase 
during the colder months, or could be as a result of other respiratory tract infections, 
present in addition to P. jiroveci (Varela et al., 2004). 
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Generalised observations made by hospital personnel concerning the surrounding 
communities indicated that a) the female population was over-worked and 
undernourished, and if presenting to hospitals for treatment were in most instances 
immunosuppressed, with living conditions and lifestyles favouring the spread of 
opportunistic infections and b) men from the region tended not to access clinic or 
hospital services (Govender et al., 2008).   
 
Of the 102 patients for whom gender information was available, 85 were female, 
while 17 were male, whether this is indicative of men in the region just not 
approaching health care facilities or a lower incidence of pneumonia in males is not 
clear. The majority of pneumonia cases were seen in the 21-40 year age group, 
comprising 73 patients, with P. jiroveci detected in 40 patients, which is consistent 
with the demographics of the HIV/AIDS epidemic in South Africa 
(www.avert.org/safricastats.htm). The high prevalence of P. jiroveci in women 
(46/85) was reflective of their high risk profile, a young female (12 years) in which P. 
jiroveci was present was HIV positive. 
 
Although closely linked with HIV infection, P. jiroveci was not necessarily co-
associated with M. tuberculosis. Fisk et al. (2003), on studying co-infection rates 
associated with PcP in patients with AIDS in developing countries, found co-infection 
with M. tuberculosis in 13-66% of cases. The finding of HIV positive and P. jiroveci 
negative patients (21%) could suggest a) that in these immunocompromised 
patients’ the immune system had not deteriorated to the extent that placed them at risk 
for PcP, b) non-exposure or c) prophylactic treatment may have been given. 
Incomplete patient records/data bases not only compromised interpretation of results 
but would also hamper community follow-ups and management of family situations. 
 
Treatment protocols for diabetes, epilepsy, asthma and meningitis all rely on the use 
of extreme drugs and therapies that regularly lead to immunosuppression of the 
host. A compromised host therefore has a higher risk of acquiring a P. jiroveci 
infection (Prescott et al., 2007). In this study the three patients with underlying 
conditions of asthma, diabetes and epilepsy were in addition to being HIV-positive 
also colonised with P. jiroveci. It should also be noted that information on one patient 
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showed that in addition to having PcP, the patient was also being treated for a 
Klebsiella pneumoniae infection. 
 
Of the total samples tested for which the HIV status was known (n=74), two were 
HIV-negative but positive for P. jiroveci (there was no information available on other 
reasons for immunosuppression or underlying conditions). The study conducted by 
Robberts, (2005) involved the collection of 636 sputa samples from different regions 
in South Africa (KwaZulu Natal, Western Cape, Eastern Cape, North West province 
and Mpumalanga). Of the 148 sputa from the Eastern Cape, five P. jiroveci positive 
results were recorded from HIV-negative patients. In other regions there was a 
significant association between a positive HIV status and PcP. In Sweden, 
Mikaelsson et al., (2006) also found that the prevalence of PcP in HIV negative 
patients had increased. 
 
P. jiroveci was detected in 54 of 102 (52.9%) sputum samples, using the 
mtLSUrRNA nested PCR protocol. According to Robberts et al., (2007) the 
mtLSUrRNA nested PCR protocol, employed against South African isolates yielded 
high levels of sensitivity (78%) and specificity (100%). The success of this method is 
thought to be as a result of it targeting a multi-copy gene, which enhances sensitivity 
and allows the detection of very low numbers of organisms (Morris et al., 2008; 
Robberts et al., 2007; Sing et al., 2000 and Torres et al., 2000). The early 
identification of P. jiroveci colonisation is important because: (1) undetected 
Pneumocystis colonisation increases the patient’s risk of pneumonia; (2) 
transmission of the infection to other hosts may occur and (3) latent infections could 
lead to permanent lung damage (Morris et al., 2005). However, PCR reactions 
cannot differentiate between viable and non-viable cells (de Oliveira et al., 2007).  
 
Although vastly limited for diagnosis, DHPS and DHFR gene analysis is of major 
importance for monitoring TMP-SMX resistance development. In this study, no 
resistance associated mutations were detected in the PCR products of 20 DHPS and 
17 DHFR genes. Crewe-Brown et al. (2004), reported TMP-SMX-resistant South 
African isolates had begun to increase at a steady rate from 2000 to 2004. A high 
prevalence of DHPS mutations were found in the Gauteng Province (38%), while 
Robberts et al., (2007) and Zar et al., (2004) both showed lower prevalence rates in 
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DHPS mutations, 1.9% and 13.3% respectively, within the Western Cape. Whilst no 
resistance mutations to TMP-SMX were demonstrated in the current study, the use of 
TMP-SMX for PcP prophylaxis has been progressively increasing country wide since 
2007. Resistance monitoring should be maintained as PcP prophylaxis to South African 
patients in the past, has not been well documented (Dini et al., 2006). 
 
M. pneumoniae was detected in one specimen. The P1 adhesin primers were found 
to be more sensitive than the 16S rRNA primers, with the most likely rationale for this 
occurrence being the high copy number of this gene within the genome of M. 
pneumoniae (Ieven et al., 1996). The prevalence of M. pneumoniae within HIV 
infected adults can range from 1.9 to 30% (Hammerschlag, 2001) although a study 
by Loens et al. (2003) concluded that M. pneumoniae did not necessarily appear to 
be responsible for lower respiratory tract infections in HIV-positive adults and 
children. It has been suggested that the low prevalence/detection of M. pneumoniae 
may be due to the low concentration of M. pneumoniae within samples (Nour et al., 
2005). 
 
Highly active antiretroviral therapy is changing the epidemiology of P. jiroveci 
pneumonia in AIDS patients, as globally the incidence of PcP has been seen to be 
decreasing, and PcP is now mostly prevalent in AIDS patients who are not receiving 
HAART or those on severe immune suppressive treatments (Bahamondes et al. 
2006). The recent surge in ARV role out in South Africa may well similarly reduce the 
prevalence of P. jiroveci in AIDS patients and complex prophylactic management, in 
that cotrimoxazole could well be administered unnecessarily. It was evident in this 
study and reported in a community-acquired pneumonia study in Limpopo that 
without the introduction of rapid microbial diagnostics the mainstay of treatment 
remains empiric, based on South African guideline approaches (Mpe et al., 2005). 
Empiric treatment regimens, however, do not promote identification and susceptibility 
testing of causative organisms and could well perpetuate the prevalence of 
atypical/less severe pneumonias in the community (Govender et al., 2008). The first 
line antibiotic administered to patients with pneumonia in the Port Elizabeth hospitals 
was/is a second generation cephalosporin, cefuroxime. As cefuroxime is not 
effective against P. jiroveci and M. pneumoniae; in the absence of a definitive P. 
jiroveci diagnosis, co-trimoxazole prophylaxis was also administered. It is important 
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that clinicians monitor a patient’s progress carefully for cases that are not responding 
to treatment, e.g. M. pneumoniae where a macrolide/ketolide or quinolone should be 
considered (Govender et al., 2008). 
 
The neonate endotracheal aspirate specimens obtained from the hospital were of a 
poor quality (i.e. some were contaminated with blood). Due to the very small volume/ 
amount available, the specimens had to be flushed out of the endotracheal tubes 
with sterile water which caused dilution of the sample material from which DNA was 
extracted. Due to circumstances at the hospital (as described in section 3.3), it was 
not possible for specimens to be transferred onto transport media prior to collection 
and delivery to NMMU for analysis which may have contributed to negative culture 
results. Unfortunately and certainly for the two neonates in which U. parvum was 
detected, all attempts to obtain information from patient files at the Dora Nginza 
(NICU) on co-infections like HIV, TB, treatment or the type of delivery were 
unsuccessful. This type of epidemiological study at a provincial hospital in Port 
Elizabeth was the first of its kind and revealed a total lack of combined approaches 
within the hospital to address community microbial health issues. It should also be 
added that staffing conditions at the hospital were quite atrocious; one of the nurses 
who assisted with the adult study contracted XDR-TB and passed away during the 
project.  
 
Despite the limitations of hospital records and patient follow-up, new information 
obtained from this under research region were a) U. parvum was demonstrated in 
two neonates with M. pneumoniae detected in one adult patient, and b) M. 
pneumoniae was not seen to be associated with HIV, TB or P. jiroveci. In the 
absence of laboratory diagnoses and other microbial indicators, mycoplasmas and 
ureaplasmas will remain persistent under the radar and even perpetuate in 
communities. 
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CHAPTER SIX 
 
ANTIBIOTIC RESISTANCE GENES OF UREAPLASMAS AND 
INTERGENERIC TRANSFER POTENTIAL 
 
 
6.1 INTRODUCTION 
 
Antibiotic resistance in addition to ureaplasmas’ intrinsic resistance to ß-
lactams/cephalosporins and clindamycin can occur either by mutation or acquisition 
of new genes carried by transposons (Bebear and Kempf, 2005). Resistance to 
macrolides by drug inactivation, active efflux or methylation of the target site have as 
yet not been reported in ureaplasmas (Pereye et al., 2007a). Mutations in the 23S 
rRNA or in ribosomal protein L4 and L22 are thought to be associated with macrolide 
resistance development in Ureaplasma spp. (Pereye et al., 2007a). Fluoroquinolone 
resistance in Ureaplasma spp. is associated with mutations in target enzymes DNA 
gyrase and topoisomerase IV (Bebear et al., 2003). Transposons carrying 
tetracycline resistance genes (tetM) have been recognised in ureaplasmas (Roberts 
and Kenny, 1986; de Barbeyrac et al., 1996). 
 
As natural exchange of chromosomal DNA between cells of mycoplasmas has only 
been proposed by Teachman et al., (2002), it is thought that mycoplasmas/ 
ureaplasmas probably do not acquire DNA by conventional transformation 
processes. The lack of a cell wall in mycoplasmas/ureaplasmas would be expected 
to facilitate the introduction of exogenous DNA into the cells that may well involve 
transient fusion of the cell membranes at the zone of contact (Razin et al., 1998).The 
very small genomes of mycoplasmas/ureaplasmas lack a substantial part of 
standard recombination mechanisms available in larger bacterial genomes, however, 
they do contain large numbers of repeat DNA sequences considered vital for 
adaptation and chronic colonisation of their hosts (Rocha et al., 2005). 
 
Artificial transformation using a polyethylene glycol (PEG) mediated procedure 
similar to that used to transform Gram-positive bacteria has been used to transform 
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M. pulmonis, M. mycoides, M. capricolum and M. gallisepticum. Electroporation has 
been used to transform M. pneumoniae (Hedreyda et al., 1993), M. gallisepticum 
and M. mycoides, but has been ineffective for species such as M. pulmonis (Voelker 
and Dybvig, 1996). Although mycoplasmal phages are known to exist, transduction 
has not been described. Several mycoplasmas have been shown to acquire the 
conjugative transposon Tn916 by mating with an enterococcal donor, but conjugal 
transfer of any genetic element including Tn916 from a mycoplasmal donor has not 
been described. Circumstantial evidence suggests that horizontal gene exchange 
has occurred between species of Mycoplasma with the IS1221 insertion sequence 
having been found in M. hyorhinis, M. hyopneumoniae and M. flocculare (Teachman 
et al., 2002). 
 
It has been reported that high-level tetracycline resistance in Neisseria gonorrhoeae 
resulted from the acquisition of a streptococcal tetM determinant found in 
streptococci/enterococci, M. hominis and U. urealyticum (Morse et al., 1986; Roberts 
and Kenny, 1986; Roberts and Kenny, 1987). It is therefore important to investigate 
whether Ureaplasma spp. can act as tetracycline resistance gene pools with the 
potential to transfer resistance to each other (as population shifts are evident) and to 
urogenital pathogens especially N. gonorrhoeae which is known to be naturally 
competent and transformable. 
 
The study was designed to determine ureaplasma antibiotic susceptibility profiles 
and analyse resistance genes/mutations associated with antibiotic resistance 
development. The transfer potential of tetracycline resistance genes between 
ureaplasmas and N. gonorrhoeae was investigated. 
 
6.2 RESULTS 
 
6.2.1 Antimicrobial susceptibility profiling 
 
Endocervical specimens (132) were cultured from which growth was attained from 
66 samples (35 U. parvum, 9 U. urealyticum, 22 U. parvum + U. urealyticum) (Table 
6.1). Ureaplasma MIC determinations to ofloxacin, erythromycin, tetracycline, 
doxycycline, azithromycin and josamycin were performed in accordance with recent 
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recommendations by the The Mycoplasma Chemotherapy Working Team of the 
IOM. MIC ranges and breakpoints were based on data compiled from multiple 
published studies (Waites and Duffy, 2008) as there is no CLSI breakpoint 
information. Throughout procedures, culture from specimens and MIC 
determinations, ureaplasma broth cultures were checked for contamination. All broth 
cultures were clear and no microbial growth was detected on chocolate agar plates 
incubated in 8-10% CO2 at 37oC for 48 h. Thirty-seven ureaplasma cultures (56.1%) 
were fully susceptible to all antibiotics tested. Twenty-one cultures (31.8%) showed 
intermediate resistance to erythromycin, azithromycin and ofloxacin while seven 
(10.6%) were resistant to tetracycline, three of which were also resistant to 
doxycycline (Table 6.2). Two cultures (including a tetracycline-resistant strain), were 
seen to exhibit azithromycin resistance. The cultures showing reduced antimicrobial 
susceptibilities were species confirmed by PCR and further investigated for genetic 
mutations in drug target regions or gene acquisition. 
 
 
 
 
 
 
 
 
Table 6.1:  Detection of Ureaplasma spp. 
 
 No. of specimens producing ureaplasma cultures 
 U. parvum 
 
U. urealyticum 
 
U. parvum + 
U. urealyticum 
 
Total 
(n = 191)* 
PCR Positive  62 14 56 132 
PCR Negative    59 
     
Culture Positive from 
PCR positive 
35 9 22 66 
*= Total number of specimens analysed 
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Table 6.2:  Antibiotic profiles of Ureaplasma spp. 
 
Antibiotic profiles U. parvum 
 
U. urealyticum 
 
U. parvum + 
U. urealyticum 
 
Total 
(n = 66)* 
Susceptible 
 
16 1 20 37 
Intermediate (I) 12 6 3 21 
OFX 4 3  7 
E   1 1 
OFX + E 6 3 2 11 
OFX + E + AZM 2   2 
 
Resistant  7 1  8 
TET 3   3 
TET + DOX 1 1  2 
TET + AZM + E (I) 1   1 
AZM + E (I) 1   1 
DOX + TET + OFX (I) 1   1 
*= Total number of culture positive specimens. OFX: ofloxacin; E: erythromycin; AZM: azithromycin; TET: tetracycline; DOX: 
doxycycline; (I): intermediate 
 
 
6.2.2 Target Gene Mutations in Antibiotic -Intermediate/ -Resistant Strains 
 
6.2.2.1 Quinolone resistance determining region (QRDR): PCR 
amplification and sequence analysis 
 
The gyrA, gyrB, parC and parE genes were amplified and sequenced to determine 
whether there were any mutations in one ofloxacin-intermediate resistant U. 
urealyticum and six U. parvum strains. 
 
Amplification of the gyrA gene produced a 320 bp fragment, while gyrB, parC and 
parE genes produced 300 bp fragments. Sequence analyses were performed by 
BLAST software comparisons against the amplified sequence of U. parvum; Serovar 
3, ATCC 27815 (GenBank accession number CP000942.1). PCR amplification and 
sequence alignments revealed that there were no mutations in gyrB and parE genes 
of strains under investigation, however mutations were observed in gyrA and parC 
genes (Figs. 6.1 and 6.2, Table 6.3). A substitution of Ser83Leu in ParC was 
demonstrated in one intermediately-resistant strain (MIC 4 µg/ml) whilst a triple 
substitution of Asp112Glu in GyrA along with Ala125Thr and Ala136Thr in ParC was 
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found in six further intermediately-resistant strains. No background mutations were 
found in any cultures with MICs 1 µg/ml. 
 
 
Table 6.3:  Ofloxacin MICs with gyrA and parC sequence analysis 
 
 
Strain Amino acid change in QRDR MIC with ATCC Broth 
(μg/ml) gyrA parC 
Up-367 Asp112Glu Ala125Thr 
Ala136Thr 
OFX: 8 (I)a 
Up-372 Asp112Glu Ala125Thr 
Ala136Thr 
OFX: 8 (I) 
Uu-384 Asp112Glu Ala125Thr 
Ala136Thr 
OFX: 8 (I) 
Up-392 Asp112Glu Ala125Thr 
Ala136Thr 
OFX: 4 (I) 
Up-402 Asp112Glu 
 
Ala125Thr 
Ala136Thr 
OFX: 4 (I) 
Up-405 None  Ser83Leu OFX: 4 (I) 
Up-417 Asp112Glu 
 
Ala125Thr 
Ala136Thr 
OFX: 4 (I) 
a: MIC ≤ 8 μg/ml (Bebear et al., 2008) 
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Figure 6.1: (A): PCR amplification the QRDR of the gyrA gene. Lane 1: 100 bp DNA ladder, (Promega); 
Lane 2: U. parvum (strain Up-402).  
(B): Sequenced region of gyrA gene of strain Up-402 compared to gyrA gene sequence that 
corresponded to bases 99339 – 99622 of the reference strain (U. parvum, serovar 3, ATCC 
27815). *Mutation at position 99433 resulted in amino acid alteration at codon 112: Asp to Glu. 
Positive and negative controls were employed but are not shown. 
 
 
 
 
 
 
 
A B 
500bp 
400bp 
300bp 
1 2 
*
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A        C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: (A): PCR amplification of the QRDR of the parC gene. Lane 1: 100 bp DNA ladder; Lane 2: negative control; 
Lane 3: U. parvum strain Up-402; Lane 4: U. parvum strain Up-405. Positive control employed not shown. 
(B): Sequenced region of parC gene of U. parvum strain Up-402 (corresponding to base position 531622 - 
531888) compared to parC gene sequence of reference strain (U. parvum, serovar 3, ATCC 27815). *Mutations 
at base position: 531803, 531805, 531836 and 531838 resulted in amino acid substitutions at codons 125 and 
136: Ala to Thr. 
(C): Sequenced region of parC gene U. parvum strain 405 (corresponding to position 531622 -531888) 
compared to parC gene sequence of reference strain U. parvum, serovar 3, ATCC 27815. 
 *Mutation at position 531678 resulted in amino acid alteration at codon 83: Ser to Leu.  
3 2 1 
B 
*
4 
500bp 
400bp 
300bp 
* 
*
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6.2.2.2 Erythromycin/ azithromycin resistance gene targets: 23S rRNA, L4 
and L22 proteins 
 
Although no erythromycin-resistant strains were found, 14 strains exhibited 
intermediate erythromycin resistance (MIC ≤ 1 µg/ml) and 2 out of the 14 were also 
intermediately resistant to azithromycin (MIC ≤ 4 µg/ml). One strain was seen to be 
resistant to azithromycin (MIC ≤ 16 µg/ml) and tetracycline with intermediate 
resistance to erythromycin while another strain was resistant to azithromycin (MIC ≤ 
16 µg/ml) with intermediate resistance to erythromycin (Table 6.2). On amplification 
and sequence analyses of the two operons (OP1 and OP2 in domain V) of 23S 
rRNA, L4 and L22 proteins of these strains, no mutations were detected. 
 
6.2.2.3 Tetracycline resistance gene analysis 
 
Seven ureaplasmas exhibited tetracycline resistance. The presence of tetM genes in 
all resistant strains was then investigated using primers directed at the 397 bp (Fig. 
6.3) and 1.7 kb tetM region (Fig. 6.4) and int-Tn gene (Fig. 6.5). Screening for tetM 
and int-Tn gene regions was extended to include all ureaplasmas whether 
tetracycline-susceptible, -intermediate or -resistant (Table 6.4). All tetracycline 
resistant strains contained 1.7 kb and 397 bp regions of tetM and the int-Tn gene. 
PCR was repeated on all susceptible strains to verify no amplicon contamination had 
occurred. Eleven susceptible strains whilst possessing int-Tn gene lacked a large 
region of the tetM gene. The remaining 48 susceptible strains did not possess the 
Int-Tn protein region (integrase) of transposon Tn1545. No plasmids were detected 
in the seven tetracycline-resistant strains using the Pure Yield plasmid miniprep kit 
(section 2.13.1). Of the three tetracycline- + doxycycline- resistant strains, two 
possessed tetM mutations at positions 2750: A to C and 2751: C to T resulting in 
histidine to proline amino acid substitutions while one tetracycline strain had only the 
tetM mutation at position 2751: C to T (Table 6.5). 
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Figure 6.3: (A): PCR amplification of the tetM gene. Lane 1: 100 bp DNA ladder; Lane 2: negative control; Lane 3: 
Up-408; Lane 4: Up-417.  
(B): Sequences corresponding to position 2538-2904 (of 397bp band) of the tetM gene in strain Up-408 
compared to S. pneumoniae tetM gene sequence (accession number = X90939.1). 
A positive control was employed but not shown. 
 
 
 
 
 
 
1 2 3 4 
300bp 
B
 
400bp 
500bp 
A 
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Figure 6.4: PCR products of the 1.7 kb tetM gene region using primers TetMF and TetMR-
2123.  
Lanes 1 and 10: Molecular weight markers (Promega 100 bp DNA ladder); Lane 
2: Negative control; Lane 3-9: Samples 251, 266, 354, 366, 385, 408, 417 
Results of sequence comparisons are discussed in Section 6.2.2.4. 
A positive control was employed not shown. 
 
  1     2     3    4    5     6     7     8     9   10 
1720bp 
500bp 
1500bp 
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Figure 6.5: (A): PCR amplification of int-Tn gene (579 bp region). Lane 1: 100 bp DNA ladder (Promega);  
Lane 2: negative control; Lane 3: Up-408; Lane 4: Up-417.  
(B): Sequences corresponding to position 844-1093 of the int-Tn gene in strain Up-417 
compared to published sequence of the genes of Tn1545 that are involved in the excision of the 
element (accession number = X61025). 
A positive control was employed but is not shown. 
 
 
400bp 
500bp 
300bp 
1 2 3 4 
B A 
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Table 6.4:  Screening of tetracycline-susceptible, -intermediate (to other antibiotics) and -resistant U. 
parvum and U. urealyticum strains for tetM (397 bp and 1.7 kb regions) and int-Tn region. 
 
 
Tetracycline No. of strains with regions associated with tetracycline resistance 
397 bp 397 bp + 1.7 kb 397 bp 
   + int-Tn gene 
397 bp + 1.7 kb 
+ int-Tn gene 
Susceptible 
(n=59) 
 
45 
 
3 
 
11 
 
Resistant 
(n=7) 
   7 
 
 
 
 
 
Table 6.5: Tetracycline and doxycycline MICs and tetM sequence analysis. 
 
 
 
Strain 
MIC broth (µg/ml) TetM detected Sequence analysis 
Tet Doxy (397 bp + 1.7 kb) Base changes: position 2750, 2751 
Up-251 32 4 Yes No 
Up-266 16 4 Yes No 
Uu-354 16 8 Yes Yes (2750: A to C) + (2751: C to T) * 
Up-366 16 8 Yes Yes (2751: C to T) (silent) 
Up-385 8 4 Yes No 
Up-408 64 4 Yes No 
Up-417 32 8 Yes Yes (2750: A to C) + (2751:C to T) * 
     
* Amino acid change = Histidine to proline 
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6.2.2.4 Ureaplasma spp. tetM sequence comparisons with S. pneumoniae, N. 
gonorrhoeae and ureaplasma GenBanked sequences 
 
The tetM gene sequences were aligned as shown in Table 6.6. Alignments were 
performed against the tetM sequence of N. gonorrhoeae strain 6418 (GenBank 
accession number: L12241) [USA, 1993, plasmid pOZ100] (Gascoyne-Binzi et al., 
1993) base numbers corresponding to nucleotides 674 – 2174. Only nucleotide 
positions that differed are shown across the strains. The genes aligned are: S. 
pneumoniae: X90939: [Italy, 1995, Transposon Tn5251 (Provvedi et al., 1996) 
nucleotides 2553 – 4040 and U. urealyticum SV9-Seattle: U08812 [1988, 
Transposon Tn916 doxycycline-susceptible (Sanchez-Pescador et al., 1988) 
nucleotides 2436 – 3877. The leader 600 nucleotides of the tetM gene exhibited 
considerable diversity between strains and the region was schematically represented 
in Figure 6.6.  
 
6.2.2.5 Ureaplasma spp. int-Tn sequence comparisons with a S. pneumoniae 
GenBanked sequence 
 
Sequences of the seven tetracycline-resistant ureaplasma int-Tn genes were aligned 
with S. pneumoniae Tn916 int-Tn (X61025) nucleotides 758-1337 (Table 6.7). On 
examining alignments, based on common nucleotide alterations there were three 
major int-Tn types: Type 1, Deletions were observed yet other than a short region 
(bases 981-1009) nucleotide alterations to those of S. pneumoniae Tn916 int-Tn 
were not evident for strains Up-408, Up-417, Up-366 and Uu-354; Type 2, nucleotide 
changes throughout (bases 1-1135) common to strains Up-251 and Up-385; Type 3, 
no initial nucleotide alterations (bases 1-914) then specific alterations for strain Up-
266.   
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Table 6.6:  TetM sequence alignments of the seven tetracycline-resistant Ureaplasma spp. strains and GenBank tetM genes. 
 
 
Sequence comparisons were performed against the tetM sequence of N. gonorrhoeae: L12241 (Gascoyne-Binzi et al., 1993). Only nucleotide positions that 
differed from N. gonorrhoeae L12241 are shown across the strains.  
N. gonorrhoeae strain 6418: L12241 [USA, 1993, plasmid pOZ100] (Gascoyne-Binzi et al., 1993). Base numbers correspond to nucleotides 674 –2174. 
 
The tetM genes aligned are: 
Sp= S. pneumoniae: X90939: [Italy, 1995, Transposon Tn5251 (Provvedi et al., 1996). Base numbers correspond to nucleotides 2553 – 4044. 
Uu-S= U. urealyticum SV9: U08812 [Seattle, 1988, Transposon Tn916 doxycycline-susceptible (Sanchez-Pescador et al., 1988). Base numbers correspond 
to nucleotides 2436 – 3877. 
Up-251= U. parvum current study: doxycycline-susceptible. 
Up-266= U. parvum current study: doxycycline-susceptible. 
Up-385= U. parvum current study: doxycycline-susceptible.  
Up-408= U. parvum current study: doxycycline-susceptible.  
Up-417= U. parvum current study: doxycycline-resistant.  
Up-366= U. parvum current study: doxycycline-resistant.  
Uu-354= U. urealyticum current study: doxycycline-resistant. 
 
W=nucleotide wobble, strains exhibiting excessive problems were re-sequenced.         d=Nucleotide deletion 
-= Not determined for strains Up-251 and Up-266 nucleotides 343-378, as sequence interpretation was not possible. 
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Uu-S                       A         
                                
Up-251                     C w     C     
Up-266  w w d w d w w T w d w d G d w w d C C            
Up-385                       A w w d  w w   
Up-408 T    w                  A         
Up-417                       A         
Up-366 T                      A    d     
Uu-354                              w d 
                                
 
 
 
 
 1 
3 
0 
7 
1 
3 
2 
3 
1 
3 
3 
8 
1 
3 
4 
0 
1 
3 
5 
7 
1 
3 
5 
8 
1 
3 
6 
0 
1 
3 
6 
1 
1 
3 
6 
2 
1 
3 
6 
3 
1 
3 
6 
4 
1 
3 
6 
5 
1 
3 
6 
9 
1 
3 
7 
2 
1 
3 
7 
6 
1 
3 
8 
1 
1 
3 
8 
6 
1 
3 
8 
9 
1 
3 
9 
3 
1 
3 
9 
5 
1 
4 
0 
0 
1 
4 
0 
1 
1 
4 
0 
3 
1 
4 
0 
9 
1 
4 
1 
5 
1 
4 
1 
6 
1 
4 
1 
7 
1 
4 
1 
8 
1 
4 
1 
9 
1 
4 
2 
4 
1 
4 
2 
6 
1 
4 
2 
8 
1 
4 
3 
1 
1 
4 
3 
2 
1 
4 
3 
4 
1 
4 
3 
5 
1 
4 
3 
6 
Ng g t a g a a a g a g t t a g c t c g a c t t c c c a a a g g g t t t a a c 
                                      
Sp                                      
Uu-S                                      
                                      
Up-251   d w   w w  w   d d d d  d T d   d d  d   d  d w    G  
Up-266       w   d          w           d     G  
Up-385 w  d  G   w   C  d  d d w  d    d d d  w d w A   w  G   
Up-408   d        w     d   d  d  d d d     A    d  G  
Up-417  d       w             d               d 
Up-366                d   d    d d  d    A  w    d  
Uu-354   d   d      d       d  d  d d  d   d  A      d 
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 1 
4 
3 
7 
1 
4 
4 
2 
1 
4 
4 
3 
1 
4 
4 
4 
1 
4 
4 
5 
1 
4 
4 
7 
1 
4 
5 
1 
1 
4 
5 
6 
1 
4 
5 
9 
1 
4 
6 
0 
1 
4 
6 
3 
1 
4 
6 
4 
1 
4 
6 
7 
1 
4 
6 
9 
1 
4 
7 
2 
1 
4 
7 
3 
1 
4 
7 
5 
1 
4 
7 
7 
1 
4 
8 
0 
1 
4 
8 
2 
1 
4 
8 
3 
1 
4 
8 
4 
1 
4 
8 
6 
1 
4 
9 
7 
Ng t a t t g t a a a a t g t t t t a a t t t a a t 
                         
Sp                         
Uu-S                         
                         
Up-251 d    - - - - -  - - - - -  - - -      
Up-266           - - - - -  - - -      
Up-385  w w   C d w d   d d  G          
Up-408   w d   C d d  d  d      C      
Up-417     A   w   w w  d d  w w d G w w w  
Up-366   d d       - - - - -  - - -      
Uu-354        d  d  d  d d d  d C      
                         
 
A schematic diagram of tetM sequence comparisons (Fig 6.6) was prepared from bases 1-600 with the format: clear sections identical to N. gonorrhoeae; 
blue: S. pneumoniae; green: U. urealyticum SV9, other colours: are independent to Ureaplasma spp strains from current study. 
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GenBank strains 
             
N. gonorrhoeae pOZ100              
             
S. pneumoniae Tn5251                
             
U. urealyticum (Seattle)            
 
 
Strains current study 
            
Up-251          -------      
             
Up-266          ------        
             
Up-385              
             
Up-408                  
 
 
            
Up-417                    
             
Up-366              
             
Uu-354            
   
Nucleotide base positions 
  
  100 200 300 400 500  600 
 
Figure 6.6: Schematic representation of aligned tetM gene sequences from the different tetracycline-resistant Ureaplasma spp strains from current study.  
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Table 6.7:  Ureaplasma spp strains sequence comparisons of a 579 bp region of int-Tn gene based on the S. pneumoniae Tn1545 int-Tn (X61025), 
nucleotides 758 – 1337. 
 
Base no. 
 
7 
6 
6 
7 
7 
8 
7 
8 
1 
7 
8 
4 
7 
9 
0 
7 
9 
9 
8 
0 
2 
8 
0 
5 
8 
0 
7 
8 
0 
9 
8 
1 
1 
8 
1 
6 
8 
1 
7 
8 
1 
9 
8 
2 
0 
8 
2 
1 
8 
2 
2 
8 
2 
5 
8 
2 
6 
8 
2 
9 
8 
3 
2 
8 
3 
8 
8 
3 
9 
8 
4 
1 
8 
4 
9 
8 
5 
0 
8 
5 
4 
8 
5 
6 
8 
5 
9 
8 
6 
1 
8 
7 
3 
8 
7 
7 
8 
8 
0 
8 
8 
2 
8 
8 
3 
8 
8 
5 
8 
8 
9 
8 
9 
1 
S. pneumoniae 
 
c c a a c a a g t a a a c c t g a c t a c t t t t a g a a t a t t t a t t 
Up-251  d  G T  C T d d  G   d      G   G   d C G  C G   A  C  
Up-266                                       
Up-385   d  T  C T d d  G   d d d    G   G   d C  G C G C d  d C  
Up-408  d                       d              
Up-417              d    d                     
Up-366                                       
Uu-354 d     d    d d  d  d   d d d  d d  d d    d      d  d 
 
 
 
Base no. 
 
8 
9 
5 
8 
9 
6 
8
9
8
9 
0 
0 
9 
0 
1 
9 
0 
3 
9 
0 
6 
9 
1 
4 
9 
1 
5 
9 
1 
6 
9 
1 
8 
9 
1 
9 
9 
2 
7 
9 
3 
4 
9 
3 
8 
9 
4 
0 
9 
4 
1 
9 
4 
8 
9 
5 
1 
9 
5 
2 
9 
5 
9 
9 
6 
6 
9 
6 
7 
9 
6 
8 
9 
7 
0 
9 
7 
2 
9 
7 
6 
9 
8 
1 
9 
8 
2 
9 
8 
5 
9 
9 
1 
1 
0 
0 
0 
1 
0 
0 
1 
1 
0 
0 
3 
1 
0 
0 
4 
1 
0 
0 
5 
1 
0 
0 
9 
1 
0 
1 
0 
1 
0 
1 
9 
1 
0 
2 
0 
1 
0 
2 
2 
1 
0 
2 
7 
S.pneumoniae 
 
g c a c a a c t g g c t t a g t t a a a a a c a a g t a a c c c t a a c t t c g a t 
Up-251 d  G d T       G  G  A       T  G    G  d   T   C      
Up-266        C C C  G  G d d A T  G G  T T G T d  G A  d A  d G  A T T d G 
Up-385 d d G d T  d    d  d   A       T  G   G   d G  d   d      
Up-408       d    d  d      d   d         d   d         
Up-417 d                           G    G  T  G C      
Up-366                      d         d            
Uu-354      d d    d  d      d         G    G  T G  C      
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Base no. 
 
1 
0 
3 
0 
1 
0 
3 
5 
1 
0 
3 
7 
1 
0 
3 
9 
1 
0 
4 
1 
1 
0 
4 
2 
1 
0 
4 
4 
1 
0 
4 
5 
1 
0 
4 
9 
1 
0 
5 
0 
1 
0 
5 
1 
1 
0 
5 
3 
1 
0 
5 
7 
1 
0 
6 
0 
1 
0 
6 
3 
1 
0 
6 
7 
1 
0 
7 
2 
1 
0 
7 
6 
1 
0 
7 
8 
1 
0 
7 
9 
1 
0 
8 
0 
1 
0 
8 
2 
1 
0 
8 
3 
1 
0 
8 
5 
1 
0 
8 
7 
1 
0 
9 
0 
1 
0 
9 
1 
1 
0 
9 
3 
1 
0 
9 
5 
1 
0 
9 
7 
1 
1 
0 
4 
1 
1 
0 
9 
1 
1 
1 
2 
1 
1 
1 
5 
1 
1 
2 
3 
1 
1 
3 
5 
S. pneumoniae 
 
a a t t a a t g g c a t t t t a c a g a c g t c a a g a a a a a t g a a
Up-251 C   C  G d  T  C    d  T    T  C T G  d   G  G  T G G
Up-266 T  d  d d   A T  G G G A G T   T  d d T G  d C d   G G T G G
Up-385 C   C  G d d A  d d     T d d  d  C T G d d  G  d   T d G
Up-408  d   d         d  d       d d             
Up-417                                     
Up-366                      d C              
Uu-354                                     
 
 
 
 
Base no. 
 
1 
1 
3 
9 
1 
1 
4 
5 
1 
1 
4 
7 
1 
1 
6 
1 
1 
1 
6 
2 
1 
1 
7 
3 
1 
1 
7 
4 
1 
1 
8 
0 
1 
1 
9 
6 
1 
2 
0 
4 
1 
2 
0 
7 
1 
2 
0 
8 
1 
2 
0 
9 
1 
2 
2 
5 
1 
2 
2 
6 
1 
2 
3 
4 
1 
2 
3 
5 
1 
2 
6 
6 
1 
2 
8 
0 
1 
2 
8 
2 
1 
2 
8 
4 
1 
2 
9 
4 
1 
2 
9 
8 
S. pneumoniae 
 
t a a t t c a a g t t t t a a g g t a t g t a
Up-251  d   C   G A C   C  G  A     d  
Up-266 A  G  C  G G  C  C  G  A  d d d A   
Up-385  d  d    d  d d   G  d      d d 
Up-408      d                  
Up-417                      d d 
Up-366                        
Uu-354                      d d 
 
 
d= Nucleotide deletion 
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6.2.3  Antibiotic Resistance Gene Transfer 
 
6.2.3.1 Screening of N. gonorrhoeae cultures for tetracycline resistance 
prior to transformation experiments 
 
Four N. gonorrhoeae strains were screened for tetracycline recipient suitability. 
Strains were screened employing Etests and included if they exhibited inhibitory 
concentrations of ≤0.25 μg/ml. 
 
6.2.3.2 Transformation/culture co-incubation type experiments 
 
The four N. gonorrhoeae recipients were broth culture optimised to fulfil 
transformation criteria for DNA addition/uptake, exponential (1x107 cfu/ml) to early 
stationary phase (1x108 cfu/ml). Donor DNA from Up-417 resistant to tetracycline 
(MIC 32 μg/ml) and possessing int-Tn and tetM 1.7 kb regions was added to N. 
gonorrhoeae when cultures had reached approximately 1x107 cfu/ml. After a two 
hour uptake period, viability was approximately 1-2x 108 cfu/ml. Fresh media was 
then added to ensure the broth could sustain growth whilst any DNA that had 
undergone recombination could be expressed. At the end of this expression period, 
culture viability was approximately 1-3x108 cfu/ml. No tetracycline-resistant N. 
gonorrhoeae transformants (frequency <3-9x107) were detected after performing 
Etests. 
 
In order to increase detection frequencies after transfer and expression periods 
recipient cultures were challenged with suitable concentrations of tetracycline. No 
tetracycline-resistant N. gonorrhoeae transformants were obtained using a co-culture 
type protocol between N. gonorrhoeae recipients and tetracycline-resistant 
Ureaplasma donors (culture and DNA). Incubation of a susceptible U. parvum 
recipient (tetracycline MIC ≤ 0.25µg/ml) with DNA from tetracycline-resistant U. 
parvum (3 strains) and U. urealyticum (1 strain) produced transformants with MICs 
ranging between 4-8 µg/ml. PCR analysis on these low-level tetracycline-resistant 
transformants revealed that the 1.7kb region of the tetM gene was not present. 
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Transformation was also conducted with E. coli JM109 competent cells. E. coli 
JM109 commercially available competent cells (Promega) were transformed by 
donor DNA (pGEM-3Z vector) which served as a positive control and two colonies on 
LB agar plates with ampicillin were recovered. In contrast no transformants were 
obtained with donor tetM DNA from the Ureaplasma spp strains.  
 
6.2.3.3 Electroporation 
 
Electroporation (refer to section 2.14.4) using N. gonorrhoeae plasmid containing 
tetM and DNA from tetracycline-resistant U. parvum and U. urealyticum strains into 
N. gonorrhoeae recipients was unsuccessful. 
 
Electroporation was also conducted employing an E. coli control strain DH5α as the 
recipient. E. coli DH5α bacteria were transformed with control pUC18 plasmid DNA 
resulting in growth of E. coli colonies (n=8) on LB with ampicillin. However, no 
transformation occurred using the control E. coli cells with DNA from Ureaplasma 
strains on transfer to LB agar plates containing tetracycline. No transformants 
resulted on employing an E. coli DH5α-pUC18 transformant as the recipient when 
DNA from Ureaplasma spp. was added, with selection performed on LB plates 
containing ampicillin and tetracycline. 
 
 
6.3 DISCUSSION 
 
One U. urealyticum and seven U. parvum strains exhibited resistance to one or more 
of the antimicrobial agents tested (ofloxacin, azithromycin, tetracycline and 
doxycycline) and were seen to have MICs greater than normal ranges previously 
published by Waites et al., (2005), Bebear et al., (2008) and Bebear and Kempf 
(2005). All strains were susceptible to josamycin. 
 
Twenty ureaplasmas were found to be intermediately-resistant to ofloxacin, based on 
MIC ranges for Ureaplasma documented by Bebear et al., (2008), of which 13 had 
MICs ≤ 1-2 µg/ml; three strains had MICs of 8 µg/ml while the other four strains 
showed MICs of 4 µg/ml. No isolates were resistant to erythromycin with only 
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intermediate resistance (MIC ≤4 µg/ml) observed. Two strains (Up-276, Up-266) 
were resistant to azithromycin (MICs 16 µg/ml). Three tetracycline-resistant strains 
(Uu-354; Up-366; Up-417) were concurrently resistant to doxycycline with four 
tetracycline-resistant strains exhibiting intermediate resistance to doxycycline. Four 
U. parvum strains were resistant/intermediately-resistant to more than one antibiotic, 
Up-266 azithromycin and tetracycline; Up-367 ofloxacin erythromycin and 
azithromycin; Up-402 ofloxacin and azithromycin; Up-417 ofloxacin and tetracycline. 
 
Putative molecular mechanisms of antibiotic resistance were investigated based on 
target genes identified by previous investigators (Bebear et al., 1997; Bebear et al., 
2000; Blanchard et al., 1992; de Barbeyrac et al., 1996; Pereyre et al., 2007a; 
Beeton et al., 2009b). Ofloxacin was used as the representative fluoroquinolone that 
targets DNA gyrase and topoisomerase IV, mutations in gyrA, parC and parE genes 
having been shown to be associated with fluoroquinolone resistance (Bebear et al., 
1999; 2000; 2003; Bebear and Kempf, 2005; Duffy et al., 2006; Zhang et al., 2002). 
A substitution of Ser83Leu in ParC was identified in one intermediate-resistant strain 
Up-405 (MIC=4 µg/ml) while a triple substitution of Asp112Glu in GyrA along with 
Ala125Thr and Ala136Thr in ParC all within the QRDR was found in six 
intermediately-resistant strains (Up-367, Up-372, Up-384; MICs 8 µg/ml. Up-392, Up-
402, Up-417; MICs 4 µg/ml). 
 
In contrast, Beeton et al., (2009a), reported that the triple mutation of Asp112Glu in 
GyrA along with Ala125Thr and Ala136Thr in ParC was not related to a resistance 
phenotype, but had resulted from species-specific polymorphism which are found in 
all U. parvum and U. urealyticum. However, Ser83Leu is one mutation that remains a 
candidate for fluoroquinolone resistance development, with further multiple 
substitutions being required to mediate a resistant phenotype. Investigators found 
that strains with Ser83Leu substitutions in ParC showed varying degrees of 
resistance to fluoroquinolones (Bebear et al., 1999; 2000; 2003; Bebear and Kempf, 
2005; Duffy et al., 2006; Zhang et al., 2002) while others found that only isolates with 
the triple and Ser83Leu substitutions exhibited full resistance (Bebear et al., 2003; 
Zhang et al., 2002). Six strains from the current study had only the triple mutation not 
related to a resistance phenotype (species-specific polymorphism) while one had the 
Ser83Leu mutation alone. 
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Bebear et al., (2003) showed that isolates with ofloxacin MICs 4-8 µg/ml and 
ciprofloxacin MICs 16-128 µg/ml, contained the triple mutation either with/ without a 
Ser83Leu substitution. On examining species specific polymorphisms proposed by 
Beeton et al., (2009a) no unique resistance candidate mutations appear to be 
evident. The ParC Ser83Leu substitution is homologous to resistance mediating 
mutations identified in many other fluoroquinolone-resistant bacteria, including S. 
aureus and S. pneumoniae (Piddock, 1999). 
 
Fluoroquinolones are known to have preferential sites of action: gyrase for Gram-
negative bacteria and topoisomerase IV for Gram-positive bacteria. The proposed 
evolution of ureaplasmas from Gram-positive progenitors may be responsible for the 
higher incidence of mutations within topoisomerase IV relative to gyrase. Resistance 
mechanisms and gene mutations have still to be clarified (Beeton et al., 2009a). 
 
No erythromycin-resistant strains were found and no mutations were detected in 
OP1 and OP2 in domain V of 23S rRNA, L4, L22 proteins in intermediate-resistant 
strains or in two strains which exhibited azithromycin resistance. Pereyre et al. 
(2007) have shown that in vitro, U. parvum mutants derived after passage in 
increasing concentrations of erythromycin produced mutations in 23SrRNA operons 
and L4, L22 ribosome associated proteins. Characterisation of in vitro-selected 
mutants of U. parvum that were resistant to macrolides revealed no significant 
difference in MICs, with or without reserpine indicating the absence of a putative 
efflux mechanism (Pereye et al., 2007a). The methyltransferase enzyme (Erm 
family) or enzymes modifying macrolides have not been identified in 
mycoplasmas/ureaplasmas (Bebear and Kempf, 2005). As no mutations were found, 
the azithromycin intermediate resistance observed may even be due to media pH 
change that has been shown to produce false resistance profiles (Waites and Duffy, 
2008). Dongya et al. (2008), identified point mutations in 23S rRNA operons of U. 
urealyticum isolates that were resistant to macrolides: josamycin, clarithromycin, 
roxithromycin and azithromycin, unfortunately erythromycin was not tested. Beeton 
et al. (2009b), on sequence analysis of an isolate with an MIC ≥ 64 µg/ml, found no 
mutations in 23S rRNA operons or L22, only a 6-bp deletion in L4. Jensen et al. 
(2008) detected three different mutations at positions 2058 and 2059 (E. coli 
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numbering) in 23S rRNA domain V of M. genitalium that was resistant to 
azithromycin and erythromycin (MICs >8µg/ml). 
 
Tetracycline resistance in Mollicutes is mediated by transferable genetic 
elements/transposons containing tetM genes (Roberts and Kenny, 1986). In the 
current study, seven strains with MICs 8-64 µg/ml were seen to harbour a 1.7 kb 
tetM gene region and an int-Tn gene that encodes integrase and excision functions 
of transposon Tn1545. Eleven-susceptible strains contained int-Tn gene regions but 
lacked a large portion of the tetM gene as only a 397-bp fragment of tetM was 
detected. The remaining 48 strains only contained a 397-bp region of tetM. 
Degrange et al. (2008), identified two tetM containing M. hominis isolates that were 
tetracycline susceptible, one isolate had a 1260-bp insertion in the leader peptide 
sequence which prevented successful transcription while no mutation in tetM of the 
other isolate was found. Beeton et al. (2009b), also found no explanation for the 
presence of tetM in a susceptible isolate and attributed the finding to possible 
amplicon contamination. 
 
Three of the seven tetracycline-resistant strains were concurrently resistant to 
doxycycline. Blanchard et al. (1992), have similarly reported that tetM in M. hominis 
and U. urealyticum conferred resistance to tetracycline but not necessarily to 
doxycycline; 8/21 tetracycline-resistant strains were resistant to doxycycline, 2 had 
intermediate resistance to doxycycline and 11 were susceptible. It was proposed by 
Oggioni et al. (1996), that amongst tetM genetic mosaics different spectra of activity 
to different tetracyclines may be present, although further investigations were 
advocated. Beeton et al. (2009b) recently conducted tetM sequence comparisons 
between tetracycline- + doxycycline-susceptible strains with tetracycline-resistant 
and tetracycline- + doxycycline-resistant strains of ureaplasmas and found no amino 
acid alterations that could be attributed to either tetracycline or doxycycline 
resistance. Induction of tetM gene transcription by doxycycline has been considered 
not to be as strong as tetracycline, yet Degrange et al. (2008) on investigating M. 
hominis strain passages to increasing sub-inhibitory concentrations of doxycycline 
observed for one strain that doxycycline enhanced tetM transcription. It was 
therefore suggested that tetM gene expression in M. hominis is regulated by 
transcription attenuation that involves activation or inhibition of transcription 
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termination at a position between the promoter and the tetM gene (Degrange et al., 
2008). Beeton et al. (2009b), just placed a statement that the tetM tetracycline-
resistant U. parvum strain investigated was additionally resistant to doxycycline with 
no comment on expression. 
 
On comparing tetM gene sequences of the seven tetracycline-resistant strains with 
GenBank sequences of tetM genes from N. gonorrhoeae, S. pneumoniae and U. 
urealyticum SV9-Seattle, the genes of five strains were seen to be highly mosaic. It 
was not possible to compare sequences with a previously described doxycycline-
resistant Ureaplasma strain SV9-Vancouver that had been registered in GenBank, 
as the sequence had been withdrawn without explanation. Sequence analysis was 
problematic in that although a quality 1.7 kb PCR product was produced, baseline 
was noisy over some regions and nucleotide wobbles evident particularly in strain 
Uu-354. Sequencing was conducted twice with 1.7 kb primers, once with 319 bp 
primers and once with 1.38 kb primers. As the tetM gene of some stains was found 
to contain highly diverse regions primer incompatibility may well have been 
responsible for sequence inconsistencies. Unfortunately primers of Beeton et al. 
(2009b) that have been shown to produce 901 bp tetM fragments failed amplify the 
region for the seven strains. 
 
On aligning sequences, in the tetM leader region, blocks both similar and different to 
those of the three GenBank strains were evident and unique regions were also noted 
in three strains from the present study. Three recombination hot spot sites across 
strains that also corresponded to S. pneumoniae and/or U. urealyticum SV9-Seattle 
were seen around bases 172, 300 and 425. A fourth recombination region between 
bases 376-392 was common only to five study strains (Up-385, Up-408, Up-417, Up-
366 and Uu-354). The terminal end whist containing few nucleotide alterations was 
seen to exhibit multiple deletions.  
 
The three tetracycline- + doxycycline-resistant strains Up-417, Up-366 and Uu-354 
exhibited a region between bases 172-244 that was similar to the N. gonorrhoeae 
but with a tight cluster of base differences between 198-214 that were similar to 
Enterococcus faecalis and Staphylococcus aureus (Oggioni et al., 1996). Oggioni et 
al. (1996), also recognised that the only significant differences between these E. 
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faecalis and S. aureus strains were at the ribosomal binding site 115 nucleotides 
upstream of the structural gene. The doxycycline-resistant U. parvum strain of 
Beeton et al. (2009b) was reported to be similar to the U. urealyticum SV9-Seattle 
strain. For reasons unknown, no comparisons or comment was made by Beeton et 
al. (2009b) to mosaic structures of U. urealyticum reported by Soroka et al. (2002). 
Soroka et al. (2002), on investigating tetM determinants in urogenital U urealyticum 
isolates, described three tetM genes that were identical to tetM of a GenBanked 
Ureaplasma sequence (U08812) and two that showed new allelic variants. One of 
these strains had a clipped U. urealyticum block which was also evident in the 
present study. 
 
As no plasmids were demonstrated in the present study or by other investigators, 
tetM genes in the ureaplasmas were considered chromosomally located. Oggioni et 
al. (1996), showed that the tet locus and Tn917 exhibited vast differences in 
sensitivity to restriction endonucleases, Tn917 with few restriction sites whilst on 
integration, tetM like other chromosomally located gene loci could be subjected to 
recombination events generating mosaic structures. According to Beeton et al. 
(2009b) as mutations/mosaics within tetM are similar in doxycycline-susceptible and 
-resistant strains, expression of tetM appears key to doxycycline resistance.  
 
On sequence alignment of int-Tn genes from the seven tetracycline-resistant strains 
with S. pneumoniae Tn1545 int-Tn, three types of int-Tn genes were characterised. It 
was interesting to note that for the four strains in which tetM mosaic structure was 
the most evident the int-Tn genes (Type 1) were the least diverse. As int-Tn is a 
functional gene, integrase with incision and some excision properties, it appears in 
the three strains where nucleotide alterations had occurred most extensively that 
tetM genetic exchange may have been compromised. Of the four strains possessing 
a Type 1 int-Tn upstream of tetM, three were the tetracycline- doxycycline-resistant 
strains and one a tetracycline-resistant strain.     
 
The mosaic tetM genes described both in the current study and that of Soroka et al. 
(2002) and int-Tn of the current may well predetermine which upstream transposon 
promoter/insertion regions would affect survival under selective pressure. In a study 
investigating doxycycline-resistant populations of streptococci before and after 
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doxycycline treatment a novel transposon CTn6002 was demonstrated (Warburton 
et al., 2007). CTn6002 was described as a composite transposon containing Tn916, 
with a leader region similar to Tn5251, open reading frames similar to lactobacilli, a 
novel open reading frame, and it was also capable of in vitro conjugation. Roberts 
(2005), commented that there was no clear role for mosaic tet genes other than to be 
a unique feature of a small group of organisms/those from the same environment, 
but that mosaic genes would certainly influence PCR/probe detection techniques. 
Whilst Warburton et al. (2007), made comment that on performing PCR detection of 
tetM and int-Tn genes that thorough characterisation and prevalence determinations 
be performed for the identification of individual members of Tn916. Mycoplasmas 
and ureaplasmas are constantly minimising their genomic sizes which would account 
for lost tetM regions. Such essential excision processes could well generate 
recombination sites at which different tetM and int-Tn types and leader transposon 
regions/promotors could integrate when strains are again challenged with 
tetracycline/ doxycycline. 
 
Although preliminary in vitro reciprocal transformation attempts to achieve high-level 
tetracycline/doxycycline resistance were unsuccessful, ureaplasmas may donate or 
receive DNA to/from other microorganisms during co-infection/co-colonisation at the 
sites of infection. Bacterial genomes are prone towards deleting non-essential DNA, 
and the small, reduced genomes of host-dependent bacteria, attest to the tendency 
for bacteria to delete the most expendable sequences from their genomes. Hence, 
bacterial genomes are sampling rather than accumulating sequences and 
counterbalancing gene acquisition with gene loss (Ochman et al., 2000). 
 
In a clinical setting, cells are under stress due to antimicrobial treatment, and 
capsules may be damaged/disintegrated and cell lysis stimulated which could 
facilitate DNA uptake. Other factors regulating gonococcal transformation that are 
important for efficient DNA uptake are (a) type IV pilus and proteins associated with 
pilus; pilliated frequencies can exceed 20% whilst in non-pilliated variants 
frequencies are far reduced, 1x10-7 and (b) donor DNA that possesses a ten base 
sequence (GCCGTCTGAA) called the DNA uptake sequence (DUS) that is 
frequently present in neisserial chromosomes (Hamilton and Dillard, 2006). It has 
been shown that N. gonorrhoeae strains can lose piliation and high frequency 
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competence uptake due to multiple non-selective passages in vitro (Bogdan et al. 
2002). Transformation with plasmids can be 1000-fold less efficient than 
chromosomal DNA although it is not clear as to expected frequencies when donor 
DNA is a transposon/transposon related gene. Transposon located gene integration 
may be limited, yet transposons are ideally primed for recombinational success 
especially concerning integration into a resident transposon and transposon genes 
are readily incorporated into resident gene cassettes. Filter mating experiments on 
S. pneumoniae with donor DNA from transposons resulted in frequencies of 8x10-8 
for Tn1545 and 5x10-7 for Tn916 (McDougal et al., 1998). 
 
Electroporation using N. gonorrhoeae plasmid containing tetM and DNA from 
tetracycline-resistant U. parvum and U. urealyticum strains into susceptible N. 
gonorrhoeae recipients were unsuccessful. It has been reported that many strains of 
Neisseria are fragile and unable to survive the high voltage discharge generated 
across their membrane by electroporation (Bogdan et al., 2002). No tetracycline-
resistant N. gonorrhoeae transformants were obtained using co-culture/DNA 
protocols between N. gonorrhoeae recipients and tetracycline-resistant Ureaplasma 
donors. 
 
One U. parvum recipient, on exposure to donor DNA from one tetracycline-resistant 
U. urealyticum and three U. parvum strains, produced transformants with low-level 
tetracycline resistance (MICs 4-8 µg/ml). PCR analysis performed on these 
transformants did not detect 1.7 kb tetM gene regions. Tetracycline resistance can 
occur by four different mechanisms: ribosomal protection (RP) mechanism, 
tetracycline efflux, enzymatic inactivation of tetracycline and modification of the 
ribosomal target (Kazimierczak et al., 2008). The absence of tetM genes in the 
transformants obtained in this investigation suggests that other genetic element(s) 
conferred low-levels of tetracycline resistance, such as the expression of a 
tetracycline efflux mechanism. Non-specific transformation as a result of horizontal 
gene transfer may occur through a complicated process (Neela et al., 2009), and low 
transfer frequencies observed with certain bacterial species could be due to the 
presence of restriction systems that destabilise exogenous DNA (Courvali, 1994).  
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The tetM genes of ureaplasmas are highly diverse, clearly showing that acquisition 
of different regions has occurred from various sources. In addition three int-Tn genes 
of different Tn916-Tn1545 origins appear evident. These findings may in part have 
affected genetic transfer studies. In vivo exchange is feasible as genital 
microorganisms possess a variety of transposon located tetracycline resistance 
genes that include a) ribosomal protection genes: mosaic tetM in N. gonorrhoeae, 
mycoplasmas, ureaplasmas, lactobacilli and Gardnerella vaginalis; tetS in 
lactobacilli; tetO in N. gonorrhoeae; tet36 in lactobacilli and b) efflux gene: tetK in 
lactobacilli (Roberts, 2005; Soroka et al., 2002). 
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CHAPTER SEVEN 
 
 
CONCLUSIONS 
 
 
In the medical arena, mycoplasmas and ureaplasmas have been termed “stealth 
pathogens” as they are difficult to culture and have therefore remained under the 
radar as they may well have been missed as causes of disease. In the 
agricultural arena, mycoplasmas have for years been recognised as major 
pathogens. In addition, recently great strides have been made to detect and track 
tetracycline resistance in livestock, feed and produce. With new interest from 
commercial companies and the introduction of PCR techniques into diagnostic 
laboratories more information on prevalence and antibiotic resistance profiling is 
becoming available. 
 
During the study period, detection of mycoplasmas and ureaplasmas employing 
conventional culture was problematic in that quality controlled commercially 
prepared agar was expensive and not consistently available. Commercial kits for 
detecting mycoplasmas and ureaplasmas did not perform well when compared to 
PCR. Due to workloads, the introduction of culture techniques would be 
challenging for diagnostic laboratories in South Africa and it is recommended that 
for screening, especially respiratory specimens, that PCR diagnostics be 
implemented. The Takara kit was excellent but yet again expensive and based 
classification of ureaplasmas on the previous system whereby both U. parvum 
and U. urealyticum species were detected as U. urealyticum (biotypes 1 and 2). 
The primers employed in the study had been extensively used in the research 
setting and can be recommended. However, it would be important for multiplex-
PCR techniques to be assessed against South African isolates before 
incorporation into diagnostic standard operating procedures. 
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Without an agar culture format and international recommendations, susceptibility 
testing of mycoplasmas and ureaplasmas is reliant on selective broth 
procedures. It should be noted that whilst commercial U9 broth is a suitable 
medium for culture Ureaplasma spp., it does allow the growth of both U. parvum 
and U. urealyticum and therefore prior to susceptibility testing, specific ATCC 
recommended broths should be employed and species determined by PCR. The 
best performing antibiotic susceptibility screening kit was found to be the SIR kit. 
PCR for antibiotic resistance gene detection is well developed but for quinolones 
(mutation detection) sequencing is necessary and whilst the tetM primers 
provided quality amplified fragments sequencing was not ideal. In addition a set 
of primers that had been shown to amplify a region of tetM failed to produce a 
fragment. As tetM was seen to be highly mosaic in strains of the current study, it 
is recommended that at least two primer pairs are used. Further investigations 
should be conducted to determine whether mycoplasmas and ureaplasmas 
possess other tetracycline resistance gene classes that encode ribosome 
protection proteins, by employing degenerate primers. 
 
The study on endocervical specimens revealed single and co-colonisation with 
mycoplasmas, ureaplasmas and C. trachomatis appeared to be age related. 
Microbial population shifts were evident but as susceptibility monitoring is not 
conducted in the general population, consequences as a result of syndromic 
sexually transmitted disease antibiotic management are not known. There was 
no association found between M. hominis and Ureaplasma spp. and preterm 
labour in the population group studies and also no significant association with U. 
parvum. Failure to establish a statistically significant relationship between U. 
parvum and preterm delivery lends to further investigations as the sample size 
was too small. Comparisons of colonisation with HIV status in the current study 
showed no association between M. hominis, Ureaplasma spp.; C. trachomatis 
and HIV infection. In the South African public sector, diagnostic testing is not 
performed for C. trachomatis, mycoplasmas or ureaplasmas and therefore 
surveillance on prevalence/co-colonisation and antimicrobial resistance 
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development of these micro-organisms against changing syndromic 
management programmes requires further monitoring. 
 
The findings on community-acquired pneumonia in adults and the presence of U. 
parvum DNA in the two cases of neonatal pneumonia in the Port Elizabeth region 
requires further prevalence and epidemiological based investigations and 
extension of diagnostic approaches to provide for informed therapeutic decisions. 
It was evident that robust integrated hospital and pathology laboratory patient 
data systems suitable for South Africa must be designed and implemented, as 
efficient health management systems they are vital to ensure that community 
health issues pertaining to both respiratory illness and sexually transmitted 
infections can be responsibly addressed. 
 
The overall prevalence of Mycoplasma spp. and Ureaplasma spp. from 
endocervical specimens collected during 2005 were 34% and 13.5% 
respectively. However, the follow on series in 2006 collected for antimicrobial 
susceptibility testing showed dramatic population shifts in that Ureaplasma spp. 
were found in 69% of specimens and no Mycoplasma spp. were detected. This 
could not have been due to the inherent resistance of ureaplasmas to 
clindamycin, (as clindamycin is not routinely used at all in South Africa) or to 
quinolone/erythromycin/azithromycin resistance as high-level resistance to these 
antibiotics was not demonstrated. The one AZM resistant strain may be 
considered a false positive as Ureaplasma spp. are very sensitive to pH changes 
in the media. Although high-level quinolone resistance was not detected in 
ureaplasmas, on analysing intermediate-resistant strains, one strain had the 
Ser83Leu mutation alone which is related to a low level resistant phenotype. 
 
The findings of tetM genes/remnants in all isolates both tetracycline-resistant and 
–susceptible, was of major interest and have not been described before at this 
level. Seven strains were resistant to tetracycline with dual doxycycline 
resistance observed in three strains. To-date, only two mycoplasmas and two 
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ureaplasmas exhibiting tetracycline and doxycycline resistance have been 
documented. On sequence alignment, tetM genes from seven tetracycline-
resistant strains against GenBank sequences of N. gonorrhoeae, Streptococcus 
pneumoniae and U. urealyticum, leader regions were seen to be highly mosaic in 
structure. Some of these regions were similar to those of the GenBank strains 
and others unique to strains in current study. Interestingly, a tight cluster of base 
differences 198-214, was found only in the three doxycycline-resistant strains 
and were seen to be similar to Enterococcus faecalis and Staphylococcus 
aureus. Four hot spot recombination sites were identified that could certainly 
have influenced the formation of the mosaic structures, upstream insertion 
sequences/open reading frames and leader transposon regions that regulate 
expression. On sequence characterisation of int-Tn genes three profile types 
were evident. The type most resembling that of S. pneumoniae appeared linked 
to the tetM genes that exhibited highly mosaic structures. 
 
Further studies are required to a) determine whether positive Ureaplasma 
selective pressure is still present or whether mycoplasmas have re-emerged, 
even possibly as a consequence of tetracycline/doxycycline gene resistance 
transfer from ureaplasmas and b) elucidate tetM gene expression that results in 
doxycycline resistance. A revised South African Sexually Transmitted Infection 
Treatment Guidelines includes doxycycline for treatment of conditions such as 
urethritis and vaginal discharge syndrome, where ureaplasmas have been 
implicated (Lewis and Maruma, 2009). It will therefore be of great interest to 
assess if continued usage of doxycycline impacts on Ureaplasma and 
Mycoplasma prevalence and resistance development/acquisition. 
 
The finding of a number of tetracycline-resistant/intermediate-resistant and even 
susceptible strains harbouring the int-Tn gene (Tn916 - Tn1545 family) and tetM 
regions in conjunction with tetM diversity, indicates that ureaplasmas are 
involved in tetracycline and doxycycline resistance interchange. Although high-
level tetracycline resistance gene transfer was not seen to occur from 
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ureaplasmas to N. gonorrhoeae, this does not exclude the possibility of in vivo 
transfer from other microorganisms that may originally have acquired resistance 
genes from ureaplasmas. Further work should be conducted on reciprocal 
antibiotic resistance gene transfer between urogenital microflora to assess 
impact of integrated transposons from different origins on antibiotic resistance 
expression, stability and influence on genomic evolutionary restructuring.  
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